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Abstract 
 
This thesis focuses on developing efficient, atom-economic synthesis routes for 
functionalised 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one libraries. 1,4-
Benzodiazepines (BZDs) are often referred to as “privileged scaffolds” due to their 
important biological activities; therefore, finding new efficient methods for synthesising 
such analogues is highly desirable in pharmaceutical and medicinal research. 
 
Chapter 1 introduces the project detailing the biological importance and applications of 
BZDs. The classical synthetic routes towards BZDs and some of the limitations for 
efficient and rapid BZD-based library synthesis, followed by the aims of the project. 
 
Chapter 2 presents a late-stage C-H activation method for synthesising ortho-arylated 5-
phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one, including a library of over twenty 
novel analogues. The microwave-mediated palladium catalysed arylation method is also 
applicable to nordazepam (7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-
one), the active metabolite of diazepam. Further diversification of the compounds is 
achieved by N-alkylation and/or H/D exchange, which affords elaborated 
pharmaceuticals. 
 
Chapter 3 describes an alternative catalytic visible light-mediated photoredox method for 
ortho-arylated 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-ones. The protocol uses 
aryldiazonium salts in refluxing methanol and showcases an interesting phenomenon 
known as the “nuisance effect” with 2- or 4-fluorobenzenediazonium salts. It results in 
both fluoroaryl and methoxyaryl- products, the latter result from a nucleophilic aromatic 
substitution (SNAr) on the fluorobenzenediazonium salt (nuisance effect). The results 
from biological tests of the benzodiazepine libraries against GABAA receptors indicated 
that the C-7 substituent is vital for activities in GABA and only the 7-chloro-
benzodiazepines show any reasonable activities, although ortho arylation is detrimental 
to bioactivity. A computational DFT analysis of the reaction mechanism from our 
collaborators is also discussed in the Chapter. 
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Chapter 4 contains a brief overview of C-H functionalisation protols. Moreover, in this 
Chapter, the photoredox C-H activation method combined with the nuisance effect are 
extended to other privileged scaffolds.  This Chapter describes the synthesis of small 
libraries of 2-phenylpyridines and 1-phenyl-2-pyrrolidinones. The nuisance effect proves 
to be effective in creating small arrays of compounds from a single reaction and in X-ray 
screening arrays for biological testing. A number of 1-phenyl-2-pyrrolidinone analogues 
display promising biological activities towards NUDT7, a peroxisomal coenzyme A 
diphosphatase of current interest.  
 
Chapter 5 focuses on the synthesis of a series of N1-arylated 5-phenyl-1,3-dihydro-2H-
1,4-benzodiazepin-2-ones. The N-arylation occurs in one-step using a single 1,4-
benzodiazepine precursor with unsymmetrical diaryliodonium salts in aqueous ammonia 
as a base.  
 
Chapter 6 reports the scale-up synthesis of 6-(1H-indol-4-yl)-8-methoxy-1-methyl-4H-
[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-4-acetic acid methyl ester, TC-AC-28. This 
BZD derivative is a highly selective bromo and extra terminal (BET) bromodomain 
inhibitor and a useful epigenetic tool compound. The near gram-scale, seven-step 
synthesis of this key chemical probe compound enabled it to be available for researchers 
through Tocris, one of our industry sponsors, and where I spent 3 months as part of my 
CASE award.  
 
Chapter 7 concludes the thesis and concentrates on future directions.  
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Chapter 1 
 
 
1.1 Benzodiazepines 
 
Benzodiazepines (BZDs) are most famous for their successful and wide use in treating 
disorders such as anxiety, depression and insomnia since the 1960s.1 Shortly after their 
discovery, BZDs largely replaced other anxiolytics and sedatives in the market, due to 
their superior pharmacological and toxicological evaluation. BZD usage reached its peak 
during 1975-1980. In 1979 ca. 31 million prescriptions were issued for benzodiazepines 
in the U.K. alone and they are widely used as central nervous system (CNS) agents even 
today.2 Being clinically effective and popular for their psychotropic effects, BZDs were 
hailed as wonder drugs and the Rolling Stones even released a hit single in 1960s about 
Valium, a potent BZD-anxiolytic, calling it “Mother’s Little Helper”, describing how it 
helped women to go through their busy days. However, just like every rose has its thorn, 
concerns soon appeared for the side effects and dependence developed among patients 
for BZDs.3–5 During 1990, manufacturers of BZD drugs faced the largest class-action 
lawsuit by 14,000 patients and 1,800 law firms in the U.K., for allegedly withholding 
potential dependence information on BZDs from medical staff. Moreover, in 2013, more 
than 7000 people died of BZD-overdose.6 The slightly controversial status of BZDs also 
presents new opportunities and challenges for chemists in developing improved BZD 
analogues without the side effects. Despite, their long-standing clinical use as anxiolytics, 
what makes BZDs attractive in medicinal research is their ability to bind not only to the 
receptors in the CNS but also to a diverse array of other protein and enzyme receptors by 
modifying the substituents on the BZD core. This class of compounds are therefore often 
referred to be “privileged” in drug discovery, i.e., they have the capacity to interact with 
multiple proteins and alter the course of diseases.7 The therapeutic potential of 
compounds containing BZD moieties has captured the interest of synthetic chemists in 
finding new protocols for developing a range of functionalised BZDs. A major part of 
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this project indeed is concerned with developing effective routes for synthesising a range 
of novel 1,4-benzodiazepin-2-one analogues. 
 
This chapter entails the story of the accidental discovery of BZD derivatives as CNS 
acting agents and how they work, the subsequent development of a range of BZD 
analogues targeting numerous enzymes and proteins, various routes for synthesising 
BZDs and finally the aims of the project. 
 
1.2 The discovery  
 
BZDs are bicyclic compounds consisting of a benzene nucleus attached to a seven-
membered ring containing two nitrogen atoms.8 Leo Sternbach first synthesised BZDs 
during the 1950s when Roche laboratories initiated a project for making new 
tranquilisers, since this class of therapeutics were rising in clinical demands at the time. 
Initially, Sternbach attempted to synthesise a series of novel benzheptoxdiazines for the 
project, as these were a relatively unexplored but chemically interesting group of 
compounds.  
 
 
 
Figure 1.1: Structure of a benzheptoxdiazine 
 
However, the project was soon abandoned as none of the synthesised compounds 
displayed any interesting biological properties and studies also revealed that the 
compounds were not actually benzheptoxdiazines but were, in fact, quinazoline 3-
oxides.9 About two years later in 1957, during a lab clean up, Sternbach’s co-worker, Earl 
Reeder, found two untested samples - a crystalline base and its hydrochloride salt. The 
compound was synthesised by treating quinazoline N-oxide with methylamine.10 
Although these two compounds were not tested initially due to lack of interest, they 
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decided to submit the samples for pharmacological testing, anticipating a negative result 
and expecting to conclude the work on quinazoline 3-oxide with this result. Surprisingly, 
the compound showed unusually interesting properties in the initial screenings for 
sedative and tranquilliser effects. Further studies showed that the compound was actually 
a benzodiazepine derivative, the product of an unusual novel ring enlargement of the 
quinazoline derivative as shown in Scheme 1.1.   
 
 
 
Scheme 1.1 Formation of a benzodiazepine by ring enlargement of a quinazoline – oxide 
 
This compound, with the generic name chlordiazepoxide (7-chloro-2-methylamino-5-
phenyl-3H-1,4-benzodiazepine-4-oxide), displayed higher anticonvulsant activities than 
any other marketed drugs at the time such as chlorpromazine and phenobarbital (Figure 
1.2).9,11   Within a very short time a patent was approved for 2-amino-1,4-benzodiazepine 
compounds. Chlordiazepoxide was subsequently introduced in the market within a record 
time during 1960, under the trade name Librium®, due to its promising clinical and 
toxicological evaluation.12   
 
 20 
 
N
S
Cl
N
HN NH
O
OO
Chlorpromazine Phenobarbital
 
 
Figure 1.2: Structures of chlorpromazine and phenobarbital 
 
Owing to their valuable clinical properties, a vast number of benzodiazepines were 
synthesised and their pharmacology was studied extensively.13 Structure-activity-
relationship (SAR) investigations revealed that the 5-phenyl-1,4-benzodiazepine ring 
system was a key feature for biological activity (Figure 1.3). Another significant 
substituent for the biological property was found to be R2 at C-7. Electron withdrawing 
groups at C-7 potentiated biological activity whereas electron-donating groups at the 
same position had the opposite effect. A substituent on the ortho-position of the phenyl 
ring (R3) was associated with increased activity, on the other hand, a substituent in the 
para-position (R4) decreased it significantly. An alkyl group at the N-1 position also 
produced a positive effect on the activity.14  
 
N
N
OR1
R3
R4
R2
 
 
Figure 1.3: 5-Phenyl-1,4-benzodiazepin-2-one 
 
Extensive clinical and experimental data established that BZDs possessed superior 
efficacy than other depressants such as barbiturates and propanediol carbamates. 
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Benzodiazepines have rapid onset of action, low toxicity and effective therapeutic 
actions.15 Additionally, they display weaker hepatic enzyme inducing properties and 
therefore cause fewer drug-drug interaction by this mechanism. BZDs also have a larger 
difference between the “effective” dose and the “lethal” dose compared to other 
anxiolytics. Due to this increased safety of BZDs in the context of overdose, along with 
other pharmacological and toxicological advantages, BZDs largely replaced other types 
of sedatives and hypnotics in the market.16 Subsequently, a host of 1,4-benzodiazepine 
compounds became available for clinical use, most of which were anxiolytics, some were 
hypnotics and some were even used in the treatment of epilepsy. In other words, BZDs 
started dominating the market for treating insomnia, muscle spasm, anxiety, depression, 
stress and epilepsy.  
 
One of the most potent and most well-known benzodiazepines is diazepam (Valium®), 
other therapeutics include nitrazepam (Mogadon®), oxazepam (Serax®), medazepam 
(Nobrium®), flurazepam (Dalmane®), chlorazepate (Tranxilium®), bromazepam 
(Lexotan®), alprazolam (Xanax®), flunitrazepam (Rohypnol®) and clobazam 
(Frisium®), clonazepam (Klonopin®) and lorazepam (Ativan®).17 The structures of 
some clinically used BZDs are shown in Figure 1.4. 
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Figure 1.4: Structures of clinically available benzodiazepines 
 
However, during the 1980s the side effects of BZDs and dependence developed for this 
class of drugs became concerning. The over enthusiastic prescription of BZDs was an 
alarming fact as well.4,5,18 Over the years concerns over benzodiazepine use have been 
associated with side effects such as drowsiness and ataxia, over-prescription, misuse of 
the drug, and developing dependence and withdrawal symptoms when discontinued.19 In 
the past years benzodiazepines have been reported to be the second most misused 
therapeutic and the second most frequently used drug for suicide attempts, surpassed only 
by the opioids.18,20 Due to these concerns, significant effort is still ongoing to develop 
improved BZD-based drugs without the side effects. 
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 1.3 Pharmacology  
 
There have been extensive studies in understanding the use, biochemical effects and 
actions of the BZDs, and how and where they bind to produce the psychotropic effects.  
Each BZD derivative differs from the others based on their chemical structure and 
pharmacokinetic properties, however, in general all BZDs share a common mechanism 
of action in producing the clinical effects.14 All BZDs are involved in enhancing the 
actions of gamma-aminobutyric acid (GABA), a widely distributed inhibitory 
neurotransmitter (Figure 1.5) in the CNS. GABA acts by binding to specific receptors 
known as GABA-receptors, in the plasma membrane during the synaptic neuronal 
process. This opens up ion channels on the neuron allowing negatively charged chloride 
ions to enter the neuron. This leads to an overall negative change in the transmembrane 
potential which makes the cell less responsive to other neurotransmitters resulting in 
reduced excitation.21   
 
HO
O
NH2
 
 
Figure 1.5: gamma-aminobutyric acid 
 
There are at least two classes of known GABA receptors: GABAA are ionotropic 
receptors that contain a central ligand-gated ionophore and GABAB are guanine 
nucleotide-binding (G-protein) protein-coupled complexes, which are metabotropic 
receptors meaning they are connected to the ion channel on the plasma membrane through 
G proteins.  GABAA complex is the key medium for performing inhibitory control in the 
CNS. There are five specific binding domains for GABA, barbiturates, picrotoxin, 
anaesthetics and benzodiazepines on the GABAA receptor. The GABA-binding site is 
located near/on the ionophore-channel and is candidly responsible for the opening of the 
Cl- channel.22  
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Figure 1.6: the GABAA receptor and the binding domains 
 
Drugs such as BZDs and barbiturates are known as positive allosteric modulators for 
GABAA receptor – once they bind to their binding sites, this causes a conformational 
change in GABAA receptor allowing GABA to bind and this in turn alters the ion channel 
allowing more chloride ion flow into the cell by increasing the frequency or duration of 
the channel opening. This leads to hyperpolarisation of the neuron, thus, decreasing the 
possibility of an action potential and inducing sedative effects. However, this effect is 
only observed when GABA or a GABA agonist is also present. The positive allosteric 
modulators have no effects on their own.23  
 
The composition of GABAA receptors varies from region to region in the CNS and affects 
their affinity to bind to GABA and drugs such as BZDs, barbiturates and neuro active 
steroids.24–26 Each GABAA receptor typically consists of 5 subunits. Over the years, 19 
different GABAA receptor subunits have been identified; these include six α, three β, three 
γ, π, δ and three ε, θ, ρ. The most common types of GABAA receptors consist of two α, 
two β and one γ subunits.27 The benzodiazepine binding sites are known to form in the 
interface between α and γ subunits. BZDs only display binding affinity towards α subunits 
containing histidine (e.g. α1, α2, α3 and α5 subunits) but, do not show any affinity when 
they contain arginine (e.g., α4, α6 subunits).28 Moreover, the affinities of different BZDs 
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vary towards the binding sites consisting of different subunits. For instance, BZDs that 
show higher affinity for α1 subunit tend to produce sedative effects, whereas BZDs with 
higher affinity for the receptors containing α2 mediate anti-anxiety effects.29 Rational drug 
design to target specific receptor subtypes has been possible utilising such pharmacology 
of BZDs.30  
 
BZDs are typically administered orally but they can also be administered intramuscularly, 
intravenously or rectally.  BZDs and their metabolites are highly lipophilic leading to 
rapid absorption and distribution. The onset and duration of action of any BZD are 
influenced by the distribution and absorption rates.31 The absorption and distribution rates 
are largely depended on the chemical characteristic of the BZD and the binding affinity 
towards the varying GABAA receptors. BZDs can be categorised by their biochemical 
half-life values: long-acting BZDs have half-life values of longer than 24 hours and often 
have active metabolites; BZDs with half-life values ranging from 5 to 24 hours are 
described as intermediate or short-acting BZDs and these often do not have any active 
metabolites; ultrashort-acting BZDs have half-lives of below 5 hours. Notably, half-lives 
of the drugs may overlap amongst the groups of BZDs and vary among individuals.32 
 
BZDs such as chlordiazepoxide, diazepam, clobazam and flurazepam are often classified 
as long-acting BZD and have active metabolites with much longer half-lives than the 
parent molecules. Demethylated-diazepam, nordazepam, is a common metabolite of this 
class of BZDs and has a half-life exceeding 200 hours. The advantages of long-acting 
drugs include their ability to produce an effect for anxiety and insomnia by a single 
bedtime dosage, however, it can also have undesired drowsiness and poor coordination 
throughout the day. Therefore, drug accumulation is a common occurrence in multiple 
doses of long-acting BZDs. Rare side effects of these drugs include nausea, dizziness, 
confusion and nightmares. The clearance of these drugs is affected by old age and liver 
diseases.33  
 
Intermediate to short-life BZDs include lorazepam, alprazolam, oxazepam and 
bromazepam. Due to shorter half-lives and generally lack of active metabolites, drug 
accumulation during longer therapy is not prominent. Drug-accumulation is essentially 
non-existent in multiple dose therapy of ultrashort acting BZDs such as midazolam and 
triazolam. Short and ultrashort BZDs are used for hypnotic effects where residual daytime 
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effects need to be avoided. This type of BZDs can also be used for their amnesia effect 
before minor and major surgeries, however, blackout is also one of the considerable side 
effect caused by these drugs.34 Although pharmacokinetic classification is valuable in 
understanding the pharmacological actions of the BZDs, it is not comprehensive to 
explain all of their clinical actions.  
 
Most benzodiazepines are oxidatively metabolized by the P450 enzyme system and 
excreted in urine. Being the substrates of CYP3A4 enzyme, some BZDs can interfere 
with therapeutics that are inhibitor or inducer of this enzyme. Especially, the long-acting 
BZDs with active metabolites can significantly decrease the rate of clearance for these 
therapeutics.35 
 
 1.4 1,4-Benzodiazepine as a privileged scaffold 
 
In 1988 Evans et al., first used the term “privileged scaffold” for the 1,4-benzodiazepine 
core structure to describe their ability to interact with a diverse array of protein receptors 
and therefore able to be utilised in treating different types of diseases.36 Therefore, being 
privileged, BZD derivatives are not only active on the BZD receptors in the CNS, they 
display biological activities towards a wide range of enzymes and protein receptors. Over 
the years, many other properties have been attributed to this class of compounds. Some 
of these include anti–viral, anti-inflammatory, anti-tumour, anti-HIV and anti-microbial 
properties.37   
 
Evans et al., reported that diazepam-like BZD drugs could be modified to develop 
cholecystokinin (CCK)-1 antagonists with increased activity than that of asperlicin, a 
natural compound that was already known to exhibit activity on CCK receptors.38 CCK 
is a class of peptide hormone that is widely found in the gastrointestinal tract (GIT) and 
in the brain, and is responsible for regulating various functions in the GIT and the nervous 
system. In the GIT, CCK is responsible for pancreatic secretion, regulating gastric, bowel 
motility and gallbladder contraction and thereby plays vital roles in GI disorders such as 
pancreatitis, gastric reflux, gastro-paresis and dyspepsia. CCK is associated with anxiety, 
nociperception, memory, learning and satiation in the CNS.39–41 CCK performs its roles 
by binding to G-protein coupled CCK receptors. There are two types of CCK receptors: 
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CCK-1 (previously known as CCK A) and CCK-2 (previously known as CCK B). CCK-
1 shows high binding affinity towards sulfated CCK, whereas, CCK-2 displays equal 
binding affinity towards gastrin and CCK hormones.42   
 
Asperlicin’s (the original compound with a binding affinity towards CCK-1) structure 
was used as a guide to developing the BZD based antagonist, devazepide, with much 
higher binding affinity than asperlicin.7 Devazepide was developed by installing the 5-
phenyl-1,4-benzodiazepin-2-one ring in the left part and 3-hydroxyindoline unit in the 
right part of asperlicin (Figure 1.7). Devazepide became the first specific non-peptide 
BZD antagonist with high binding affinity (IC50 of 0.8 nM) towards CCK-1.  
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Figure 1.7: The development of a CCK-1 antagonist 
 
Modification of privileged scaffolds became a useful approach in medicinal chemistry to 
develop various receptor agonists and antagonists. As a result, a vast number of 1,4-
benzodiazepine analogues were then developed as gastrin/CCK (1 and 2) receptor 
antagonists.40,43–47 Figure 1.8 shows a few selected structures of such CCK receptor 
antagonists.  
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Figure 1.8: 1,4-benzodiazepine CCK receptor antagonists 
 
An extensive number of 1,4-benzodiazepine ligands have been synthesised and used for 
various applications in many other G-protein coupled receptors (GPCRs).  Some of these 
developments are outlined below. 
 
Neurokinin (NK-1) receptors are expressed both in the CNS and peripheral nervous 
system (PNS) and are implicated in inflammation, contraction of muscles, stress signals 
and pain. This class of receptors share intriguing structural similarities with CCK 
receptors. Both classes bind to their non-peptide ligands in a similar pattern between the 
transmembrane helices. Therefore, following the successful development of BZD based 
non-peptide antagonists for CCK-receptors, a number of BZD containing antagonists 
were reported for NK-1 receptors possessing analgesic and anti-inflammatory 
properties.48,49 
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Figure 1.9: Structure of an NK1 receptor antagonist 1.1: Ki 10 nM 
 
Another member of the GPCR family includes the kappa opioid receptors (KORs), a 
highly distributed type of receptors in the areas of the brain involved in cognitive 
function, motivation and emotion. Tifluadom is a BZD analogue that has uses in analgesia 
and in for the treatment of visceral pain due to its activity in the KORs as a κ-selective 
opioid agonist.50  
 
 
 
Figure 1.10:  Structure of a k-selective opioid agonist 
 
BZD derivatives have been developed as antagonists of platelet-activating factor (PAF), 
a phospholipid mediator of platelet aggregation, inflammation and many leukocyte 
functions.51 Additionally, glycoprotein (GP) IIb-IIIa is a key receptor for mediating 
platelet aggregation.52,53 Platelets are activated by various agonists that give rise to the 
binding of fibrinogen and other adhesive ligands to platelet GPIIb-IIIa. As uncontrolled 
aggregation can result in thrombotic disorders, there has been significant effort towards 
developing therapeutics to control platelet aggregation by inhibiting the binding of 
platelet GPIIb-IIIa to fibrinogen.54 The binding occurs via the interaction of activated 
platelet GPIIb-IIIa and the RGD sequence, the key structural motif of fibrinogen that is 
found in the II’ Arg-Gly-Asp β-turn conformation. The 1,4-benzodiazepine scaffold was 
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functionalised to develop RGD sequence mimetics and resulted in numerous potent 
antagonist of platelet GPIIb-IIIa.55,56 
 
 
 
Figure 1.11: Structures of selective glycoprotein GPIIb-IIIa antagonists 
 
Above are the structures of a few BZD based potent inhibitors of platelet aggregation. 
G6788 is synthesised by inserting aspartate and argininyl side chains on the 1,4-
benzodiazepine scaffold and G6249 (IC50 120 nM) is the active metabolite of the double 
prodrug G6788. A glycine side chain on the right part and another extension on the left 
side of the BZD nucleus yielded inhibitor SB-208651 (IC50 65 nM). The activity was 
further improved in SB214857 (lotrafiban) by replacing the benzamide group with less 
basic piperidine group (IC50 28 nM).57,58 
 
Endothelin (ET) was identified as a potent vasoconstrictor in 1988.59 The receptors for 
this class of protein, ETA and ETB are distributed in the smooth muscle cells of the blood 
vessel of kidney, liver, heart, spleen, the smooth muscle of the lungs and parts of the 
brain. They play vital roles in strong vasoconstriction, fibrosis and cell reproduction.60,61 
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ET is implicated in the physiological disorder of kidney, cardiovascular such as renal 
failure, heart attack, hypertension and atherosclerosis.60–62 It is proposed that a reasonable 
approach to developing new treatments and drugs to prevent these disorders could be by 
targeting the ET receptors. Accordingly, in 2004, a potent class of ET receptor antagonists 
were reported based on the 1,4-benzodiazepin-2-one subunit. One of the most potent 
antagonists, 1.2 is presented in Figure 1.12. 1.2 displays over 30 times higher binding 
affinity towards ETA (IC50 2.5 ± 0.4 nM) than ETB (IC50 83.6 ± 8.8 nM).63 
 
 
 
Figure 1.12: Structure of an endothelin antagonist 
 
Bradykinin is a linear peptide hormone implicated in bronchial and vascular smooth 
muscle contraction, vasodilation and causes blood pressure to fall. This peptide performs 
its functions through two types of receptors, namely B1 and B2. Bradykinin induces acute 
pain after tissue injury by serving as the agonist on the B1 and B2 receptors.64 Considerable 
effort has been carried out in order to develop antagonists of these receptors due to the 
physiological disorders caused by bradykinin. Spectroscopic analysis and computational 
studies suggested that the binding of bradykinin to the B2 occurs through the adoption of 
bradykinin C-terminal β-turn conformation comprising residues Ser6-Pro7-Phe8-Arg9. 
The binding affinity of one of the most potent antagonists of the B2 receptors, HOE 140 
(H-D-Arg0- Arg1-Pro2-Hyp3-Gly4-Thi5-Ser6-D-Tic7-Oic8-Arg9-OH) also depended on its 
ability to adopt the β-turn conformation. Since the BZD scaffold was already known to 
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be a good β-turn peptidomimetic, chemists developed a number of B1 and B2 receptors 
antagonists based on the BZD nucleus.65–67 
 
 
 
 
 
Figure 1.13: Structures of selected bradykinin antagonists 
 
BZD derivatives have been reported as oxytocin receptor antagonists. Oxytocin is a 
peptide hormone that plays vital role in premature birth and labour.52,53,68 Other 
applications of BZD core based analogues in GPCRCs include vitronectin receptor 
antagonists,69 fibrinogen receptor antagonist70 anti arrhythmic agents,71 and calcitonin 
gene related peptide receptor antagonists.72  
 
1.4.1 Benzodiazepines as PPI inhibitors 
 
Protein-protein interactions (PPIs) govern many biological processes including 
proliferation, chemotaxis, endocytosis. They play crucial roles in a range of biological 
events including gene transcription, cell growth, viral entry into cells and drug 
resistance.73 Therefore, mis-regulation in PPIs can give rise to a multitude of diseases 
such as diabetes, HIV and many types of cancers, making PPIs an important target to 
design novel drugs. However, inhibiting PPIs with small molecules have proven to be 
rather challenging as protein surfaces are often very large (750 – 4600 Å).74 It has been 
established that many interactions between the larger proteins are facilitated by smaller 
IC50 1.90 nM 
 
IC50 9.2 µM 
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protein secondary structural elements. The secondary structural domains can be often 
recognised by a minimal set of precisely arranged residues that interact on the surface of 
another protein. Three major secondary structural domains that mediate the PPIs are α-
helix, β-turn and β-sheets. There has been substantial effort to design mimetics of these 
crucial targets.75 
 
β-turn motifs are typically composed of four amino acid residues (i, i+1, i+2, i+3 
residues). In proteins, β-turns are one of the major secondary structures that reverse the 
direction of chain propagation and provide a platform for intermolecular interactions with 
other protein surfaces.83 BZDs were described to be privileged scaffolds due to their 
ability to mimic β-turns. Figure 1.14 represents structures of a functionalised BZD 
compound and a β-turn. Through computational modelling it has been shown that the 4 
vectors of the BZD derivative 1-2, 3-4, 5-6 and 7-8 (Figure 1.14) correspond to the 4 
vectors 1’-2’, 3’-4’, 5’-6’, 7’-8’ of a β-turn.76 The RMSD (root mean square deviation) 
values for overlap of the BZD vectors with β-turn vectors were calculated to be less than 
1 Å. These findings have later been reconfirmed and extended to suggest that BZD 
scaffolds are an excellent starting point for designing β-turn mimetics.37  
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Figure 1.14: Structures of a BZD and a β-turn 
 
Given the established record of BZD derived β-turn mimetics, chemists looked to expand 
the range into other protein secondary structural motifs such as the α-helices. 
Approximately one third to half of all protein secondary structures are comprised of α-
helices and thereby frequently found at the interface of PPIs. α-Helix motifs are often 
composed of 10 residues and 3 turns: i, i + 3 or i + 4 and i + 7 positions. There are hotspots 
in PPIs that span over a small space using a relatively small number of hydrophobic 
residues, making them attractive druggable targets. Numerous middle space (MW = 500 
– 1500 Da)77 and Lipinski-like (MW<500 Da) peptidomimetics, mimicking the alpha-
helical arrangements which are abundant in such PPI,  have been made available, such as 
terphenyls and nutlins.78,79 These molecules typically project the i, i+3 or i+4 and i+7 
hydrophobic residues.   
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Figure 1.15: Alpha-helical peptidomimetics 
 
A series of functionalised 1,4-benzodiazepines have also been synthesised as α-helix 
mimetics. The substituents of functionalised BZDs have proven to be in similar spatial 
arrangements as the residues on α-helices (i, i + 3 or i + 4 and i + 7) with calculated 
RMSD value of approximately 1 Å. Tris-substituted 1,4-benzodiazepin-2,5-diones have 
proven to mimic the side chains of the  α-helix motif derived from the tumour suppressor 
protein p53 and thereby inhibit the PPI between HDM2 and p53. The binding of p53-
HDM2 prevents the regular function of p53, therefore, an inhibitor of p53-HDM2 
interaction is a potential lead for new cancer therapeutics. Crystallography and NMR 
studies revealed that optimally functionalised BZD project a similar binding 
conformation as the α-helix motif of p53.75,80,81  
 
 
Kd 80 nM              Kd 4.80 µM 
 
Figure 1.16: Enantiomers of tri-substituted 1,4-benzodiazepin-2,5-diones: P53-HDM2 binding inhibitors 
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1.4.2 Benzodiazepines in epigenetic targets 
 
Epigenetics with the literal meaning “above genetics”, is the study of heritable changes 
that occur in post-translational modification (PTM) giving rise to new phenotypes that 
are not encoded in the DNA sequence.82 In other words, epigenetics are heritable changes 
in the gene expression that do not involve changes in the DNA sequence. Epigenetics 
play significant roles in the development of diseases and therefore are major targets for 
developing potential therapeutics.  
 
The basic, positively charged histone proteins pack the negatively charged DNA strands 
tightly into the nucleus. Approximately 147 base pairs of double-strand DNA are tightly 
wrapped around a histone octamer to form a nucleosome, the basic unit of chromatin.83 
Since 1960, it has been established that histones are modified post-translationally.84 
PTMs simply refers to modification of proteins that occurs after or during protein 
biosynthesis. There are a large number of different histone PTMs that perform various 
crucial roles. These include the regulation of the structure and function of chromatins and 
recruitment of remodelling enzymes that use the energy from ATP hydrolysis to 
reposition the nucleosome. Therefore, PTMs not only influence the transcription of DNA, 
as chromatin is ubiquitous it can also affect many other DNA processes including DNA 
replication, recombination and repair.85 
 
There is a wide range of PTMs such as lysine acetylation, arginine and lysine methylation, 
proline isomerization and serine/threonine/tyrosine phosphorylation that occur in 
proteins.86 Lysine acetylation is one of the most frequently occurring reversible PTMs in 
proteins. This process is highly regulated by the opposing effect of two classes of 
enzymes, histone acetyl transferases (HATs) that generate the acetylation, commonly 
known as the writing process and histone deacetylases (HDACs) that remove the 
acetylation, known as the erasing process (Scheme 1.2).87 HATs transfer an acetyl group 
enzymatically from acetyl-coenzyme A (acetyl CoA) to the ε-amino group of the lysine 
side chain on the histone N-terminal tail region.88 This process leads to neutralisation of 
the positively charged histones and thereby weakens interaction between histones and 
DNA which can cause conformational change and destabilise the nucleosome structure.89 
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Scheme 1. 2: Acetylation and deacetylation process of lysine 
 
1.4.2.1 Bromodomains 
 
Bromodomains (BRDs) are epigenetic reader proteins that recognise the acetyl lysine 
residues on histones and play a crucial role in the regulation of the transcriptional 
process.88 These proteins were first identified in the 1990s in the brahma gene of 
Drosophila melanogaster and are known to be involved with various diseases.90 For 
instance, they are implicated in oncogenic rearrangements that lead to highly oncogenic 
fusion proteins. Aggressive types of cancer may occur due to the presence of oncogenic 
fusion proteins. BRDs are also known to be involved in key transcription factors that 
mediate inflammatory responses. They play vital roles in regulation of the transcription 
of some viral proteins. Therefore, these proteins are attractive targets for understanding 
and developing new drugs for diseases such as cancer, inflammation and viral 
infections.88  
 
In the transcriptional process and chromatin reorganisation, BRDs act by translating the 
chemical modifications executed by HATs and HDACs. Figure 1.17 is the schematic 
representation of HATs writing the acetylation motif which is read by BRD modules and 
erased by HDACs.91  
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Figure 1.17: HAT (writer) acetylating a lysine side chain on histone, read by a BRD and erased by 
HDAC 
 
A total of 61 BRDs have been identified in the human proteome that are present in 46 
different nuclear and cytoplasmic proteins. The BRDs are classified into 8 subfamilies 
based on their structural similarities (Figure 1.18). They consist of 110 amino acids that 
form a highly conserved structure comprised of a left-handed bundle of four α-helices 
(αZ, αA, αB and αC), linked by flexible loops (ZA and BC loops) that form a 
hydrophobic pocket with binding sites for acetyl lysine.92 Despite the high variations of 
the loop region, the binding pockets contain highly conserved amino acid residues that 
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recognise the acetyl lysine motif and form H-bonding in addition to water mediated 
interactions with the acetyl group. 48 of the 61 BRDs contain an asparagine residue in 
their bonding pocket that plays a key role in the recognition of acetylated-lysine motif. 
These are known as typical BRDs. The 13 atypical BRDs contain either a tyrosine, 
threonine or an aspartic acid in the place of asparagine.93,94 
 
Figure 1.18: Bromodomain family tree with 8 subfamilies (I-VIII) 
 
As mentioned, BRDs are linked with various diseases including many types of cancers. 
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Both the functions and dysfunctions of BRDs have proved to be involved in the 
development of diseases. For instance, the human immunodeficiency virus type 1 (HIV-
1) trans-activator protein Tat, that promotes the viral replication in infected cells, is 
activated by the binding of human BRD, p300/CBP-associated factor (PCAF) and 
acetylated lysine residue of Tat.95 On the other hand, dysfunctional BRDs have been 
reported to be involved in diseases, including human squamous carcinoma that is 
developed due to a fusion protein arising through recurrent chromosomal translocation.96  
HDAC inhibitors (HDACis) have been targeting many of the mechanisms linked to 
epigenetic diseases. There are numerous HDAC inhibitors currently used in cancer 
treatments and some developed for CNS disorders, however, most of these are non-
selective.97–99 A better understanding of BRDs in recent years has opened up new 
opportunities to target these interactions. The interaction between the hydrophobic pocket 
of the BRDs and the neutral lysine acetyl motif is relatively weak. These interactions can 
be targeted by small molecules that can interfere with the protein-protein 
interaction.100,101 Combining HDAC inhibitors and BRD inhibitors have proven to be 
useful strategy in some cases.102 Numerous BRD inhibitors have been developed in recent 
years. An overview of the BRD inhibition process is illustrated in Figure 1.19. 
The first potent BRD inhibitors were reported by Structural Genomic Consortium (SGC) 
and the Dana-Faber Cancer Institute,103 followed by a second one at the same time from 
GlaxoSmithKline (GSK).104 The first potent inhibitors (+)-JQ1, a thieno- 1,4-diazepine 
and I-BET726, a 1,4-benzodiazepine inhibited BRDs in the bromodonaim and extra 
terminal (BET) family (Figure 1.20).  
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Figure 1.19: Overview of BRD inhibition. Reader proteins BRDs recognise the acetylated lysine motif on 
histone tails and promote target gene transcription 
 
The BET family consist of BRD2, BRD3, BRD4 and BRDT, which are ubiquitously 
expressed, except BRDT, which is only expressed in testis. They share common features 
comprising two amino-terminal BRDs with a binding site for acetylated lysine and a 
divergent carboxy-terminal recruitment domain.105 BET BRDs are implicated in several 
types of cancers, directly involved in the regulation of cancer related genes such as c-
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MYC. Inhibiting the binding of BET protein with MYC locus reduces the cell 
proliferation.106,107 The BET family is also involved in cell cycle regulations and BRD4 
is known as a global regulator of gene transcription.  
 
High-resolution crystal structures and assay data show that only the (+)-JQ1 enantiomer 
binds to the acetyl lysine motif. The triazolo-nitrogen of JQ1 forms a hydrogen bond with 
the asparagine residue, the binding being stabilised by hydrophobic interactions with BET 
residues. X-ray structures revealed that (+)-JQ1 adopts the conformation that mimics the 
acetyl-lysine motif and binds to the acetylated lysine binding site occupying the entire 
binding pocket. (+)-JQ1 was first reported to bind competitively to acetylated lysine 
binding sites of BRD4 in nuclear protein in testis (NUT) midline carcinoma (NMC). 
BRD4 forms a fusion oncoprotein with NUT that regulates proliferation and 
differentiation of aggressive squamous cell carcinoma. (+)-JQ1, the BRD4 inhibitor, 
produces specific anti-proliferation effect in NMC by displacing the BRD4 
oncoprotein.103 Subsequently, studies published the efficacy of (+)-JQ1 in various solid 
tumours such as colon cancer,108 breast cancer,109 pancreatic cancer,110 prostate cancer,103 
lung cancer,111 glioblastoma112 and in haematological malignancy.113,114 
 
Like JQ1, I-BET726 also binds to the acetyl lysine binding pocket, the important 
hydrogen bonding interaction of acetyl lysine binding to asparagine residue within the 
BRD4-bromodomain is mimicked by the triazole ring of I-BET726.104 This BZD based 
structure also reduces the growth of NMC-malignant cells. GSK started clinical trials of 
I-BET726 for the treatment of NMC malignancy and subsequently extended this to other 
types of cancer such as colorectal cancer, lung cancer, breast cancer and MYCN driven 
solid tumour subjects. 
 
Other BZD based BET bromodomain inhibitors include OTX015 and CPI203. OTX015 
is a BRD2, 3 and 4 inhibitor with stronger anti-proliferation effects than (+)-JQ1 and a 
substantial anti-tumour effect in glioblastoma mouse models.115 It also shows similar 
effects as (+)-JQ1 in leukemic cell lines where it inhibits the cell growth and leads to 
apoptosis. OTX015 is undergoing six clinical trials currently for several types of cancer 
such as NMC, glioblastoma and pancreatic ductal carcinoma.105 CPI203 is still at the 
preclinical stage but shows similar activities with some clinically approved drugs for 
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cancer treatment. For instance, it downregulates MYC expression and inhibits cell 
proliferation in pancreatic neuroendocrine tumours (PanNET).116 
 
 
 
 
Figure 1.20: Structures of selective BZD based BET-bromodomain inhibitors 
 
As stated, HDAC inhibition is another attractive strategy to target epigenetic associated 
diseases such as cancer, inflammation and CNS disorders. So far, 18 different human 
HDACs have been identified, 11 of which are Zn2+ dependent and known as the classical 
HDACs. The rest structurally distinct, silent information regulator related proteins 
(sirtuins) are NAD+ dependent. The classical HDACs are further divided into three 
classes: class I, consisting of HDACs 1, 2, 3 and 8, class IIa comprises HDACs 4, 5, 7, 9, 
class IIb HDACs 6, 10 and class IV HDAC 11. Class III belongs to the sirtuins comprising 
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sirt1 to sirt7.117 A significant effort in the past decade has resulted in a number of 
clinically approved HDACis in the market. These include the hydroxamic acid, vorinostat 
(SAHA),118–121 the cyclic peptide, romidepsine,122–125 the hydroxamate, Belinostat126–128 
and the most recently approved in 2015, Panobinostat (LBH589 or Farydak®) for the 
treatment of multiple myeloma (Figure 1.21).129,130  
 
 
 
 
Figure 1.21: Structures of selected clinically approved HDACis 
However, there is still a genuine need for improved HDACis as most of the known ones 
lack selectivity and specificity, and this leads to various undesired side effects.117 In recent 
years, a number of BZD-based HDAC inhibitors have been reported. Classical HDACis 
typically comprise of a chelating moiety (often a hydroxamate group) that is able to 
chelate the Zn2+ located below the active site, connected through a suitable chain-linker 
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to a hydrophobic recognition motif (cap) that can bind at the enzyme surface. BZD-based 
HDACis have been reported where the BZD ring acts as the cap. Although BZD-based 
HDACis are still at the developmental stage, studies are showing promising aspects for 
generating highly potent and selective BZD derivatives as selective HDACis. There have 
been substantial efforts to design potent HDACis based on a hybridization between 
clinically approved structures such as SAHA and the 5-phenyl-1,4-benzodiazepine 
moiety, with the BZD acting as an aryl cap (the NHOH is deprotonated to NHO-, which 
binds to Zn2+). For instance, 1.3 shows similar inhibitory activities to SAHA against 
HDAC 1 and HDAC 6 (Figure 1.22).131,132  
 
 
 
 
Figure 1.22: HDACi 1.3 - hybrid between SAHA and a 5-phenyl-1,4-benzodiazepine-2-one 
 
Compound 1.4 in Figure 1.23 was reported to show HDAC inhibitory activity and 
antiproliferative against non-small lung cancer cell line H661. A number of similar BZD 
analogues were prepared which showed low micro molar activity in H661 cells.133  
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Figure 1.23: 1,4-benzodiazepine-2,5-dione-based HDAC inhibitor (IC50 6 µM) with antiproliferative 
activities in H661 cells. 
 
Compounds 1.5 and 1.6 in Figure 1.24 are potent HDACis as presented in Table 1.1. 
 
 
 
 
Figure 1.24: BZD based HDACis 
 
Table 1.1: HDAC IC50 (µM) values of BZD analogues 
  HDAC IC50 (µM)   
 1 3 6 8 
1.5 0.46 0.18 0.58 8.11 
1.6 1.44 0.22 2.63 >30 
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The above discussion demonstrates BZDs’ potency in a diverse array of proteins. Due to 
their usefulness in treating various diseases, this project took the notion that BZDs can be 
an effective starting point to develop new therapeutics including addressing currently 
undruggable protein targets. Therefore, a major part of the project focuses on developing 
effective, step and atom-economic protocols to synthesise libraries of BZD analogues.  
 
 1.5 Synthesis routes, limitations & the project aims 
 
Over the last four decades, major efforts have been focused on developing various routes 
to synthesise 1,4-benzodiazepin-2-one analogues. The following paragraphs highlight 
some of the selected synthetic routes in this area and look into the limitations of current 
approaches for the rapid synthesis of BZD-based libraries. Subsequently, drawing from 
these limitations and taking consideration the potency of BZDs, this introductory Chapter 
concludes with a brief discussion on the aims of this body of work. 
 
1.5.1 Solid-phase synthesis  
 
The solid-phase synthesis approach was originally developed by Robert Bruce Merrifield 
to synthesise peptide molecules. In this process, the reactant is bound to an insoluble 
material and synthesised step-by-step in reactant solution. Excess reagents and by-
products can be easily removed and purified by washing. Ellman et al. reported the solid-
phase synthesis of 1,4-benzodiazepin-2-ones where they synthesised the derivatives from 
three different components: amino acids, 2-aminobenzophenones and alkylating agents. 
Functionalised N-Fmoc aminoenzophenones are coupled with 4-
hydroxymethylphenoxyacetic acid (HMP) cleavable linker.134,135 As shown in Scheme 
1.2, the HMP linker may be coupled through a carboxyl or hydroxyl group on either 
phenyl ring of the 2-aminobenzophenone. Support-bound starting material 1.8a and 1.8b 
are then synthesised by coupling the linker-substituted 2-aminobenzophenones 1.7a and 
1.7b to the solid support using standard amide-bond coupling methods.  
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Scheme 1.3: The amide coupling of linker-substituted aminobenzophenones 1.7a, 1.7b to the solid 
support. 
 
The Fmoc protecting group is removed from 1.8 by treating with piperidine in DMF to 
initiate the synthesis of BZD derivatives. The resulting unprotected aminobenzophenone 
is coupled to an α-N-Fmoc amino acid fluoride as presented in Scheme 1.4. Due to the 
poor nucleophilicity of 2-aminobenzophenones, regular activation methods for solid-
phase peptide synthesis are not successful in this coupling step. However, the activated 
R-α-N-Fmoc amino acid fluorides developed by Carpino et al. proved to be effective, 
even for electron-deficient 2-aminobenzophenones, in this coupling step to yield the 
amide product 1.9 (Scheme 1.4).136,137 The amine is deprotected by removing the Fmoc 
group by treatment with piperidine. The resulting free amine is further treated with 5% 
acetic acid in N-methylpyrrolidinone (NMP) at 60 oC to afford 1.10, which can 
subsequently be alkylated using an excess of a base that is basic enough to fully 
deprotonate the anilide. Lithiated acetanilide or lithiated 5-(phenylmethyl)-2-
oxazolidinone are generally employed in this step to provide the fully functionalised 1,4-
benzodiazepines 1.11. The final benzodiazepine products 1.12 is afforded in high yield 
by treatment with acid cleavage cocktail trifluoroacetic acid (TFA)/dimethyl 
sulphide/H2O (95:5:5).138–140 
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Scheme 1.4: Solid-phase synthesis of 1,4-benzodiazepin-2-one derivatives 
 
Additionally, Ellman et al. employed a Stille coupling reaction to synthesise a variety of 
aminoaryl ketones on solid support, in order to increase the diversity of 1,4-
benzodiazepines prepared via solid-phase synthesis. The Stille coupling is particularly 
advantageous as it requires mild conditions, tolerates a diverse functionality and a wide 
range of commercially available acid chlorides, which are compatible with the BZD 
synthesis protocol, although tin reagents are rather toxic.141,142 
 
There are five steps involved in preparing 2-(4-biphenyl)isopropyloxycarbonyl (Bpoc) 
protected (aminoaryl) stannane 1.13 from commercially available substances. HMP 
linker is generally employed for solid support and the reaction is carried out using a 
diverse range of acid chlorides in the presence of the catalyst Pd2(dba)3.CHCl3. The Bpoc 
group is removed from 1.14 by quick treatment with 3% TFA in dichloromethane (DCM). 
The 1,4-benzodiazepine analogues 1.15 are then synthesised from the deprotected 
support-bound aminoaryl ketone according to previously described synthesis route.  
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Scheme 1.5: Stille coupling reaction employed for synthesis of aminoaryl ketones 1.14 
 
Although this synthetic route is more versatile with respectable  yields ranging from 52% 
to 82%, it is a lengthy process requiring over 10 steps.143,144 
 
1.5.2 Multicomponent synthesis 
 
A multicomponent reaction (MCR) is a versatile synthetic way to develop a diverse range 
of substituted heterocyclic molecules. Among the various routes employed in 
synthesising libraries of substituted 1,4-benzodiazepin-2-ones the isocyanide-based 
MCRs are certainly noteworthy. The Ugi four-component reaction (Ugi-4CR) is the key 
step of such MCRs. The reactions are performed with anthranilic or N-Boc protected 
anthranilic acids, aldehydes and convertible isocyanides. Bifunctional reagents such as 
ethyl glyoxylate, N-Boc-α-aminoaldehydes,  α-amino acid esters, and N-Boc-1,2-
diaminoethanes have been used in alternative Ugi-4CR syntheses of BZDs.145–147 
 
Scheme 1.6 shows that a1,4-benzodiazepin-2-one derivative 1.21 synthesised by a Ugi-
4CR, followed by deprotection and cyclisation steps. The substituted aminophenyl ketone 
1.16 performs as an amine component in the Ugi-4CR. The mechanism is proposed to 
involve the formation of an imine with by condensation of the amine with the aldehyde 
1.17. This is followed by the addition of the carboxylic acid and imino carbon across the 
isocyanide carbon. The resulting acylated isoamide undergoes further rearrangement to 
afford the Ugi product 1.20. The next step involves removing the Boc-group from the Ugi 
product 1.20, which then undergoes condensation with the orthogonal ketone group to 
afford the 1,4-benzodiazepine derivatives 1.21 in the cyclization step. 
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Scheme 1.6: Multicomponent synthesis of BZDs 
It is noteworthy that the reaction occurs in one-pot, i.e., the crude Ugi product 1.20 is not 
isolated, rather treated with TFA in 1,2-dichloroethane (DCE) in situ to give the final 
product.145  
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1.5.3 Multi-step synthesis method 
 
Spencer et al. reported a three-step synthesis of substituted BZD derivative 1.23 by 
modifying previous protocols using the coupling reagent 2-ethoxy-1-ethoxycarbonyl-1,2-
dihydroquinoline (EEDQ).138,149 The readily available 2-aminobenzophenone is coupled 
with Boc-NHCH(R2)CO2H at room temperature.  
 
 
Scheme 1.7: A multi-step synthesis method for 5-phenyl-1,3-hidyro-2H-1,4-benzodiazepin-2-one 
 
The carbonyl group in the BocNHCH(R2)CO2H undergoes an amide coupling with the 
amino group in the ortho- keto aniline 1.22 and undergoes further cyclisation to form a 
seven-membered ring, with the aid of EEDQ coupling agent resulting in the BZD 
analogues 1.23.  1.23 can be further functionalised by alkylating at the N-1 position. 1.24 
is achieved by treating 1.23 with sodium hydride and then alkylating with appropriate 
alkyl or benzyl halide.73,150 
 
 1.6 Limitations for efficient library synthesis of BZD analogues 
 
The efficiency in rapid library synthesis of privileged scaffolds such as BZDs is still 
extremely desirable in medicinal chemistry as many of the BZD synthesis routes require 
several steps making it inefficient for library generation. For instance, a typical route for 
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functionalising at the C-5 position requires several repetitive steps as shown in Scheme 
1.8.  
 
 
  
 
Scheme 1.8: A typical synthetics route to 5-(2-arylohenyl)-1,3-hidyro-2H-1,4-benzodiazepin-2-one 
 
The reaction starts with the aniline 1.25 and two equivalents of appropriate Grignard 
reagent. It requires cold temperature, dry conditions and an acidic workup to yield the 
ortho-keto aniline 1.23, which further undergoes coupling and cyclisation steps as 
described in Scheme 1.7 and 1.8. Therefore, library generation of varying ortho-
substituted BZDs becomes inefficient since such groups need to be introduced early in 
the synthetic sequence followed by repetitive coupling and cyclisation steps every time.  
 
In an attempt to address this issue, Spencer et al., have previously reported a synthetic 
route for ortho-substituted BZDs (Scheme 1.9). Firstly, BZD-based palladacycles were 
synthesised by C-H activation and treating 1.28 with Na2PdCl4 in ethanol resulting in the 
palladacycle 1.29. The insoluble palladacycle affords the soluble product 1.30 by 
treatment with triphenylphosphine in DCM, which could be fully characterised by e.g. 1H 
NMR and X-ray crystallography. 1.28 underwent stoichiometric reaction with 
arylboronic acid (Scheme 1.9) to afford the ortho-arylated BZD analogue 1.31.152 
 
 54 
 
 
 
Scheme 1.9: Ortho-arylated BZD analogue from BZD-based palladacycles 
 
Subsequently, the group was able to undertake preliminary steps towards the synthesis of 
ortho-arylated BZDs using a palladacycle in a catalytic C-H activation. The catalytic 
reaction employed 1.5 equivalent of diaryliodonium tetrafluoroborate, 5 mol% palladium 
(II) acetate in acetic acid at 100 oC for 12 hours with the highest conversion rate of 61%. 
However, the product proved to be inseparable from starting material and potential side 
products (Scheme 1.10) using standard column chromatography.151 
 
 
 
Scheme 1.10: Attempted ortho-arylation of BZD by catalytic C-H activation 
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1.7 Thesis aims 
 
Following from the above discussion, it can be argued 
that despite the commercial availability and the 
traditional synthetic routes for 5-phenyl-1,3-dihydro-
2H-1,4-benzodiazepin-2-one skeletons, one-step 
synthestic routes for BZD-based library generation 
are yet to be successfully developed. Therefore, this 
project seeks to explore the possibility and scope for 
efficient and atom economical BZD-based library 
generation routes avoiding any repetitive steps. In 
doing so, the project initially focused on the ortho-
arylation (introduction of R1) following on from our 
previous work.151 Subsequently, it explores the scopes 
for one-step N-arylations as shown in Figure 1.25 (R1, 
R2). 
 
In Chapter 2, microwave irradiation is employed rather than thermal heating. Although 
microwave chemistry involves a high equipment cost, the benefits of controlled 
microwave heating are manifold: 152–157 
 
- It significantly reduces the reaction times, often with higher yields and fewer side 
reactions. 
 
- The reaction can be heated at higher temperatures and the choice of solvent is not 
dependent on its boiling point but rather on the dielectric properties of the reaction 
medium. This can be easily adjusted by addition of ionic liquids. 
 
- The overall process is more energy efficient than thermal heating, since the whole 
reaction medium is heated simultaneously as opposed to thermal heating where, 
reaction mixture in contact with the vessel is heated first (Figure 1.26). 
 
 
Figure 1. 25: Functionalisation scopes 
of BZD skeleton for library generation 
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- Microwave irradiation is amenable to parallel and automatic sequential processing 
format. 
 
 
 
Figure 1. 26: Microwave heating (left) vs Thermal heating (right) after 60 seconds153   
 
Therefore, higher efficiency in library generation of ortho-arylated BZDs is anticipated 
to be achieved by microwave heating. The comparison of thermal heating vs microwave 
is shown in Scheme 1.11. 
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Scheme 1.11: Reaction time in conventional heating vs. microwave heating for synthesis of C-H arylated 
BZDs 
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Chapter 2 
 
Late Stage C H Activation of a Privileged Scaffold; 
Synthesis of a Library of Benzodiazepines 
 
2.1 Introduction 
 
The need for efficiency in rapidly producing a library of closely related analogues cannot 
be understated in drug discovery where natural product derivatives or complex molecules, 
often synthesized by multistep reactions, are fine-tuned to respond to inadequacies in 
terms of their biological activity, selectivity, pharmacokinetics and undesirable toxicity. 
The ability to add functionality to a bioactive core at the final or penultimate synthetic 
step to enable SAR (structure activity relationship) studies can drive efficiency and speed 
up hit-to-lead and lead optimization strategies.1–18 
 
We have a longstanding interest in benzodiazepines, which represent an important class 
of privileged heterocycles.19–30 Typical routes for the introduction of different R groups 
at the 5-position are inefficient since such reactions are early in the synthetic sequence 
and this is followed by repetitive coupling/cyclisation chemistries (Scheme 2.1). 
 
NH2
N
Ar
MgBr
i) 2
NH2
O
Ar
N
H
N
O
Ar
FmocHN
O
OH
i)
ii) Base.
iii) Cyclisation.
ii) H+
coupling agent
 
 
Scheme 2.1: A classical route to a 5-(2-arylphenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one 
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2.2 Results and Discussion 
 
Our approach sought to vary the 5-substituent via a late-stage C-H activation; in essence, 
a benzodiazepine building block could be synthesized, once, on a large scale using the 
coupling/cyclisation chemistry discussed above, then functionalised by introducing the 
new functional groups at the last step, adding atom and step economy31 to the library 
generation process. Our test case was the chelation-assisted C-H activation of the valium 
(diazepam)-like benzodiazepine 2.0 using palladacycle chemistry to afford 2.1 (Table 
2.1).32–37 Notably, Cintrat et al. showed ortho-halogenation34 of the aryl group can be 
achieved under similar conditions, opening up the possibility of carrying out 
complementary Pd-mediated couplings.  A rapid screen of conditions showed that this 
was indeed possible and that the best conversion, by 1H NMR, involved acetic acid as 
solvent, microwave conditions,38,39 and employed 5 mol% Pd(OAc)2 as catalyst and 
Ph2IBF440–44 as the arylating agent (Entry 2). The use of a mesityl-aryl iodonium salt gave 
similar promising results (entry 4) and will be exploited further on (vide infra). Further 
iterations (Table 2), including the use of classical, thermal conditions, lower Pd loadings, 
additives such as silver salts,45,46 led to no or little improvement, although higher 
concentrations of reagents led to slightly improved conversions (Entry 9, Table 2). 
 
Table 2. 1: Optimization of C-H Activationa  
 
 
 
Entry R-X 
(equiv.) 
Catalyst (mol%) Time 
(h) 
Temp. 
(oC) 
Conversion by 
NMR/ LC-MS 
(%) 
Solvent 
1 Ph2IBF4 
(1.5) 
- 1.5 125 0 AcOH 
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2 Ph2IBF4 
(1.5) 
Pd(OAc)2 (5) 1.5 125 55 AcOH 
3 Ph2IBF4 
(1.5) 
Pd(OAc)2 (5) 1.5 125 5 EtOAc 
4 [Mes-I-
Ar]OTf 
(1.5) 
Pd(OAc)2 (5) 1.5 125 50 AcOH 
5 PhBr (1.5) Pd(OAc)2 (5) 1 125 0 AcOH 
6 Ph2IBF4 
(1.5) 
 
1.5 125 22 AcOH 
7 Ph2IBF4 
(2.5) 
(MeCN)2PdCl2 (10) 1.5 125 0 AcOH 
8 Ph2IBF4 
(1.5) 
(MeCN)2PdCl2 (10) 1.5 125 0 DCE 
9 Ph2IBF4 
(1.5) 
Pd(OAc)2 (2.5) 1.5 125 0 AcOH 
 
a All reactions were conducted in a CEM Explorer microwave unless stated otherwise. DCE = 1,2-
dichloroethane; EtOAc = ethyl acetate.  
b Conventional heating. 
 
Table 2.2: Further optimisation studiesa 
 
 
Entry Ph2IBF4 
(equiv.) 
Pd(OAc)2 
(mol%) 
Time 
(h) 
Temp. 
(oC) 
Conversion 
by NMR (%) 
AcOH 
(mL) 
1b 1.5 5 64 100 44 5 
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2c 1.5 100 1.5 125 0 5 
3 1.5 5 0.15+0.5 150+120 28 5 
4 1.5 10 2 130 47 5 
5 2.5 10 1 125 51 5 
6 1.5 10 1 125 48 5 
7 1.5 5 1.25 125 54 5 
8 1.5 10 1.5 125 55 5 
9 1.5 5 1 125 58 2.5 
10 1.5 5 1 125 33 2.5 
11d 1.5 5 1 125 20 2.5 
12f 1.5 5 1 125 16 2.5 
13g 1.5 5 1 125 54 2.5 
14h 1.5 5 1 125 30 2.5 
 
a All reactions were conducted in a CEM Explorer microwave unless stated otherwise.  
b Conventional heating. 
c Analysis of the crude mixture, after PPh3 treatment, showed evidence that the palladacycle was formed. 
d Ag2O added (1.5 equiv.) 
e Ag2O added (1.5 equiv. at 100 oC) 
f AgOAc added (1.5 equiv. at 100 oC) 
f AcOH degassed, reaction under N2. 
h AcOH dry and degassed, reaction under N2. 
 
Using our “optimised” approach we synthesised a range of benzodiazepines via this last-
stage C-H activation protocol. Critically, we were able to confirm the C-H activation had 
occurred in the ortho-position as anticipated from a chelation controlled process by 
crystal-structure determinations of a number of products (vide infra)47 (Figure 2.1). We 
synthesized a series of fluorinated aromatics 2 due to their advantageous role of fluorine 
in medicinal chemistry.48 
 72 
 
 
 
 
 
Figure 2.1: Ortho-arylated BZDs 
 
At this stage, we were still somewhat dissatisfied with this approach since we were 
confined to a N1-methyl substituent in the final product. A broader diversity would be 
enabled by having a N-protected or free amide group, enabling further diversification 
after the arylation reaction. To test the more attractive latter hypothesis, preliminary 
studies on the C-H activation process were carried out (Scheme 2.2) and established that:  
 
i) Stoichiometric chelation-assisted C-H activation is indeed possible on the 
unsubstituted N-H amide since the palladacycle 3 can be isolated.  
 
ii) An attempted interception of the palladacycle intermediate, by a Pd-catalyzed 
H/D exchange,49–52 did not lead to the expected product 1c. Instead, this reaction, 
furnished uniquely the D2-methylene compound 1d, which could also be 
accomplished in the absence of the metal catalyst by merely stirring in deuterated 
acetic acid in the microwave, similar to previous findings on H/D exchange.53,54  
 
 73 
 
 
 
Scheme 2.2: Deuteration and palladation reactions of 2.0 
 
Next, we produced a library of benzodiazepines lacking a N1-substituent (Figure 2.2). Of 
note, we were also able to produce arylated nordazepam55 derivatives; nordazepam was 
quickly made by an adaptation of a microwave protocol.56 Yields, in general, were 
superior to those for their N-methylated analogues, mainly with electron-poor arenes, 
whereas the electron-rich 2.14 and 2.15 were made in moderate yield (note: the 2-tolyl 
derivative of 2.15 did not form, possibly due to steric effects). We were pleasantly 
surprised to be able to obtain the hindered 2.16, albeit under more forcing microwave 
conditions. Analogue 2.18 was made from a mesityl-containing aryliodonium salt. 
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a 150 oC reaction temperature 
b From its corresponding (4-nitrophenyl(2,4,5-trimethylphenyl)iodonium salt 
 
Figure 2.2: C-H arylation of 1N-H benzodiazepines 
 
Products were separated initially using a mass-triggered LC-MS protocol57 but we found 
that a reversed-phase LC-MS method was equally useful and we were also able to recover 
traces of unreacted starting material. Moreover, diarylated products were often observed 
in the crude reaction mixtures and, in some cases, were isolated (Scheme 2.3, e.g. 2.20, 
2.22). The yields of 2.21 and 2.22 were rather low, even when using a higher temperature. 
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Scheme 2.3: Nordazepam mono- and diarylations 
 
Following our earlier studies (Scheme 2.2) we prepared a small number of deuterated 
derivatives 2.23 – 2.25 (Scheme 2.4). Compound 2.23, the deuterated analogue of 2.10, 
was prepared by a one-pot dual C-H activation/H-D exchange by simply carrying out the 
catalytic arylation protocol in CD3CO2D whereas 2.24, 2.25 were simply prepared by 
stirring the arylated precursors in CD3CO2D in a microwave.  
 
Deuterated benzodiazepine products were easily characterized, e.g. by 2H NMR (note: 
ND tends to revert to NH when the samples are concentrated in air). 
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Scheme 2.4: Synthesis of deuterated elaborated benzodiazepines 
 
A further illustration of the diversity achievable is that the resulting elaborated 
nordazepam derivatives can be N-alkylated to afford substituted diazepam and pinazepam 
analogues (Figure 2.3). 
 
 
 
Figure 2.3: Ortho-arylated pharmaceuticals 
 
 
 77 
 
2.3 Conclusion 
 
In summary, we have synthesized a library of benzodiazepines via a late stage C-H 
activation reaction. Future work may aim to address the drug-likeness of the products by 
e.g. lowering their clogP, testing their biological activity, as well as applying this 
chemistry to other systems related to benzodiazepines such as benzotriazepines.58–62 
CCDC-1422838 – CCDC-1422844 contain the supplementary crystallographic data for 
this paper. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.  
 
2.4 Experimental details for Chapter 2 
 
All commercially purchased materials and solvents were used without further purification 
unless specified otherwise. NMR spectra were recorded on a Varian VNMRS 500 (1H 
500 MHz, 13C 126 MHz) and VNMRS 400 (19F 376 MHz, 2H 61 MHz and 31P 162 MHz) 
spectrometer and prepared in deuterated solvents such as CDCl3 and DMSO-d6. 1H and 
13C chemical shifts were recorded in parts per million (ppm). Multiplicity of 1H-NMR 
peaks are indicated by s – singlet, d – doublet, dd – doublets of doublets, t – triplet, pt – 
pseudo triplet, q – quartet, m – multiplet and coupling constants are given in Hertz (Hz).  
Electronspray ionisation – high resolution mass spectra (ESI-HRMS) were obtained using 
a Bruker Daltonics Apex III where Apollo ESI was used as the ESI source. All analyses 
were conducted by Dr A. K. Abdul-Sada. The molecular ion peaks [M]+ were recorded 
in mass to charge (m/z) ratio.  
 
LC-MS spectra were acquired using Shimadzu LC-MS 2020, on a Gemini 5 m C18 110 
Å. column. All X-ray analyses were performed at the UK National Crystallography 
Services, Southampton. All elemental analyses were carried out at the Elemental Analysis 
Service, London Metropolitan University. Purifications were performed by flash 
chromatography on silica gel columns or C18 columns using a Combi flash RF 75 PSI, 
ISCO unit. 
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2.4.1 1-Methyl-5-biphenyl-2-yl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
(2.1)  
1-Methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (0.15 g, 0.60 mmol), 
diphenyliodonium tetrafluoroborate (0.33 g, 0.90 mmol) and palladium (II) acetate (6.0 
mg, 5 mol %) were combined in glacial acetic acid (4 mL) and stirred for 1h at 125 oC in 
the microwave. Thereafter the cooled reaction mixture was filtered over celite, washed 
with dichloromethane (DCM, 10 mL) and concentrated under reduced pressure. The 
residue was dissolved in DCM (20 mL), washed with saturated sodium bicarbonate and 
the organic layer was collected using a (hydrophobic frit) phase separator. The solution 
was concentrated under reduced pressure to yield an orange product. The crude material 
was purified by flash chromatography (30 g C18, acetonitrile: water, 30 % to 90 %) and 
the final product was obtained (0.083 g, 43 %) as a white powder.  
 
1H-NMR (500 MHz) CDCl3: δ = 7.78 (d, J = 7.9 Hz, 1H), 7.57 – 7.49 (m, 2H), 7.29 (dd, 
J = 6.7, 1.9 Hz, 1H), 7.26 – 7.20 (m, 1H), 7.11 – 7.20 (m, 3H), 6.93 (d, J = 6.4 Hz, 2H), 
6.91 – 6.85 (m, 3H), 4.83 (d, J = 11.0 Hz, 1H), 3.73 (d, J = 11.0 Hz, 1H), 3.15 (s, 3H). 
13C-NMR (126 MHz) CDCl3: δ = 173.0, 169.5, 139.5, 143.0, 142.1, 140.8, 138.6, 131.2, 
130.5, 130.1, 130.0, 129.1, 128.7 (2C), 127.7 (2C), 127.5, 126.4, 123.3, 120.0, 56.3, 34.9.  
 
HRMS-ESI (m/z) Calculated for C22H18N2O [+H] +: 327.1497, found: 327.1492. 
Elemental Analysis: Calculated for C22H18N2O (%): C, 80.96, H, 5.56, N, 8.58; found: C, 
80.69, H, 5.32, N, 8.54. 
 
2.4.2 1-Methyl-5-(2’-fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (2.2) 
This was synthesised on a 0.31 mmol scale by the same procedure as 2.1 and bis(2-
fluorophenyl)iodonium tetrafluoroborate (0.18 g, 0.49 mmol) was used instead of 
diphenyliodonium tetrafluoroborate. The final product was obtained (0.052 g, 49 %) as a 
white powder.  
 
1H-NMR (500 MHz) CDCl3: δ = 7.78 (dd, J= 5.8, 3.4 Hz, 1H), 7.52 (dd, J= 5.8, 3.4 Hz, 
2H), 7.31 (dd, J= 5.5 Hz, 3.5 Hz, 1H), 7.26 – 7.23 (m, 1H), 7.11 – 7.05 (m,  1H), 6.98 
(dd, J= 7.9, 1.7 Hz, 1H), 6.96-6.92 (m, 2H), 6.91 (d, J= 3.1 Hz, 1H), 6.89 (d, J= 2.2 Hz, 
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1H), 6.72 (pt, J= 9.0 Hz, 1H), 4.78 (d, J= 10.8 Hz, 1H), 3.68 (d, J= 10.8 Hz, 1H), 3.14 (s, 
3H).  
 
13C-NMR (126 MHz) CDCl3: δ = 171.7, 170.3, 158.9 (d, 1JFC = 247.3 Hz), 142.8, 139.7, 
135.6, 131.5 (d, 3JFC = 3.1 Hz), 130.8, 130.4, 129.9, 129.4, 129.1, 128.6 (d, 3JFC = 8.0 
Hz), 128.5 (d, 2JFC = 16.1 Hz), 128.4, 128.1, 123.4, 123.3 (d, 4JFC = 3.8 Hz), 119.9, 115.0 
(d, 2JFC = 22.3 Hz), 56.6, 35.0. 19F-NMR (376 MHz) CDCl3: δ = -115.1 (1F).  
HRMS-ESI (m/z) Calculated for C22H17FN2O [+H] +: 345.1398, found: 345.1390. 
Elemental Analysis: Calculated for C22H17FN2O (%): C, 76.73, H, 4.98, N, 8.13; found: 
C, 76.59, H, 4.82, N, 8.26. 
 
2.4.3 1-Methyl-5-(3’-fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (2.3) 
The same procedure as 2.1 was used but bis(3-fluorophenyl)iodonium tetrafluoroborate 
(0.18 g, 0.90 mmol) was used instead of diphenyliodonium tetrafluoroborate. The final 
product was obtained (0.111 g, 54 %) as a white powder.  
 
1H-NMR (500 MHz) DMSO-d6: δ 7.70 (d, J = 7.4 Hz, 1H), 7.64 – 7.55 (m, 2H), 7.35 (d, 
JFH = 7.4 Hz, 2H), 7.18 – 7.13 (m, 2H), 6.96 (pt, J = 7.8 Hz, 2H), 6.74 (d, J = 7.8 Hz, 
1H), 6.71 (d, JFH = 7.7 Hz, 1H), 6.67 (d, J = 10.0 Hz, 1H), 4.55 (d, J = 11.0 Hz, 1H), 3.69 
(d, J = 11.0 Hz, 1H), 3.10 (s, 3H). 
 
13C-NMR (126 MHz) DMSO-d6: δ = 172.3, 168.9, 162.1 (d, 1JFC = 244.9 Hz), 143.1 (d, 
3JFC = 11.9 Hz), 140.5, 138.6, 132.1, 131.1, 130.4, 130.4 (d, 3JFC = 4.3 Hz), 130.3, 129.4, 
129.1, 128.3, 125.0, 124.0, 121.1, 115.5 (d, 2JFC = 21.8 Hz), 114.0 (d, 2JFC = 20.9 Hz), 
114.1, 56.6, 34.8. 19F-NMR (376 MHz) DMSO-d6: δ = -113.4 (1F).  
 
HRMS-ESI (m/z) Calculated for C22H17FN2O [+H] +: 345.1398, found: 345.1394. LCMS 
purity (UV) = 96 %, retention time (tR) 15.13 min. 
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2.4.4 1-Methyl-5-(3’-trifluoromethylbiphenyl-2-yl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (2.4) 
The same procedure as 2.1 was used but bis(3-trifluoromethylphenyl)iodonium 
tetrafluoroborate (0.45 g, 0.90 mmol) was used instead of diphenyliodonium 
tetrafluoroborate. The final product was obtained (0.095 g, 40 %) as a white powder.  
 
1H-NMR (500 MHz) CDCl3: δ = 7.79 – 7.74 (m, 1H), 7.57 – 7.53 (m, 2H), 7.36 (d, J = 
7.7 Hz, 1H), 7.26 – 7.23 (m, 2H), 7.21 (d, J = 7.7 Hz, 1H), 7.17 (d, J = 1.6 Hz, 1H), 7.16 
– 7.14 (m, 1H), 6.94 – 6.85 (m, 3H), 4.81 (d, J = 10.9 Hz, 1H), 3.69 (d, J = 10.9 Hz, 1H), 
3.10 (s, 3H).  
 
13C-NMR (126 MHz) CDCl3: δ = 172.0, 169.7, 142.8, 141.9, 140.6, 139.1, 132.3, 131.2, 
130.4, 130.6, 130.0 (q, 2JFC = 29.9 Hz), 129.9, 129.8, 129.1, 128.1, 127.9, 125.2 (q, 3JFC 
= 3.2 Hz), 123.7 (q, 1JFC = 272.9 Hz), 123.4, 123.1 (q, 3JFC = 3.8 Hz), 119.9, 56.7, 34.7. 
19F-NMR (376 MHz) CDCl3: δ = -63.3 (s, 3F).  
 
HRMS-ESI (m/z) Calculated for C23H17F3N2O [+H] +: 395.1366, found: 395.1381. 
LCMS purity (UV) = 95 %, tR 18.14 min. 
 
2.4.5 1-Methyl-5-(4’-trifluoromethylbiphenyl-2-yl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (2.5) 
The same procedure as 2.1 was used but bis(4-trifluoromethylphenyl)iodonium 
tetrafluoroborate (0.45 g, 0.90 mmol) was used instead of diphenyliodonium 
tetrafluoroborate. The final product was obtained (0.104 g, 44 %) as a white powder.  
 
1H-NMR (500 MHz) DMSO-d6: δ = 7.72 – 7.68 (m, 1H), 7.61-7.58 (m, 2H), 7.48 (d, J = 
7.9 Hz, 2H), 7.37 – 7.28 (m, 2H), 7.12 – 7.05 (m, 3H), 6.97 – 6.90 (m, 1H), 6.74 (dd, J = 
7.9, 1.6 Hz, 1H), 4.54 (d, J = 10.9 Hz, 1H), 3.64 (d, J = 10.9 Hz, 1H), 3.04 (s, 3H).  
 
13C-NMR (126 MHz) DMSO-d6: δ = 171.6, 169.2, 145.0, 143.1, 140.3, 139.2, 131.8, 
131.0, 130.4, 130.2, 129.7, 129.5 (2C), 128.9, 128.6, 127.6 (q, 2JFC = 31.6 Hz), 125.1 (q, 
3JFC = 3.7 Hz, 2C), 124.6 (q, 1JFC = 272 Hz), 123.9, 120.8,  56.9, 34.7. 19F-NMR (376 
MHz) CDCl3: δ = -61.15 (s, 3F). 
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HRMS-ESI (m/z) Calculated for C23H17F3N2O [+H] +: 395.1366, found: 395.1374. 
Elemental Analysis: Calculated for C23H17F3N2O (%): C, 70.04, H, 4.34, N, 7.10; found: 
C, 69.95, H, 4.38, N, 6.98. 
 
2.4.6 Palladacycle (2.6) 
5-Phenyl-1H-1,4-diazepin-2(3H)-one (0.20 g, 0.85 mmol) and sodium 
tetrachloropalladate (0.23 g, 0.78 mmol) were combined in ethanol (20 mL) for 48 hours 
at room temperature. The orange precipitate was filtered and washed with further ethanol 
(10 mL) and chloroform (10 mL). An orange solid powder was collected after drying in 
vacuo (0.25 g, 69 %). The product was too insoluble for NMR analysis.  The product 
from above reaction (0.15 g, 0.33 mmol) and triphenylphosphine (0.08 g, 0.30 mmol) 
were combined in dichloromethane (10 mL) and stirred overnight. The resulting 
unwanted precipitate was filtered through celite and the filtrate was concentrated in 
vacuo. Hexane was added to the concentrated crude product to induce precipitation, 
filtered and dried under vacuum. The product was obtained (0.12 g, 63 %) as a yellow 
solid.  
 
1H-NMR (500 MHz) CDCl3: δ = 9.29 (s, 1H), 7.81 – 7.75 (m, 6H), 7.72 (d, J = 8.4 Hz, 
2H), 7.59 (pt, J = 7.8 Hz, 1H), 7.44 – 7.41 (m, 3H), 7.39 – 7.34 (m, 5H), 7.30 (d, J = 8.4 
Hz, 2H), 7.04 (d, J = 7.7 Hz, 1H), 6.83 (pt, J = 7.3 Hz, 1H), 6.57 – 6.49 (m, 2H), 6.15 (d, 
J = 12.2 Hz, 1H), 3.81 (d, J = 12.2 Hz, 1H).  
 
13C-NMR (500 MHz) CDCl3: δ = 182.3, 171.6, 159.1, 147.8, 138.6, 135.5 (2C), 135.4 
(4C), 135.0 (2C), 132.5, 131.4, 131.2, 131.0, 130.9, 130.6 (2C), 130.4, 130.2, 128.0 (4C), 
127.9 (2C), 124.3, 123.5, 123.4, 121.9, 53.9. 31P-NMR (162 MHz) CDCl3: δ = 42.4 (s, 
1P).  
 
HRMS-ESI (m/z) Calculated for C33H26ClN2OPPd [-Cl-]+ : 603.0812 , found: 603.0837. 
Elemental Analysis: Calculated for C33H26ClN2OPPd.0.9 CH2Cl2(%): C, 56.88, H, 3.91, 
N, 3.91; found: C, 56.69, H, 4.02, N, 3.84. 
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2.4.7 5-Phenyl-5-biphenyl-2-yl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
(2.9) 
5-Phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (0.14 g, 0.59 mmol), 
diphenyliodonium tetrafluoroborate (0.33 g, 0.90 mmol) and palladium (II) acetate (6.0 
mg, 5 mol %) were combined in degassed glacial acetic acid (4 mL) and stirred for  1h at 
125 oC. Thereafter the cooled reaction mixture was filtered over celite, washed with DCM 
(10 mL) and concentrated under reduced pressure. The residue was dissolved in DCM 
(20 mL), washed with saturated sodium bicarbonate and the organic layer was collected 
using a (hydrophobic frit) phase separator. The solution concentrated under reduced 
pressure to yield an orange product. The crude material was purified by flash 
chromatography (30 g C18, acetonitrile: water, 30 % to 90 %). Starting material, 5-
phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one was recovered (0.031 g, 0.13 mmol) 
and the final product was obtained (0.079 g, 56 %) as a white powder. 
 
1H-NMR (500 MHz) DMSO-d6: δ = 10.33 (s, 1H), 7.57 (dd, J = 7.1, 1.8 Hz, 1H), 7.55 
(dd, J = 7.5, 1.6 Hz, 1H), 7.52 – 7.47 (m, 1H), 7.34 (dd, J = 7.6, 1.4 Hz, 1H), 7.19 – 7.14 
(m, 1H), 7.12 – 7.04 (m, 3H), 6.95 – 6.90 (m, 2H), 6.79 (dd, J = 7.9, 6.4 Hz, 2H), 6.74 – 
6.70 (m, 1H), 4.04 (s, 2H).  
 
13C-NMR (126 MHz) DMSO-d6: δ = 172.3, 169.7, 141.5, 140.5, 139.8, 139.2, 131.3, 
130.9, 130.2, 130.1, 129.4, 128.6 (2C), 128.3, 128.0 (2C), 127.6, 127.1, 122.6, 120.7, 
57.3.  
 
HRMS-ESI (m/z) Calculated for C21H16N2O [+H] +: 313.1335, found: 313.1336. 
Elemental Analysis: Calculated for C21H16N2O (%): C, 80.75, H, 5.16, N, 8.97; found: C, 
80.64, H, 5.06, N, 9.08. 
 
2.4.8 5-(2’-Fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
(2.10) 
The same method as 2.9 was used but bis(2-fluorophenyl)iodonium tetrafluoroborate 
(0.36 g, 0.90 mmol) was used instead of diphenyliodonium tetrafluoroborate. Starting 
material, 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one, was recovered (0.021 g, 
0.09 mmol) and the final product was obtained (0.114 g, 69 %) as a white powder.  
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1H-NMR (500 MHz) DMSO-d6: δ = 10.25 (s, 1H), 7.59 – 7.49 (m, 3H), 7.35 – 7.30 (m, 
1H), 7.22 (ddd, J= 6.7, 2.0 Hz, 3JFH = 8.4 Hz, 1H), 7.16 – 7.10 (m, 1H), 6.97 – 6.87 (m, 
3H), 6.86 – 6.85 (m , 2H), 6.83 (d, J = 8.2 Hz, 1H), 3.97 (s, 2H).  
 
13C-NMR (126 MHz) DMSO-d6: δ = 175.9, 174.6, 163.4 (d, 1JFC = 247.3 Hz), 145.3, 
143.8, 140.3, 136.2 (d, 4JFC = 3.2 Hz), 136.1, 135.8, 135.4, 134.5, 134.4 (t, 3JFC = 4.1 Hz), 
133.1, 132.9 (d, 2JFC = 15.6 Hz), 132.7, 128.9 (d, 3JFC = 3.5 Hz), 127.4, 125.5, 120.1, 
120.0 (d, 2JFC = 22.1 Hz), 62.1. 19F-NMR (376 MHz) DMSO-d6: δ = -113.4 (1F).  
 
HRMS-ESI (m/z) Calculated for C21H15FN2O [+H] +: 331.1241, found: 331.1232. 
Elemental Analysis: Calculated for C21H15FN2O (%): C, 76.35, H, 4.58, N, 8.48;        
found: C, 76.23, H, 4.68, N, 8.47. 
 
2.4.9 5-(3’-Fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
(2.11) 
The same method as 2.9 was used but bis(3-fluorophenyl)iodonium tetrafluoroborate 
(0.36 g, 0.90 mmol) was used instead of diphenyliodonium tetrafluoroborate. Starting 
material, 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one was recovered (0.045 g, 
0.19 mmol) and the final product was obtained (0.095 g, 72 %) as a white powder. 
 
1H-NMR (500 MHz) DMSO-d6: δ = 10.36 (s, 1H), 7.59 (dd, J = 1.8 Hz, 3JFH= 7.2, 1H), 
7.56 (dd, J = 7.4, 1.7 Hz, 1H), 7.54 (dd, J = 7.4, 1.5 Hz, 1H), 7.36 (dd, J = 7.5, 1.5 Hz, 
1H), 7.21 (ddd, J = 8.5, 1.6 Hz, 3JFH= 7.1, 1H), 7.15 – 7.10 (m, 1H), 6.92 – 6.87 (m, 1H), 
6.86 – 6.80 (m, 2H), 6.73 (dd, J = 7.7, 1.6 Hz, 2H), 6.70 (d, J = 10.0 Hz, 1H), 4.05 (s, 
2H).  
 
13C-NMR (126 MHz) DMSO-d6: δ = 172.0, 169.8, 161.8 (d, 1JFC = 243.9 Hz), 142.9 (d, 
3JFC = 8.0 Hz), 140.2, 139.8, 139.3, 131.5, 130.9, 130.2, 130.1, 129.9 (d, 3JFC = 8.4 Hz), 
129.5, 128.2, 128.1, 124.9, 122.7, 120.6, 115.3 (d, 2JFC = 21.9 Hz), 113.9 (d, 2JFC = 21.0 
Hz), 57.3. 19F-NMR (376 MHz) DMSO-d6: δ = -113.4 (1F).  
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HRMS-ESI (m/z) Calculated for C21H15FN2O [+H] +: 331.1241, found: 331.1239. LCMS 
purity (UV) = 100 %, tR 12.19 min. 
 
2.4.10 5-(3’-Trifluoromethylbiphenyl-2-yl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (2.12) 
The same method as 2.9 was used but bis(3-trifluoromethylphenyl)iodonium 
tetrafluoroborate (0.45 g, 0.90 mmol) was used instead of diphenyliodonium 
tetrafluoroborate. Starting material, 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one, 
was recovered (0.022 g, 0.09 mmol) and the final product was obtained (0.119 g, 63 %) 
as a white powder.  
 
1H-NMR (500 MHz) DMSO-d6: δ = 10.22 (s, 1H), 7.63 – 7.53 (m, 3H), 7.42 (d, J = 7.9 
Hz, 1H), 7.38 (dd, J = 7.4, 1.5 Hz, 1H), 7.34 (pt, J = 7.9 Hz, 1H), 7.20 – 7.14 (m, 3H), 
6.85 – 6.79 (m, 2H), 6.75 (dd, J = 8.2, 1.5 Hz, 1H), 4.03 (s, 2H).  
 
13C-NMR (126 MHz) DMSO-d6: δ = 171.7, 169.8, 141.6,  140.1, 139.9, 139.2, 132.6, 
131.5, 130.9, 130.2 (2C),  129.6, 129.1, 129.0 (q, 2JFC = 31.8 Hz), 128.4, 128.0, 125.0 (q, 
3JFC = 3.7 Hz), 124.3 (q, 1JFC = 272.6 Hz), 123.8 (q, 3JFC = 3.7 Hz), 122.6, 120.6, 57.4. 
19F-NMR (376 MHz) DMSO-d6: δ = -61.2 (s, 3F).  
 
HRMS-ESI (m/z) Calculated for C22H15F3N2O [+H] +: 381.1209, found: 381.1211. 
Elemental Analysis: Calculated for C22H15F3N2O.0.3 CH2Cl2 (%): C, 66.00, H, 3.87, N, 
6.90; found: C, 66.19, H, 3.97, N, 6.99. 
 
2.4.11 5-(4’-Trifluoromethylbiphenyl-2-yl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (2.13) 
The same method as 2.9 was used but bis(4-trifluoromethylphenyl)iodonium 
tetrafluoroborate (0.45 g, 0.90 mmol) was used instead of diphenyliodonium 
tetrafluoroborate. Starting material, 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one, 
was recovered (0.036 g, 0.15 mmol) and the final product was obtained (0.097 g, 58%) 
as a white powder.  
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1H-NMR (500 MHz) DMSO-d6: δ = 10.46 (s, 1H), 7.62 (pt, J = 6.7 Hz, 2H), 7.59 – 7.53 
(m, 1H), 7.44 (d, J = 7.9 Hz, 2H), 7.40 (d, J = 7.5 Hz, 1H), 7.18 (pt, J = 7.6 Hz, 1H), 7.13 
(d, J = 7.8 Hz, 2H), 6.80 (d, J = 7.8 Hz, 2H), 6.75 (d, J = 7.9 Hz, 1H), 4.05 (s, 2H).  
 
13C-NMR (126 MHz) DMSO-d6: δ = 171.7, 169.9, 144.6, 140.1, 139.7, 139.3, 131.5, 
131.2, 130.4, 130.3, 129.5, 129.4 (2C), 128.5, 128.1, 127.7 (q, 2JFC = 31.6 Hz), 124.9 (q, 
3JFC = 4.1 Hz, 2C), 124.6 (q, 1JFC = 272.8 Hz),  122.8, 120.6, 57.3. 19F-NMR (376 MHz) 
DMSO-d6: δ = -61.0 (s, 3F).  
 
HRMS-ESI (m/z) Calculated for C22H15F3N2O [+H] +: 381.1209, found: 381.1206. 
Elemental Analysis: Calculated for C22H15F3N2O (%): C, 69.47, H, 3.98, N, 7.36; found: 
C, 69.30, H, 3.88, N, 7.44. 
 
2.4.12 5-(4’-Methoxybiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-
one (2.14) 
The same method as 2.9 was used but 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
(0.095 g, 0.40 mmol) and bis(4-methoxyphenyl)iodonium tetrafluoroborate (0.26 g, 0.60 
mmol) were used instead of diphenyliodonium tetrafluoroborate. Starting material, 5-
phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one was recovered (0.016 g, 0.07 mmol) 
and the final product was obtained (0.039 g, 35%) as a white powder.  
 
1H-NMR (500 MHz) CDCl3: δ = 8.36 (s, 1H), 7.69 (d, J = 7.4 Hz, 1H), 7.53 – 7.42 (m, 
2H), 7.28 (d, J = 7.5 Hz, 1H), 7.16 (pt, J = 7.7 Hz, 1H), 6.94 – 6.80 (m, 4H), 6.70 (d, J = 
8.1 Hz, 1H), 6.61 (d, J = 8.1 Hz, 2H), 4.30 (s, 2H), 3.72 (s, 3H).  
 
13C-NMR (126 MHz) CDCl3: δ = 173.2, 170.5, 158.6, 141.6, 137.3, 133.3, 131.2, 130.0, 
130.1, 129.9, 129.8 (2C), 129.7, 129.6, 127.0, 123.2, 120.0, 113.1 (2C), 110.0, 56.3, 55.3.  
 
HRMS-ESI (m/z) Calculated for C22H18N2O [+H] +: 343.1441, found: 343.1447. LCMS 
purity (UV) = 99 %, tR 10.49 min. 
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2.4.13 5-(3’-Methylbiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-
one (2.15) 
The same method as 2.9 was used but 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
(0.100 g, 0.42 mmol) and (3-methylphenyl)(2,4,6-trimethylphenyl)iodonium triflate 
(0.31 g, 0.62 mmol) were used instead of diphenyliodonium tetrafluoroborate. Starting 
material, 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one was recovered (0.012 g, 
0.05 mmol) and the final product was obtained (0.070 g, 58%) as a white powder.  
 
1H-NMR (500 MHz) CDCl3: δ = 8.41 (s, 1H), 7.71 (dd, J = 8.0, 1.9 Hz, 1H), 7.53 – 7.45 
(m, 2H), 7.31 – 7.28 (m, 1H), 7.17 – 7.12 (m, 1H), 6.96 – 6.91 (m, 1H), 6.88 – 6.81 (m, 
3H), 6.78 – 6.73 (m, 2H), 6.67 (dd, J = 8.0, 1.0 Hz, 1H), 4.29 (s, 2H), 2.18 (s, 3H).  
 
13C-NMR (126 MHz) CDCl3: δ = 173.2, 170.7, 142.2, 140.6, 139.6, 137.4, 137.1, 131.0, 
129.9, 129.8, 129.7, 129.6, 129.5, 128.8, 127.4, 127.3, 127.2, 125.8, 123.0, 119.9, 56.4, 
21.1.  
 
HRMS-ESI (m/z) Calculated for C22H18N2O [+H] +: 327.1492, found: 327.1483. 
Elemental Analysis: Calculated for C22H18N2O (%): C, 80.96, H, 5.56, N, 8.5; found: C, 
80.93, H, 5.42, N, 8.65. 
 
2.4.14 3-Benzyl-5-(2’-fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (2.16) 
The same method as 2.9 was used but 3-benzyl-5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (0.17 g, 0.52 mmol) instead of 5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one, and bis(2-fluorophenyl)iodonium tetrafluoroborate (0.29 g, 0.78 
mmol) was used instead of diphenyliodonium tetrafluoroborate and the reaction was 
carried out at 150 oC. The final product was obtained (0.090 g, 41%) as a white powder.   
 
1H-NMR (500 MHz) CDCl3: δ = 7.83 (s, 1H), 7.57 – 7.43 (m, 3H), 7.37 – 7.24 (m, 5H), 
7.24 – 6.87 (m, 7H), 6.73 (pt, J = 9.1 Hz, 1H), 6.64 (d, J = 8.0 Hz, 1H), 3.75 – 3.54 (m, 
2H), 3.35-3.40 (m, 1H).  
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13C-NMR (126 MHz) CDCl3: δ = 170.3, 170.1, 158.8 (d, 1JFC = 247.1 Hz), 139.9, 139.2, 
136.8, 135.8, 131.7, 131.2, 130.8, 130.5, 129.9, 129.8 (2C), 129.5, 128.9 (d, 3JFC = 8.2 
Hz), 128.5 (d, 3JFC = 4.0 Hz), 128.4, 128.3, 128.2 (2C), 128.1, 126.1, 123.3, 120.0, 114.9 
(d, 2JFC = 21.8 Hz), 64.8, 37.4. 19F-NMR (376 MHz) DMSO-d6: δ = -115.9 (s, 1F).  
 
HRMS-ESI (m/z) Calculated for C28H21FN2O [+H] +: 421.1711, found: 421.1709. 
Elemental Analysis: Calculated for for C28H21FN2O (%): C, 79.98, H, 5.13, N, 6.66; 
found: C, 79.85, H, 4.97, N, 6.73. 
 
2.4.15 7-Chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
(Nordazepam) 
5-Chloro-2-aminobenzophenone (0.621 g, 3.15 mmol), N-(3-dimethylaminpropyl)-N-
ethylcarbodiimide hydrochloride (0.604 g, 3.15 mmol) and N-Boc-glycine (0.550 g, 3.15 
mmol) were combined in toluene (6 mL) and irradiated in the microwave for 30 min at 
150 oC. Trifluoroacetic acid (2 mL) was then added to the mixture and it was irradiated 
for a further 20 min at 150 oC. The cooled solution was neutralized by an aqueous 3 N 
NaOH solution (50 mL) and extracted with dichloromethane (3 x 30 mL). The organic 
layers were dried over MgSO4 and evaporated. The crude material was purified by 
column chromatography (ethyl acetate: DCM, 10% to 40%) and the final product was 
obtained (0.29 g, 34 %) as a white solid powder. 
 
1H-NMR (500 MHz) CDCl3: δ = 9.41 (s, 1H), 7.53 (d, J = 7.6 Hz, 2H), 7.50 – 7.44 (m, 
2H), 7.41 (pt, J = 7.5 Hz, 2H), 7.30 (d, J = 2.4 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 4.33 (s, 
2H).  
 
13C-NMR (126 MHz) CDCl3: δ = 171.7, 169.8, 138.7, 137.3, 131.8, 130.7, 130.6, 129.6 
(2C), 128.9, 128.5, 128.4 (2C), 122.6, 56.5.  
 
HRMS-ESI (m/z) Calculated for C15H11ClN2O [+H] +: 271.0633, found: 271.0627. 
LCMS purity (UV) = 100 %, tR 12.40 min. 
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2.4.16 7-Chloro-5-biphenyl-2-yl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
(2.17) 
The same method as 2.9 was used but 7-chloro-5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (0.16 g, 0.6 mmol) was used instead of 5-phenyl-1,3-dihydro-2H-
1,4-benzodiazepin-2-one. Starting material, 7-chloro-5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one, was recovered (0.010 g, 0.04 mmol) and the final product was 
obtained (0.118 g, 61%) as a white powder.  
 
1H-NMR (500 MHz) DMSO-d6: δ = 10.44 (s, 1H), 7.63 (dd, J = 7.6, 1.5 Hz, 1H), 7.61 – 
7.57 (m, 1H), 7.54 – 7.50 (m, 1H), 7.36 (dd, J = 7.6, 1.4 Hz, 1H), 7.21 (dd, J = 8.7, 2.5 
Hz, 1H), 7.12 (dd, J = 8.1, 6.5 Hz, 2H), 7.10 – 7.05 (m, 1H), 6.91 (dd, J = 7.2, 1.7 Hz, 
2H), 6.78 (d, J = 8.7 Hz, 1H), 6.63 (d, J = 2.4 Hz, 1H), 4.09 (s, 2H).  
 
13C-NMR (126 MHz) DMSO-d6: δ = 170.8, 169.4, 141.6 140.5, 139.0, 138.2, 131.2, 
131.1, 130.5, 130.3, 129.6, 128.5 (2C), 128.4, 128.2 (2C), 127.8, 127.2, 126.4, 122.7, 
57.4.  
 
HRMS-ESI (m/z) Calculated for C21H15ClN2O [+H] +: 347.0946, found: 347.0947. 
Elemental Analysis: Calculated for C21H15ClN2O (%): C, 72.73, H, 4.36, N, 8.08; found: 
C, 72.63, H, 4.26, N, 8.15. 
 
2.4.17 7-Chloro-5-(4’-nitrobiphenyl-2-yl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (2.18) 
The same method as for 2.17 was used but (4-nitrophenyl)-(2,4,6-trimethylphenyl)
iodonium triflate (0.47 g, 0.9 mmol) was used instead of of diphenylliodonium 
tetrafluoroborate. Starting material, 7-chloro-5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one recovered (0.040 g, 0.15 mmol) and the final product was obtained 
(0.099 g, 55 %) as a white powder.  
 
1H-NMR (500 MHz) DMSO-d6: δ = 10.51 (s, 1H), 8.08 – 7.91 (m, 3H), 7.70 – 7.65 (m, 
1H), 7.64 – 7.61 (m, 1H), 7.44 – 7.40 (m, 1H), 7.27 (dd, J = 8.8, 2.6 Hz, 1H), 7.18 – 7.13 
(m, 2H), 6.76 (d, J = 8.8 Hz, 1H), 6.69 (d, J = 2.6 Hz, 1H), 4.09 (s, 2H).  
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13C-NMR (126 MHz) DMSO-d6: δ = 170.1, 169.4, 144.6, 140.1, 139.6, 139.1, 138.1, 
131.5, 131.1, 130.7, 130.1, 129.9, 129.7, 129.1, 128.6, 126.7, 125.4, 124.9, 123.8, 122.6, 
57.4.  
 
HRMS-ESI (m/z) Calculated for C21H14N3O3 [+H] +: 392.0013, found: 392.0008. LCMS 
purity (UV) = 94 %, tR 17.03 min. 
 
2.4.18 7-Chloro-5-(2’-fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (2.19) 
The same method as 2.17 was used but bis(2-fluoropheny)liodonium tetrafluoroborate 
(0.36 g, 0.9 mmol) was used instead of diphenylliodonium tetrafluoroborate. Starting 
material, 7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one, was recovered 
(0.010 g, 0.04 mmol) to give the final product (0.13 g, 64%) as a white powder and the 
diarylated product 5c’ was collected as a white powder (0.026 g, 10%).  
 
1H-NMR (500 MHz) DMSO-d6: δ = 10.37 (s, 1H), 7.66 – 7.61 (m, 1H), 7.59 – 7.54 (m, 
2H), 7.34 (d, J = 7.3 Hz, 1H), 7.31 – 7.23 (m, 1H), 7.21 – 7.11 (m, 1H), 6.97 (pt, J = 7.5 
Hz, 1H), 6.91 (d, J = 9.5 Hz, 1H), 6.87 (dd, J = 6.8 Hz, 3JFH =  8.6 Hz, 1H), 6.82 (d, J = 
8.6 Hz, 1H), 6.76 (d, J = 2.5 Hz, 1H), 4.03 (s, 2H).  
 
13C-NMR (126 MHz) DMSO-d6: δ = 169.8, 169.5, 158.7 (d, 1JFC = 244.8 Hz), 139.82, 
138.1, 135.5, 131.4, 131.2, 131.1, 130.9, 130.2, 129.8 (d, 3JFC = 8.0 Hz), 129.6, 129.2, 
128.6 (d, 3JFC = 9.8 Hz), 128.0 (d, 2JFC = 15.6 Hz), 126.6, 124.3 (d, 4JFC = 3.5 Hz), 122.7, 
115.3 (d, 2JFC = 22.1 Hz), 57.3. 19F-NMR (376 MHz) DMSO-d6: δ = -120.4 (1F).  
 
HRMS-ESI (m/z) Calculated for C21H14FN2O [+H] +: 365.0851, found: 365.0847. 
Elemental Analysis: Calculated for C21H14FN2O (%): C, 69.14, H, 3.87, N, 7.68; found: 
C, 68.93, H, 3.70, N, 7.64. 
 
2.4.19 7-Chloro-5-(2,2’-difluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (2.20) 
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1H-NMR (500 MHz) CDCl3: δ = 7.77 (s, 1H), 7.59 (pt, J = 7.7 Hz, 1H), 7.44 (d, J = 7.7 
Hz, 2H), 7.26 – 7.00 (m, 8H), 6.87 (pt, J = 9.2 Hz, 2H), 6.49 (d, J = 8.6 Hz, 1H), 3.85 (s, 
2H).  
 
13C-NMR (126 MHz) CDCl3: δ = 168.3, 167.7, 159.0 (d, 1JFC = 243.8 Hz, 2C), 139.0, 
137.9, 136.4, 131.9, 131.8, 131.1 (2C), 131.0 (2C), 129.9 (d, 3JFC = 8.1 Hz, 2C), 129.5, 
129.3, 128.5, 128.3, 128.2, 126.5, 124.3 (d, 4JFC = 3.5 Hz, 2C), 122.6, 115.4 (d, 2JFC = 
22.1 Hz, 2C), 56.9. 19F-NMR (376 MHz) DMSO-d6: δ = -113.7 (2F).  
 
HRMS-ESI (m/z) Calculated for C27H17ClF2N2O [+H] +: 459.1070, found: 415.1072. 
LCMS purity (UV) = 97 %, tR 20.38 min. 
 
2.4.20 7-Chloro-5-(4’-trifluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (2.21) 
The same method as 2.17 was used but diphenyliodonium tetrafluoroborate (0.45 g, 0.9 
mmol) was used instead of diphenyliodonium tetrafluoroborate and the reaction 
temperature was 145 oC. Starting material, 7-chloro-5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one, was recovered (0.020 g, 0.066 mmol) and the final product 5d was 
obtained as a white powder (0.053 g, 24%). The diarylated product 5d’ (0.045 g, 15%) 
was collected as a brown powder. 
 
1H-NMR (500 MHz) CDCl3: δ = 8.27 (s, 1H), 7.76 (d, J = 7.0 Hz, 1H), 7.59 (dd, J = 6.7, 
6.0 Hz, 2H), 7.38 (d, J = 7.8 Hz, 2H), 7.33 (d, J = 7.0 Hz, 1H), 7.11 (d, J = 7.9 Hz, 3H), 
6.82 (s, 1H), 6.59 (d, J = 8.6 Hz, 1H), 4.30 (s, 2H).  
 
13C-NMR (126 MHz) CDCl3: δ = 171.1, 170.1, 144.5, 140.6, 138.9, 136.0, 131.4, 130.4, 
130.3, 129.8, 129.2, 129.0 (q, 2JFC = 33.0 Hz), 129.0 (2C), 128.7, 128.4, 124.5 (q, 3JFC = 
3.7 Hz, 2C), 124.0 (q, 1JFC = 272.4 Hz), 121.3, 121.2, 56.4. 19F-NMR (376 MHz) DMSO-
d6: δ = -63.2 (s, 3F).  
 
HRMS-ESI (m/z) Calculated for C22H14 ClF3N2O [+H] +: 415.0820, found: 415.0819. 
LCMS purity (UV) = 95 %, tR 19.59 min. 
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2.4.21 7-Chloro-5-(4,4”-trifluorobiphenyl-2,6-yl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (2.22) 
 
1H-NMR (500 MHz) DMSO-d6: δ = 10.43 (s, 1H), 7.69 (pt, J = 7.7 Hz, 1H), 7.57 (d, J = 
8.0 Hz, 4H), 7.50 (d, J = 7.7 Hz, 2H), 7.30 (d, J = 8.0 Hz, 4H), 7.26 (d, J = 8.8 Hz, 1H), 
6.91 (d, J = 2.4 Hz, 1H), 6.72 (d, J = 8.8 Hz, 1H), 3.71 (s, 2H).  
 
13C-NMR (126 MHz) DMSO-d6: δ = 168.4, 168.3, 145.0, 141.1, 138.3, 137.4, 131.6, 
130.6 (2C), 130.2, 129.9 (4C), 129.6, 128.4, 127.9 (q, 2JFC = 33.0 Hz, 2C), 126.7, 125.1 
(q, 3JFC = 3.7 Hz, 4C), 124.6 (q, 1JFC = 270.4 Hz, 2C), 122.5, 120.0, 118.8, 56.9. 19F-NMR 
(376 MHz) DMSO-d6: δ = -65.2 (s, 6F).  
 
HRMS-ESI (m/z) Calculated for C29H17ClF6N2O [+H] +: 559.1006, found: 559.1003. 
LCMS purity (UV) = 96 %, tR 24.92 min. 
 
2.4.22 1-Methyl-5-biphenyl-2-yl-1,3-dihydro-2D-1,4-benzodiazepin-2-one 
(2.7)  
Compound 2.1 was stirred in acetic acid–d4 at 125 oC in the microwave for 1 hour. 
Thereafter, the reaction was cooled, and the white product was collected in quantitative 
yield by evaporating the solvent.   
 
1H-NMR (500 MHz) CDCl3: δ = 7.81 – 7.72 (m, 1H), 7.56 – 7.45 (m, 2H), 7.27 (d, J = 
7.6 Hz, 1H), 7.22 (pt, J = 7.9 Hz, 1H), 7.09 – 6.98 (m, 3H), 6.92 – 6.82 (m, 5H), 3.13 (s, 
3H).  
 
13C-NMR (126 MHz) CDCl3: δ = 173.2, 169.4, 142.9, 142.2, 138.4, 131.2, 130.5, 130.2, 
130.0, 129.9, 129.2, 128.7 (2C), 127.7 (2C), 127.5, 126.5, 123.4, 120.1, 55.5 (m), 34.9. 
2H-NMR (61 MHz) CH3CO2H: δ = 4.95 (1H), 3.94 (1H).  
HRMS-ESI (m/z) Calculated for C21H16D2N2O [+H] +: 329.1617, found: 329.1614. 
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2.4.23 5-(2’-Fluorobiphenyl-2-yl)-1,3-dihydro-2D-1,4-benzodiazepin-2-one 
(2.23) 
The same method as for the synthesis of 2.19 was used but acetic acid-d4 (4 mL) was 
used instead of acetic acid as the solvent. Final product was obtained (0.09 g, 47 %) as a 
white powder.  
 
1H-NMR (500 MHz) CDCl3: δ = 8.93 (s, 1H), 7.76 – 7.69 (m, 1H), 7.55 – 7.47 (m, 2H), 
7.36 – 7.29 (m, 1H), 7.18 (pt, J = 7.7 Hz, 1H), 7.05 – 6.83 (m, 5H), 6.72 (m, 2H).  
 
13C-NMR (126 MHz) CDCl3: δ = 172.3, 171.0, 158.8 (1JCF= 246.8 Hz), 140.2, 137.3, 
135.7, 131.4 (d, 3JFC = 3.9 Hz), 131.2, 130.8, 130.0, 129.8, 129.5, 129.1 (d, 3JFC = 7.9 
Hz), 128.6, 128.1 (d, 2JFC = 15.4 Hz), 127.9, 123.3 (d, 4JFC = 3.6 Hz), 123.2, 120.2, 114.9 
(d, 2JFC = 22.2 Hz), 56.0 (m). 2H-NMR (61 MHz) CH3CO2H: δ = 4.27 (s, 2H).  
 
HRMS-ESI (m/z) Calculated for C21H13D2FN2O [+H] +: 333.1210, found: 333.1362.  
LCMS purity (UV) = 97 %, tR 11.06 min.     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
2.4.24 5-Biphenyl-2-yl-1,3-dihydro-2D-1,4-benzodiazepin-2-one (2.24) 
The same method as 2.7 was used and the product was collected in quantitative yield.  
 
1H-NMR (500 MHz) DMSO-d6: δ = 10.31 (s, 1H), 7.58 – 7.52 (m, 2H), 7.48 (d, J = 7.4 
Hz, 1H), 7.33 (d, J = 7.4 Hz, 1H), 7.15 (pt, J = 7.4 Hz, 1H), 7.10 – 7.03 (m, 3H), 6.91 (d, 
J = 7.1 Hz, 2H), 6.81 – 6.75 (m, 2H), 6.70 (d, J = 7.9 Hz, 1H).  
 
13C-NMR (126 MHz) DMSO-d6: δ = 173.2, 169.6, 141.5, 140.5, 139.8, 139.2, 131.3, 
130.9, 130.2, 130.1, 129.4, 128.6 (2C), 128.3, 128.0 (2C), 127.6, 127.1, 122.6, 120.7, 
57.0. 2H-NMR (61 MHz) CH3CO2H: δ = 4.44 (2H). 
 
HRMS-ESI (m/z) Calculated for C21H14D2N2O [+H] +: 315.1445, found: 315.1453. 
 
2.4.25 5-(3’-Trifluorobiphenyl-2-yl)-1,3-dihydro-2D-1,4-benzodiazepin-2-
one (2.25) 
The same method as 2.17 was used and the product was collected in quantitative yield.   
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1H-NMR (500 MHz) DMSO-d6: δ = 10.20 (s, 1H), 7.61 – 7.51 (m, 3H), 7.43 – 7.28 (m, 
3H), 7.19 – 7.10 (m, 3H), 6.80 (dd, J = 8.4, 5.1 Hz, 2H), 6.72 (d, J = 7.9 Hz, 1H).  
 
13C-NMR (126 MHz) DMSO-d6: δ = 171.7, 169.8, 141.6, 140.1, 139.9, 139.2 (2C), 132.6, 
131.5, 130.9, 130.2, 129.6, 129.1 (q, 2JFC = 31.7 Hz), 129.0, 128.4, 127.9, 124.9 (q, 3JFC 
= 3.7 Hz), 124.3 (q, 1JFC = 273.2 Hz), 123.8 (q, 3JFC = 3.8 Hz), 122.6, 120.5, 56.5 (CD2). 
2H-NMR (61 MHz) CH3CO2H: δ = 4.40 (2H).  
 
HRMS-ESI (m/z) Calculated for C22H13D2F3N2O [+H] +: 315.1445, found: 315.1453 
 
2.4.26 7-Chloro-1-methyl-5-(2’-fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (2.26) 
7-Chloro-5-(2’-fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one 5c (0.035 
g, 0.096 mmol) was dissolved in MeOH/THF (1 mL). Potassium carbonate (0.079 g, 0.57 
mmol), iodomethane (0.03 mL, 0.48 mmol) were added and the reaction was stirred 
overnight at room temperature (rt). Thereafter the reaction mixture was filtered over 
celite, washed through with dichloromethane and concentrated under reduced pressure. 
The final product was collected as a white powder (0.033 g, 91%).  
 
1H-NMR (500 MHz) CDCl3: δ = 7.79 – 7.73 (m, 1H), 7.54 (dd, J = 6.3, 3.1 Hz, 2H), 7.34 
– 7.28 (m, 1H), 7.19 (dd, J = 8.9, 2.5 Hz, 1H), 7.12 – 7.05 (m, 1H), 6.96 – 6.88 (m, 3H), 
6.83 (d, J = 8.9 Hz, 1H), 6.80 – 6.73 (m, 1H), 4.79 (d, J = 10.9 Hz, 1H), 3.66 (d, J = 10.9 
Hz, 1H), 3.11 (s, 3H).  
 
13C-NMR (126 MHz) CDCl3: δ = 170.3, 169.3, 158.9 (d, 1JFC = 247.7 Hz), 141.3, 138.9, 
135.6, 131.4, 131.3, 131.0 (d, 3JFC = 8.0 Hz), 130.8, 130.4, 129.9, 128.9, 128.8 (d, 3JFC = 
8.0 Hz), 128.7, 128.5 (d, 2JFC = 15.9 Hz), 128.3, 123.4 (d, 4JFC = 3.6 Hz), 121.4, 115.1 (d, 
2JFC = 22.2 Hz), 56.7, 35.0.  
 
HRMS-ESI (m/z) Calculated for C22H16ClFN2O [+H]+: 379.1008, found: 379.1012.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
LCMS purity (UV) = 98 %, tR 18.09 min. 
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2.4.27 7-Chloro-1-prop-2-yn-1-yl-5-biphenyl-2-yl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (2.27) 
7-Chloro-5-biphenyl-2-yl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (0.025 g, 0.072 
mmol) was dissolved in MeOH/THF (1 mL). Potassium carbonate (0.060 g, 0.43 mmol), 
propargyl bromide (0.027 mL, 0.30 mmol) were added and the reaction was stirred 
overnight at rt. Thereafter the reaction mixture was filtered over celite, washed through 
with dichloromethane and concentrated under reduced pressure. The final product was 
collected as a white powder (0.024 g, 88 %).  
 
1H-NMR (500 MHz) DMSO-d6: δ = 7.64 (d, J = 7.6 Hz, 1H), 7.59 (pt, J = 7.6 Hz, 1H), 
7.53 (pt, J = 7.6 Hz, 1H), 7.41 (dd, J = 8.9, 2.3 Hz, 1H), 7.34 – 7.27 (m, 2H), 7.19 – 7.12 
(m, 3H), 6.86 (d, J = 7.0 Hz, 2H), 6.67 (d, J = 2.5 Hz, 1H), 4.81 (d, J = 17.5 Hz, 1H), 
4.58 (d, J = 10.9 Hz, 1H), 3.74 (d, J = 10.9 Hz, 1H), 3.43 (d, J = 17.5 Hz, 1H), 3.37 (s, 
1H).  
 
13C-NMR (126 MHz) DMSO-d6: δ = 170.8, 168.1, 141.7, 140.9, 140.7, 138.2, 131.6, 
131.3, 130.1, 130.7, 130.4, 128.6 (2C), 128.4 (2C), 128.3, 128.1, 128.0, 127.3, 121.8, 
80.2, 75.2, 56.7, 38.0.  
 
HRMS-ESI (m/z) Calculated for C24H17ClN2O [+H] +: 385.1102, found: 385.1108. 
LCMS purity (UV) = 96 %, tR 20.90 min. 
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Chapter 3 
 
Combining Sanford Arylations on Benzodiazepines 
with the Nuisance Effect 
 
3.1 Introduction 
 
There is a growing impetus for atom economical routes to high value end products 
employing late stage functionalization (LSF) processes.1 These are particularly desirable 
in medicinal chemistry since they increase diversity and chemical space and enable rapid 
SAR (structure activity relationship) and ADME-Tox (Absorption, distribution, 
metabolism, elimination-toxicity) feedback that is key to costly, high attrition, drug 
development.  Late stage C-H activation is a powerful tool in generating novel 
compounds for biological evaluation.2–15 Chapter 2 described a palladium-catalyzed 
ortho-arylation of benzodiazepines employing iodonium salts in acetic acid under 
microwave irradiation.16,17 The harsh conditions, relatively high commercial cost, and 
multistep synthesis of iodonium salts18–20 (ArIAr’+), coupled with a poor atom economy 
(Ar-I is a byproduct) prompted us to consider a visible-light photocatalyzed Pd-mediated 
protocol involving diazonium salts (Scheme 3.0).21–25 
 
 
 
Scheme 3.0: Visible-light photocatalyzed Pd-mediated protocol for C-H arylation 
 
3.2 Results and Discussion 
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Initial reaction trials were performed on the 5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one skeleton, using the 2-fluoro-benzenediazonium salt under reflux. To 
our surprise, in addition to the expected product 3.1, we were able to isolate the ether 
product 3.4. However, reaction of the 3-fluorobenzenediazonium tetrafluoroborate led 
exclusively to the fluorobiaryl derivative 3.2, whereas the 4-fluorobenzenediazonium salt 
afforded a mixture of fluorobiaryl 3.3 and methoxy product 3.6. Repeating the reaction 
in ethanol led to the ethyl ether product 3.7, as shown in Scheme 3.1. 
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Scheme 3.1: Benzodiazepine library synthesis 
 
Characterization of 3.6 and 3.7 were enabled by determination of its solid state x-ray 
structure26 (Scheme 3.1) and by its unequivocal synthesis starting from 4-
methoxybenzenediazonium tetrafluoroborate (Table 3.1) where we found slightly better 
yields under reflux (Entry 1 vs. 2) compared to either ambient temperature or to the 
absence of photocatalyst (Entry 5). Moreover, a palladium catalyst was essential (Entry 
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4) for achieving a good yield. Microwave-mediated chemistry, in the absence of light and 
photocatalyst, gave little conversion of product. 
 
Table 3.1:  Synthesis of an anisole derivative – optimisation 
 
 
 
 
 
Entry Lamps 
26W 
Pd(OAc)2 
(mol %) 
Ru(bpy)3Cl2. 
6H2O(mol %) 
Temp. 
(oC) 
Conv. 
LC/MS (%) 
1 Yes 10 2.5 rt 52 
2 Yes 10 2.5 Reflux 61 
3 No 10 2.5 Reflux 35 
4 Yes 0 2.5 Reflux 0 
5 Yes 10 0 Reflux 57 
6 No 10 0 a 20 
 
a Microwave (MW), 125 oC, 1h. 
 
To explain the formation of the ether products we propose a competing SNAr 
(nucleophilic aromatic substitution), termed “nuisance effect,” which has historically 
been observed for halogen-substituted benzenediazonium salts, given the strong electron 
withdrawing effects of the diazo group, notably operating on the 2- and 4-substituted 
isomers.27 Indeed, simple alcoholysis of 4-fluorobenzenediazonium tetrafluoroborate, 3.8 
was achieved by reflux in the appropriate alcohol solvent (Scheme 3.2). 
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Scheme 3.2: “Nuisance effect” on diazonium salts. 
 
The C-H activation reaction was also applied to aryldiazoniums incapable of undergoing 
such a F-substitution and, hence derivatives 3.11-3.16 were synthesized in good to 
excellent yields (Scheme 3.3). Indeed, yields tend to be either similar or higher than those 
reported for the corresponding reactions involving iodonium salts, e.g. 3.11 (60% vs. 
56%), 3.12 (54% vs. 35%), 3.13 (71% vs. 55%) and 3.15 (64% vs. 63%). 
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Scheme 3.3: Other arylated benzodiazepines 
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In the synthesis of 3.15, relatively large amounts of the diarylated 3.16 were also 
observed. Such di-arylations were previously reported by us (Chapter 2).17 
 
The current and previous library of benzodiazepines (Scheme 3.1) was tested for GABA 
binding.28 None of the current benzodiazepines displayed any appreciable biological 
activity although 7-chloro-benzodiazepines, as expected, had reasonable activity, 
although were ca. 7-10 fold less active than nordazepam and diazepam controls (Entries 
1 and 2 respectively, Table 2) and were not pursued any further.  
 
Table 3.2: GABAA activity of ortho-arylated BZDs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sanford et al. proposed a possible mechanism to explain their Pd/Ru photocatalysed C-H 
arylation.21 Following is a computational study of a Pd-catalysed conducted by our 
collaborators and a Sanford-derived Pd/Ru photocalysed mechanism for the 
Entry Compound mean Ki (nM)/ SEM (nM) vs. 
GABA 
 
1 
 
51.62 ± 2.0 
2 
 
41.41 ± 4.9 
3 
 
373.45 ± 110.5 
4 
 
421.54 ± 86.1 
5 
 
303.25 ± 60.7 
6 
 
689.56 ± 480.3 
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functionalization of 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one to 5-(4’-
Nitrobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one, 3.13 (Scheme 3.4) to 
rationalise the increased yield in the presence of light and a Ru photocatalyst.  
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Scheme 3.4: The formation reaction of 3.13 with (i) and without (ii) the Ru photocatalyst, investigated 
using DFT. 
 
The detailed mechanism is shown in Scheme 5 and the reaction profile (relative to the 
reactants) in Figure 3.1. The reaction mechanism, with and without the Ru(II)-
photocatalyst, essentially follows the same path except that the oxidative addition step in 
the presence of just the Pd(II)-catalyst (path shown in green, Scheme 3.5 and Figure 3.1), 
is replaced by a single-electron-transfer (SET) process when the Ru(II)-photocatalyst is 
added (shown in red, Scheme 3.5 and Figure 3.1).  
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Scheme 3.5: The reaction mechanism for the  functionalization of benzodiazepine. From Int4 to Int7 the 
transformation follows the green path in the presence of the Pd catalyst and the red path in the presence 
of the Pd catalyst and the red path in the presence of the Pd/Ru catalysts 
 
The initial step of the catalysed mechanism involves the coordination to Pd(OAc)2 by a 
N atom on the un-functionalised benzodiazepine to provide Int1, followed by the 
formation of an agostic complex Int2 prior to C-H activation. The atomic distance 
between Pd and the agostic H in Int2 is 1.903 Å, which is in good agreement with similar 
agostic interactions in the literature: Pd---H = 1.91 Å29  and Rh---H (1.95 Å).30 The barrier 
to C-H bond activation is 41.4 kJ mol-1, and involves H migration from C to O via a six-
membered ring (TS2-3). Prior to coordination with the p-nitrobenzenediazonium (Ar-
N2+) the complex undergoes an isomerisation step (TS3-4), which involves a change in 
the C1-Pd-O3 angle from 132.0 to 172.0 degrees with an energy barrier of 27.8 kJ mol-1 
to form Int4.  
 
In the absence of the photocatalyst, Ar-N2+ interacts with the Pd(II) complex and follows 
an oxidation addition (OA) pathway, (highlighted in green, Scheme 5 and Figure 1). The 
oxidative addition via TS5-6(OA) has an energy barrier of 127.1 kJ mol-1 and involves 
the formation of an Ar-Pd(IV) complex. The N2 is then eliminated leading to Int7. 
 
When the Ru(II)-photocatalyst is present, the nitrobenzene radical (Ar*) is generated 
from Ar-N2+ (via oxidative quenching of Ar-N2+ by the photo-excited [Ru(bpy)3]2+ 
complex to form [Ru(bpy)3]3+31  and follows a single-electron-transfer (SET) pathway, 
(in red, Scheme 3.5 and Figure 3.1). The square planar geometry of the Pd(II) complex 
Int4 becomes a Pd(III) distorted-octahedral structure when the Ar binds to the Pd centre 
in Int5(SET); this is consistent with the crystal structure of other Pd(III)-complexes.32,33 
Int7 is formed directly from Int5(SET) by the transfer of an electron to the [Ru(bpy)3]3+ 
complex to recover the photocatalyst. The Gibbs free energy barrier for single electron 
transfer (SET) resulting in the formation of the Pd(IV) complex Int7 was calculated to be 
2.5 kJ mol-1 using Marcus and Savéant theor.34–38 The details of this calculation are 
provided in the Computational Method section. This barrier is very small but similar to 
literature values that range from 0.4 – 15.1 kJ mol-1.39 
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Both mechanisms (OA and SET) result in the same Pd(IV) structure for Int7. At this 
stage reductive elimination occurs via TS7-8 with a barrier of 43.2 kJ mol-1. This step 
involves the formation of a C-C bond to facilitate the functionalization of the 
benzodiazepine and the oxidation state of the Pd-center changes from Pd(IV) to Pd(II) 
(Int7 → Int8). 
 
 
 
In order to facilitate the functionalization of the benzodiazepine and the oxidation state 
of the Pd-center changes from Pd(IV) to Pd(II) (Int7 → Int8). The geometry Int8, 
involves an η2(C=C) interaction with Pd. A similar interaction was observed by Ariafard 
et al.40 and Canty et al.41 in their DFT calculations and in a palladium complex crystal 
structure.42  
 
Figure 3.1: The reaction energy profile for the formation of 4g from 1a, with (red path) and without (green path) 
a photocatalyst. Steps common to both mechanisms are shown in blue. [Ru2+] and [Ru3+] represent [Ru(bpy)3]2+ 
and [Ru(bpy)3]3+, respectively 
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It is clear from Figure 3.1 that in the presence of the Pd-catalyst, the oxidative addition 
step is rate determining with a considerable energy barrier. Large energy barrier is 
avoided as the reaction proceeds via a very low-energy single-electron-transfer process. 
This provides a rationale for the increased yield in the presence of a photocatalyst. 
 
3.3 Conclusion 
 
The C-H activation of benzodiazepines with 2- or 4-fluorobenzene diazonium salts under 
Pd catalysis with a Ru photocatalyst, in alcohol solvent, under reflux, leads to a mixture 
of both fluoroaryl and alkoxyaryl products. Reaction temperature is a key factor in 
determining the ratio of expected vs. “nuisance effect” (SNAr) products. At ambient 
temperature trace amounts of the SNAr product are detected whereas significant amounts 
can be obtained after prolonged heating under reflux. This process can also be extended 
to other aryl diazonium salts affording ortho-arylated benzodiazepines. These were tested 
for biological activity but were found to be significantly less active than e.g. nordazepam 
and diazepam controls. Density functional theory (DFT) has been used to provide a 
detailed mechanistic understanding of the functionalization of the benzodiazepines and 
to offer an explanation for the increased yield in the presence of a Ru(II)-photocatalyst. 
The Pd/Ru catalytic cycle follows the mechanism proposed by Sanford et al.21  The 
increased yield in the visible-light photocatalysed Pd-mediated protocol is attributed to 
the transformation step leading to the formation of the Pd(IV) complex. In the presence 
of the photocatalyst the reaction proceeds via a low-energy SET pathway and avoids the 
high-energy oxidative addition step in the Pd-only catalysed reaction pathway. 
 
Chapter 4 aims to extend the arylation/nuisance effect chemistry to a wider scope of 
privileged structures with different nucleophiles for application in medicinal chemistry 
library generation. 
 
3.4 Experimental details for Chapter 3 
 
General Information 
General experimental details are provided in Chapter 2.4. 
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3.4.1 4-Methoxybenzenediazonium tetrafluoroborate (3.9) 
 
A stirred suspension of 4-fluorobenzenediazonium tetrafluoroborate (0.10 g, 0.48 mmol) 
in methanol (2 mL) was heated at reflux for 1 hour. The reaction was allowed to cool to 
ambient temperature and concentrated under reduced pressure. The residue was 
precipitated by the addition of diethyl ether and collected by filtration, affording the titled 
product as a white solid (0.090 g, 85%). The spectral data were concurrent with those 
reported.43,44 
 
3.4.2 4-Ethoxybenzenediazonium tetrafluoroborate (3.10) 
 
The reaction was conducted by the same procedure as for 3.9, but ethanol (2 mL) was 
used instead of methanol and heated at 70oC for 1 hour. The titled product was obtained 
as a white solid (0.071 g, 63%). The spectral data were concurrent with those reported.45 
 
3.4.3 2-Methoxybenzenediazonium tetrafluoroborate  
 
The reaction was conducted by the same procedure as for 3.9 but 2-
fluorobenzenediazonium tetrafluoroborate (0.10, 0.48 mmol) was used instead. The titled 
product was obtained as a white solid (0.073 g, 72%). The spectral data were concurrent 
with those reported.45 
 
3.4.4 5-(2’-Fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
(3.1); 5-(2’-methoxybiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-
one (3.4) 
 
5-Phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (0.070 g, 0.3 mmol), 2-
fluorobenzenediazonium tetrafluoroborate (0.25 g, 1.20 mmol) and palladium (II) acetate 
(0.0067 g, 0.03 mmol), tris(2,2′-bipyridyl)ruthenium (II) chloride hexahydrate (0.0056 g, 
0.0075 mmol) were suspended in degassed, anhydrous methanol (5 mL). Two fluorescent 
light bulbs (26 W) were placed on either side of the reaction vessel and the reaction 
mixture was heated at reflux for 4 hours. The reaction was allowed to cool to ambient 
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temperature, diluted with ethyl acetate (50 mL), washed with water (20 mL) and aqueous 
sodium sulphite (10%, 35 mL x 2). The layers were separated and the combined aqueous 
layers were extracted with ethyl acetate (50 mL). Thereafter the combined organic layer 
was washed with brine (50 mL), dried (MgSO4) and concentrated under reduced pressure. 
The resulting crude material was purified by reversed phase chromatography 
(water/acetonitrile with 0.1% formic acid, 5 min at 0%, 30%-90%). Starting material, 5-
Phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one, was recovered (0.014 g, 0.06 mmol). 
Two products were generated; 3.1 was obtained as a white solid (0.022 g, 28%) and 3.4 
was obtained as a white solid (0.030 g, 37%). 3a: The spectral data were concurrent with 
those reported.17 
 
3.4: 1H-NMR (500 MHz) CDCl3: δ = 7.98 (s, NH, 1H), 7.68 (d, 3JHH = 7.0 Hz, ArH, 1H), 
7.52 – 7.42 (m, ArH, 2H), 7.28 (d, 3JHH = 8.0 Hz, ArH, 1H), 7.19 – 7.12 (m, ArH, 1H), 
7.06 – 6.98 (m, ArH, 2H), 6.90 – 6.83 (m, ArH, 1H), 6.80 (d, 3JHH = 7.5 Hz, ArH, 1H), 
6.69 – 6.60 (m, ArH, 2H), 6.52 (d, 3JHH = 8.0 Hz, ArH, 1H), 4.22 (s, COCH2, 2H), 3.51 
(s, O-CH3, 3H).  
 
13C-NMR (126 MHz) CDCl3: δ = 173.1(C=O), 171.1 (C=N), 156.1 (ArC), 140.8 (ArC), 
139.0 (ArC), 137.4 (ArC), 131.3 (ArC), 131.5 (ArC), 131.4 (ArC), 131.1 (ArC), 130.3 
(ArC), 129.8 (ArC), 129.6 (ArC), 129.3 (ArC), 128.9 (ArC), 127.7 (ArC), 123.3 (ArC), 
120.3 (ArC), 120.2 (ArC), 110.0 (ArC), 56.7 (COCH2), 55.3 (O-CH3).  
 
HRMS-ESI (m/z) calculated for C22H18FN2O2 [+H] +: 343.1441, found: 343.1446. LCMS 
purity (UV) = 96 %, tR 10.63 min. 
 
3.4.5 5-(3’-Fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
(3.2) 
The reaction was conducted on a 0.20 mmol scale by the same procedure as for 3.1/3.4 
but 3-fluorobenzenediazonium tetrafluoroborate (0.17 g, 0.8 mmol) was used instead of 
2-fluorobenzenediazonium tetrafluoroborate. Starting material, 5-Phenyl-1,3-dihydro-
2H-1,4-benzodiazepin-2-one was recovered (0.010 g, 0.042 mmol) and 3.2 was obtained 
as a white solid (0.040 g, 77%). The spectral data were concurrent with those reported.17 
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3.4.6 5-(4’-Fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
(3.3); 5-(4’-Methoxybiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-
one (3.6) 
This reaction was conducted on a 0.42 mmol scale by the same procedure as 3.1/3.4 and 
4-fluorobenzenediazonium tetrafluoroborate (0.35 g, 1.67 mmol) was used instead of 2-
fluorobenzenediazonium tetrafluoroborate. Starting material, 5-Phenyl-1,3-dihydro-2H-
1,4-benzodiazepin-2-one was recovered (0.015 g, 0.06 mmol) and the reaction generated 
two products; 3.3 was obtained as a white solid (0.053 g, 45%) and 3.6 was obtained as a 
white solid (0.038 g, 32%).  
 
3.3: 1H-NMR (500 MHz) DMSO-d6: δ = 10.39 (s, 1H), 7.60 – 7.55 (m, 1H), 7.55 – 7.52 
(m, 1H), 7.50 (dd, J = 7.4, 1.4 Hz, 1H), 7.33 – 7.30 (m, 1H), 7.21 – 7.17 (m, 1H), 6.92 – 
6.86 (m, 4H), 6.83 – 6.77 (m, 2H), 6.69 (dd, J = 7.9, 1.5 Hz, 1H), 4.03 (s, COCH2, 2H).  
 
13C-NMR (126 MHz) DMSO-D6: δ = 172.1 (C=O), 169.7 (C=N), 161.5 (d, 1JFC = 244.0 
Hz, ArC,), 140.4 (ArC), 139.8 (ArC), 139.2 (ArC), 136.9 (ArC), 131.5 (ArC), 130.4 (A 
rC), 130.5 (d, 3JFC = 7.5 Hz, 2 x ArC), 130.2 (ArC), 130.1 (ArC), 129.3 (ArC), 128.3 
(ArC), 127.8 (ArC), 122.7 (ArC), 120.7 (ArC), 114.9 (d, 2JFC = 22.0 Hz, 2 x ArC), 57.3  
(COCH2).  
 
HRMS-ESI (m/z) calculated for C21H15FN2O [+H] +: 331.1241, found: 331.1244. LCMS 
purity (UV) = 92%, tR 11.16 min. 3.4: The spectral data were concurrent with those 
reported. 
 
3.4.7 5-(4’-Ethoxybiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
(3.7) 
The same method as that of 3.1/3.4 was used but ethanol (5 mL) was used as the solvent 
instead of methanol.  Starting material, 5-Phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-
one was recovered (0.020 g, 0.085 mmol). Two products were generated, the titled 
product was obtained as a white solid (0.043 g, 39%) and Product 3.7 was obtained as a 
white solid (0.026 g, 22%).  
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3.7: 1H-NMR (500 MHz) CDCl3: δ = 8.20 (s, NH, 1H), 7.68 (d, 3JHH = 7.5 Hz, ArH, 1H), 
7.57 – 7.38 (m, ArH, 2H), 7.28 (d, 3JHH = 7.5 Hz, ArH, 1H), 7.15 (pt, 3JHH = 7.5 Hz, ArH, 
1H), 6.91 – 6.81 (m, ArH, 4H), 6.69 (d, 3JHH = 8.0 Hz, ArH, 1H), 6.60 (d, 3JHH = 8.0 Hz, 
ArH, 2H), 4.29 (s, COCH2, 2H), 3.94 (q, 3JHH = 7.0 Hz, O-CH2CH3, 2H), 1.36 (t, 3JHH = 
7.0 Hz, O-CH2CH3, 3H).  
 
13C-NMR (126 MHz) CDCl3: δ = 173.2 (C=O), 170.7(C=N), 157.8 (ArC), 141.7 (ArC), 
139.5 (ArC), 137.3 (ArC), 133.2 (ArC), 131.1 (ArC), 130.1 (ArC), 129.9 (ArC), 129.7 
(ArC), 129.8 (2 x ArC), 129.5 (ArC), 129.1 (ArC), 128.1 (ArC), 126.9 (ArC), 123.1 
(ArC), 113.8 (2 x ArC), 63.5 (O-CH2CH3), 56.5 (COCH2), 14.8 (O-CH2CH3).  
 
HRMS-ESI (m/z) calculated for C23H20N2O2 [+Na] +: 379.1417, found: 379.1419. LCMS 
purity (UV) = 87 %, tR 10.89 min. 
 
3.4.8 5-Phenyl-2-yl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3.11) 
The reaction was conducted by the same procedure as for 3.1/3.4 but benzenediazonium 
tetrafluoroborate (0.23 g, 1.20 mmol) was used instead of 2-fluorobenzenediazonium 
tetrafluoroborate. Starting material, 5-Phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
was recovered (0.016 g, 0.067 mmol) and 3.11 was obtained as a white solid (0.043 g, 
60%). All Spectral data were concurrent with those reported.17 
 
3.4.9 5-(4’-Methoxybiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-
one (3.12) 
The reaction was conducted on a 0.32 mmol scale by the same procedure as for 3.1/3.4 
but 4-methoxybenzenediazonium tetrafluoroborate (0.28 g, 1.28 mmol) was used instead 
of 2-fluorobenzenediazonium tetrafluoroborate. Starting material, 5-Phenyl-1,3-dihydro-
2H-1,4-benzodiazepin-2-one was recovered (0.015 g, 0.063 mmol) and 3.12 was obtained 
as a white solid (0.048 g, 54%). All Spectral data were concurrent with those reported. 
 
3.4.10 5-(4’-Nitrobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
(3.13) 
The reaction was conducted on a 0.45 mmol scale by the same procedure as for 3.1/3.4 
but 4-nitrobenzenediazonium tetrafluoroborate (0.43 g, 1.80 mmol) was used instead. 
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Starting material, 5-Phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one was recovered 
(0.020 g, 0.085 mmol) and 3.13 was obtained as a white solid (0.093 g, 71%).  
 
1H-NMR (500 MHz) CDCl3: δ = 8.78 (s, 1H), 7.94 (dd, 3JHH = 8.5, 1.5 Hz, 2H), 7.78 – 
7.72 (m, 1H), 7.60 – 7.52 (m, 2H), 7.34 – 7.28 (m, 1H), 7.22 – 7.13 (m, 3H), 6.90 – 6.83 
(m, 2H), 6.72 (d, 3JHH = 8.0 Hz, 1H), 4.31 (s, COCH2, 2H). ).  
 
13C-NMR (126 MHz) CDCl3: δ = 172.1 (C=O), 170.6 (C=N), 147.4 (ArC), 146.6 (ArC), 
139.7 (ArC), 139.6 (ArC), 137.5 (ArC), 131.7 (ArC), 130.4 (ArC), 129.9 (ArC), 129.8 
(ArC), 129.6 (ArC), 129.5 (ArC x 2), 128.7 (ArC), 128.6 (ArC), 123.3 (ArC), 122.7 
(ArC x 2), 120.1 (ArC), 56.5 (COCH2).  
 
HRMS-ESI (m/z) calculated for C21H15N3O3 [+H] +: 358.1186, found: 358.1191. 
Elemental Analysis: Calculated for C21H15N3O3 (%): C, 70.58, H, 4.23, N, 11.76, found: 
C, 70.41, H, 4.23, N, 11.60. 
 
3.4.11 5-(4’-Bromobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-
one (3.14) 
The reaction was conducted on a 0.25 mmol scale by the same procedure as for 3.1/3.4 
but 4-bromobenzenediazonium tetrafluoroborate (0.27 g, 1.0 mmol) was used instead. 
Starting material, 5-Phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one was recovered 
(0.012 g, 0.051 mmol) and 3.14 was obtained as a white solid (0.051 g, 65%).  
 
1H-NMR (500 MHz) DMSO-d6: δ = 10.44 (s, 1H), 7.56 (pt, 3JHH = 8.0 Hz, 2H), 7.54 – 
7.48 (m, 1H), 7.34 (d, 3JHH = 8.0 Hz, 1H), 7.28 (d, 3JHH = 8.0 Hz, 2H), 7.23 (pt, 3JHH = 
7.5 Hz, 1H), 6.87 (dd, J = 8.0, 5.9 Hz, 3H), 6.82 (pt, 3JHH = 7.5 Hz, 1H), 6.73 (d, 3JHH = 
8.0 Hz, 1H), 4.05 (s, COCH2, 2H).  
 
13C-NMR (126 MHz) DMSO-d6: δ = 171.9 (C=O), 169.8 (C=N), 140.2 (ArC), 139.8 
(ArC), 139.6 (ArC), 139.3 (ArC), 131.5 (ArC), 131.1 (ArC), 131.0 (ArC x 2), 130.6 
(ArC x 2), 130.3 (ArC), 130.2 (ArC), 130.1 (ArC), 129.5 (ArC), 128.2 (ArC), 128.1 
(ArC), 122.7 (ArC), 120.7 (ArC), 56.7 (COCH2).  
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HRMS-ESI (m/z) calculated for C21H15BrN2O [+H] +: 391.0441, found: 391.0449. LCMS 
purity (UV) = 95 %, tR 14.56 min. 
 
3.4.12 5-(3’-Trifluoromethylbiphenyl-2-yl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (3.15); 5-(3,3’-bistrifluoromethylbiphenyl-2,6-yl)-1,3-
dihydro-2H-1,4-benzodiazepin-2-one (3.16) 
The reaction was conducted on a 0.39 mmol scale by the same procedure as for 3.1/3.4 
but 3-trifluoromethylbenzenediazonium tetrafluoroborate (0.41 g, 1.56 mmol) was used 
instead. 3.15 was obtained as a brown solid (0.094 g, 64%) and the bisarylated product, 
3.16, was obtained as a brown solid (0.061 g, 30%). 3.15: All spectral data were 
concurrent with those reported.17 
 
3.16: 1H-NMR (500 MHz) DMSO-d6: δ = 10.01 (s, 1H), 7.66 (pt, 3JHH = 7.5 Hz, 1H), 
7.55 (d, 3JHH = 8.0 Hz, 2H), 7.50 (d, 3JHH = 7.5 Hz, 2H), 7.45 (pt, 3JHH = 7.5 Hz, 2H), 
7.41 – 7.36 (m, 4H), 7.22 – 7.18 (m, 1H), 6.96 – 6.89 (m, 2H), 6.75 (d, J = 8.0 Hz, 1H), 
3.65 (s, COCH2, 2H).  
 
13C-NMR (126 MHz) CDCl3: δ =  170.4 (C=O), 169.6 (C=N), 141.4 (ArC), 141.0 (ArC), 
138.1 (ArC), 137.4 (ArC), 132.4 (ArC x 2), 131.7 (ArC), 130.1 (q, 2JFC, 33 Hz,  ArC x 
2), 129.8 (ArC x 2), 129.4 (ArC x 2), 129.3 (ArC x 2), 128.7 (ArC), 128.2 (ArC x 2), 
125.8 (q, 3JFC, 3.5 Hz, ArC x 2), 123.9 (q, 3JFC, 272.0 Hz ArC x 2), 123.7 (q, 3JFC, 3.5 Hz, 
ArC x 2), 123.4 (ArC), 120.2 (ArC),  55.7 (COCH2). 
  
HRMS-ESI (m/z) calculated for C29H18F6NO2 [+H] +: 525.1396, found: 525.1402. LCMS 
purity (UV) = 98 %, tR 22.50 min. 
 
           
3.5 Computational Details 
Density functional theory (DFT) calculations were performed at the ωB97XD/6-
311++G(2df,2p)[SDD]//PBE/6-31+G(d,p)[SDD] level of theory, using the Gaussian09 
program.46 The Pople basis sets were used on all atoms except Pd and Ru for which the 
SDD effective core potentials were used.47 The PBE functional48 was used for the 
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geometry optimisation and frequency analysis as it combines good accuracy for Pd 
complexes with computational speed.49,50 The long-range corrected hybrid functional 
ωB97XD,51 which includes empirical dispersion corrections, was used for energies to 
ensure accurate energetics.52–55 Methanol solvent energy corrections were applied using 
the conductor-like polarisable continuum model (CPCM).56,57All stationary states were 
verified as minima or transition states by the absence or presence, respectively, of a single 
imaginary vibrational frequency. Eigenvector following was used to ensure transition 
states connected the desired minima. 
The Gibbs free energy barrier for single electron transfer (SET), Δ𝐺𝐺𝐸𝐸𝐸𝐸≠ , was calculated 
using the following equation from Marcus and Savéant theory:34–38 
Δ𝐺𝐺𝐸𝐸𝐸𝐸
≠ = Δ𝐺𝐺0≠ �1 + Δ𝐺𝐺𝑟𝑟4Δ𝐺𝐺0≠�2 (1) 
Here Δ𝐺𝐺𝑟𝑟  is the reaction energy for the electron transfer step and Δ𝐺𝐺0≠is the intrinsic 
barrier, which can be calculated as: 
Δ𝐺𝐺0
≠ = 𝜆𝜆4 (2) 
In Eq. (2), 𝜆𝜆 is the reorganisation energy and consists of the inner reorganisation energy 
of the reactants, 𝜆𝜆𝑖𝑖, and the solvent reorganisation energy, 𝜆𝜆𝑜𝑜. For outer-sphere electron 
transfer as in the present case, 𝜆𝜆𝑖𝑖 is assumed to be zero (following literature precedents)58 
thus 𝜆𝜆 is equal to 𝜆𝜆𝑜𝑜.   
The reaction energy for the electron transfer step Δ𝐺𝐺𝑟𝑟 is calculated as the energy of the 
reaction: Pd(III)-complex + [Ru(bpy3)]3+ → Pd(IV)-complex + [Ru(bpy3)]2+ (i.e. 
Int5(SET) to Int7, Scheme 5). The energy for this step is -83.4 kJ mol-1. 
The reorganisation energy 𝜆𝜆 = 𝜆𝜆𝑜𝑜 is calculated using the following equation:59  
  
𝜆𝜆𝑜𝑜 = 𝑁𝑁𝐴𝐴𝑒𝑒24𝜋𝜋𝜀𝜀0 � 1𝜀𝜀𝑜𝑜𝑜𝑜 − 1𝜀𝜀𝑠𝑠� � 12𝑟𝑟1 + 12𝑟𝑟2 − 1𝑅𝑅� (3) 
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Where 𝑁𝑁𝐴𝐴 is the Avogadro constant (6.022×1023 mol-1), e is the electronic charge 
(1.602×10-19 C), 𝜀𝜀0 is the vacuum permittivity (8.854×10-12 J-1C2m-1) and,  𝜀𝜀𝑜𝑜𝑜𝑜 and 𝜀𝜀𝑠𝑠 are 
the optical and static dielectric constant for solvent, respectively. For methanol, 𝜀𝜀𝑜𝑜𝑜𝑜 is 
1.76 and 𝜀𝜀𝑠𝑠 is 32.613.  𝑟𝑟1, 𝑟𝑟2 and R are the hard sphere radii of the donor, the acceptor, 
and their sum. In this work, the hard sphere radii approximation of [Ru(bpy)3]3+ and the 
Pd(III)-complex (Int5(SET)) were calculated using the VOLUME keyword in 
Gaussian09. The calculated [Ru(bpy)3]3+ radius is 6.18 Å and the calculated Pd(III)-
complex radius is 6.47 Å. Using these values in Eq. (3) gives 𝜆𝜆𝑜𝑜= 59.1 kJ mol-1, and hence 
Δ𝐺𝐺0
≠= 14.8 kJ mol-1. Substituting these values for Δ𝐺𝐺0≠and Δ𝐺𝐺𝑟𝑟 in Eq. (1), provides a SET 
barrier, Δ𝐺𝐺𝐸𝐸𝐸𝐸≠  = 2.5 kJ mol-1. 
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Chapter 4 
 
 
 
This Chapter is written in an article style and has not been published elsewhere. Our 
collaborators at Structural Genomics Consortium (SGC), Oxford, have performed all the 
X-ray crystallography and are responsible for the preliminary biological results presented 
in this Chapter. 
 
 
4.1 Preface 
 
Chapters 2 and 3 have demonstrated the successful use of palladium catalysed C-H 
activation in synthesising ortho-arylated BZDs. In this Chapter, the C-H activation 
method is employed for synthesising libraries of 2-phenylpyridines and 1-phenyl-2-
pyrrolidinones, which also show promising biological activity towards the NUDT7α 
protein (a peroxisomal coenzyme A diphosphatase). Although, the fragments readily bind 
at the binding pocket of NUDT7α, the quantitative data for the biological tests are still 
awaiting. 
 
In the following sections, upon a brief overview of the C-H functionalisation, this chapter 
highlights different types of C-H activation methodologies such as metal catalysed C-H 
activations. It includes the use of palladium catalysis in C-H functionalisation, which has 
been thoroughly used in this project. Subsequently, NUDT7α is introduced with a 
discussion of its functions and key roles in biological processes. This is followed by an 
analysis of the results and a brief conclusion to this Chapter. 
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4.2 C-H functionalisation 
 
Most organic molecules are made from non-renewable raw materials which include 
natural gas and crude oil. Desired organic molecules are derived by breaking and making 
new C-C bonds by transforming C-H bonds into specific functional groups. Traditionally 
C-H bond functionalisation is often achieved by initial radical functionalisation or partial 
aerobic oxidation, which are typically followed by a number of steps facilitating the 
introduction of the targeted functional groups to construct desired molecules.1–3 This 
process is known as functional group interconversion strategy and is so profoundly 
important for organic synthesis, that many organic textbooks contain topics following the 
sequence of this approach. The typical sequence starts with radical C-H functionalisation 
(halogens) followed by elimination and substitution, reductions and oxidation as well as 
carboxyl and carbonyl chemistry. However, this remarkably useful functional group 
interconversion strategy suffers from a basic disadvantage; it often results in wasteful 
processes as it involves several steps to convert the unfunctionalised raw material into 
desired products.4  
 
C-H activation with subsequent functionalisation in situ offers an approach to introduce 
substituents into molecules in a one-step synthesis. Product and site-selective C-H 
functionalisations have been referred to as the “holy grail” of catalysis research.5 The 
high bond dissociation energies (BDEs) of hydrocarbons make them very difficult to 
break and present great challenges for direct C-H functionalisation. Moreover, C-H bond 
activation is also kinetically more challenging than C-X bonds, as they do not have 
suitable lone pairs to coordinate with the catalysts.6 Successful C-H functionalisation 
methods need to surpass a number of critical challenges in addition to cleaving very 
strong and weakly coordinating bonds. Additionally, the successful catalysts in these 
processes need to possess the following criteria:  
 
- Show selectivity for a particular kind of C-H bond in a system,  
- remain stable and activated in the presence of necessary oxidants, other 
coordinating functional groups in the product or solvent, and 
- be reluctant to further functionalisation i.e., over-oxidation of the products. 
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Mechanistically, C-H bond functionalisations vary significantly, which may define the 
types of C-H bonds that can be cleaved and thereby have an influence on selectivity. One 
such mechanism is the radical rebound mechanism where an H-atom is abstracted 
followed by radical functionalisation. These mechanisms frequently occur for metal-oxo 
catalysts and sometimes for functionalisations that progress through metal nitrenoids. 
Due to the nature of the radical intermediate (4.1 in Scheme 4.1), selectivity towards weak 
C-H bonds for functionalisation is often observed in such mechanisms.7 
 
 
 
Scheme 4.1: Radical rebound mechanism 
 
In direct insertions, the unsaturated intermediate (4.2, 4.3) directly attack the C-H bond 
and form the product in one concerted step and usually proceed through metal nitrenes 
and carbenes. Although cleaving weak C-H bond is typical for these mechanisms, alkane 
C-H functionalisations have also been postulated to follow this pathway.8,9 
 
 
 
Scheme 4.2: Direct insertion C-H bond activation 
 
Organometallic C-H bond activations proceeding through intermediates with M-C bonds 
are one of the most common mechanistic pathways for C-H functionalisation. The C-H 
bond breakage in this pathway may proceed through several distinct mechanisms such as 
oxidative addition, concerted metallation deprotonation, through a 4- or 6- membered 
transition state, or sigma bond metathesis, as presented in Scheme 4.3. The specific 
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mechanism pathway for C-H cleavage generally depends on the metal, its oxidation state 
and the associated ligands. 
 
 
 
 
 
 
 
Scheme 4.3: Mechanisms for organometallic C-H bond activation 
 
C-H bond activations, through organometallic intermediates, typically break strong C-H 
bonds in a molecule. Experimental and computational studies suggest that this particular 
selectivity is due to the M-C bonds being formed in intermediates, which generally have 
higher bond energies than corresponding C-H bonds.10,11 
 
Chemists have developed many metal catalyst systems for product and site-selective C-
H functionalisation with broad synthetic applications. The following sections highlight 
some of the metal catalyst systems and their applications.   
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4.2.1 Rhodium (Rh) 
 
Cp*Rh complexes (Cp* = η5-C5Me5) are among the oldest catalyst systems developed 
for studying the different aspects of organometallic C-H bond activation. One 
disadvantage of Rh catalysts is their high price. Rhodium is amongst the most expensive 
precious metals, surpassed only by gold and platinum. Rh catalysts have proven to be 
extremely successful in C-H activations, particularly in stereoselective C-C and C-N bond 
formations. Du Bois and co-workers have reported the use of RhII complexes (containing 
carboxylate and carboxyamidate ligands) for both intramolecular (4.4) and intermolecular 
(4.5) amination with high yields and selectivities (Scheme 4.4).12,13 
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Scheme 4.4: RhII catalysed intramolecular and intermolecular amination 
 
The mechanism of C-H bond activation by Rh catalysts also depends on its oxidation 
states. For instance, RhI catalysts tend to proceed through oxidative addition since they 
can readily access the RhIII state, whereas RhIII has been shown to proceed through 
electrophilic pathways during C-H activation. Ellman et al. have reported the use of RhI 
catalyst precursors in addition reactions of C-H bonds through Rh-aryl intermediates, e.g., 
4.6 (Scheme 4.5).14,15 
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Scheme 4.5: Rh-catalysed C-H activation 
 
These protocols form new C-C bonds and have been applied in various systems such as 
olefins, imines, aldehydes and isocyanates. Important heterocycles such as 4.7, 4.8 and 
4.9 can be synthesised using such procedures.16–19 
 
 
 
Scheme 4.6: Synthesis of heterocycles by Rh-catalysed C-H functionalisation 
 
A wide range methodologies have been developed for C-H amination in the past 
decade,20–29 many of which are of Rh catalysed protocols. Most of these protocols require 
substrates with directing groups. Glorious et al. have developed mild and convenient 
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Cp*Rh catalysed amination methodologies using aryloxycarbamates (Scheme 4.7).30  The 
method shows good tolerance for substituents in ortho, meta and para positions. This 
protocol also works well with different protecting groups such as Boc (tert-
butyloxycarbonyl), Fmoc (fluorenylmethyloxycarbonyl) and Cbz (carboxybenzyl) 
groups and has variation scope for different substrates as shown in Scheme 4.7.  
 
 
Scheme 4.7: Rhodium catalysed C-H amination 
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Recently, Yu and Glorius have independently reported the use of secondary and tertiary 
chloramines as the source of amino groups (Scheme 4.8). Note, a one-pot protocol was 
developed as the chloramines are unstable and difficult to handle, therefore, the alkyl 
amines are chlorinated in situ followed by C-H amination.31,32 
 
 
 
Scheme 4.8: Rh(III) catalysed C-H amination with chloramines 
 
One creative approach in Cp*Rh catalysed methodologies is the use of a directing group 
as an oxidising group simultaneously, known as the oxidising directing group, which are 
converted under the reaction conditions as shown in Scheme 4.9.33–35 
 
 
 
Scheme 4.9: The use of oxidising directing groups in C-H activation 
 
To develop a green approach using Rh(III) catalyst for the highly regioselective synthesis 
of isoquinolones, Cheng and co-workers have recently reported the use of N-alkyl 
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benzamides and alkynes with air as the oxidant (Scheme 4.10). The best solvent was 
found to be water in the reaction.36 
 
 
 
Scheme 4.12: Regioselective synthesis of isoquinolones 
 
Hartwig et el. have developed efficient C-H borylation methods using Cp*Rh(η4-C5Me5) 
complexes. These protocols as apparent from Scheme 4.11 enable C-H functionalisations 
of aliphatic alkanes and are, in fact, highly selective towards functionalisation at primary 
C-H bonds.37,38 
 
 
 
Scheme 4.11: C-H hydroborylation of alkanes 
 
4.2.2 Ruthenium (Ru) 
 
Despite being comparatively less expensive among the precious metals, Ru complexes 
are one of the less developed catalysts for C-H bond functionalisation. Although there are 
useful procedures for C-C bond formations using Ru-catalyst systems, these systems are 
underdeveloped for other types of C-H functionalisation.39 Typical Ru catalysed C-H 
functionalisations include arylations, allylations, alkylations, alkenylations and 
acylations.40–44 The Murai coupling is an outstanding example of Ru catalysed reactions. 
This protocol allows the synthesis of alkyl arenes by the C-H arylation of olefins. The 
advantage of these types of protocols is their ability to use electron-rich alkenes, which 
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tend to be low yielding substrates in Pd-catalyzed, oxidative Heck reactions (Fujiwara-
Moritani).45–47 
 
 
 
Scheme 4.12: The Murai coupling – formation of alkyl-arenes 
 
There is a higher scope of variation in terms of the directing groups in Ru catalysis as 
these systems are not restricted to the use of strong electron donating heterocycles. For 
instance, the use of a ketone as the directing group is common in such reactions and 
ketones can be directly used for subsequent reactions, which is especially useful for 
complex molecule syntheses.48  
 
Another remarkable feature of Ru catalysts is their ability to enable C-H 
functionalisations in the meta-position to the directing group. In these protocols, the 
electrophilic ligands react with the organometallic intermediate at the para-position of the 
M-C bond rather than reacting at the M-C bond. These mechanisms are comparable to 
electrophilic substitutions, where the metal plays the role of an activating, directing 
group. In a meta-selective C-H sulfonation protocol of 2-phenylpyridines using Ru (II) 
complexes, developed by Frost and co-workers, the 2-pyridyl group facilitates the 
formation of stable Ru-Caryl bond that induces the para-directing effect. Subsequently, the 
electrophilic aromatic substitution occurs with the sulfonyl chloride to install the sulfone 
at the meta position of the chelating group. Some of the selected examples from this work 
are shown in Scheme 4.13, with a range of varied functionality and substitution 
pattern.49,50 
 
Other types of C-H functionalisation such as alkylation, bromination, nitration, 
benzylation and difluoromethylation have also been reported using meta-selective Ru 
catalysed C-H functionalisation.51–56 
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Scheme 4.13: C-H functionalisation at the meta-position 
 
Recently, some para-selective C-H functionalisations have also been reported. For 
instance, Lan and co-workers have reported a highly para-selective C-H functionalisation 
protocol, in which they perform difluoromethylation reactions on ketoxime ethers. A 
computational mechanistic study suggested that the key factor in the para-selectivity of 
the difluoromethylation is the chelation-assisted cyclo-ruthenation.57  
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Scheme 4.14: C-H functionalisation at the para-position 
 
Frost and co-workers reported a para-selective alkylation of aniline derivatives with a 
pyrimidine auxiliary. The reaction is suggested to occur via an N-H activated 
metallacycle formed in situ (Scheme 4.15). Experimental and computational studies 
indicated that Ru catalyst can undergo cyclometalation by N-H metalation forming a 
redox active Ru species and enable site-selective radical addition at the para position (the 
C-H metalation gives rise to the meta product).57,58 Interestingly, changing a few reaction 
parameters of this protocol highly favoured the formation of meta-selective products 
using identical starting material and coupling partner. The meta-selective C-H alkylation 
was achieved by a change of solvent and base. It was proposed that the N-H 
cyclometalation was favoured by carbonate bases (K2CO3) forming a para-functionalised 
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product and the use of acetate bases (KOAc) favoured the ortho-C-H cyclometalation to 
yield meta-functionalised products. 
 
 
 
Scheme 4.15:Ru-cataysed para-selective and meta-C-H alkylation of aniline derivative; Bottom: DFT 
calculations of the most stable intermediates for the competing N-H and C-H activations with carbonate 
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base (R = OH) favouring para-functionalisation and with acetate base (R = Me) favouring meta-
functionalisation.58 
 
The use of Ru(II) catalysis has also been employed in C-H amination. For instance, 
several research groups including Chang, Ackermann, Ding and Sahoo have 
independently reported C-H amidation of heterocycles using [RuCl2(p-cymene)]2 as the 
catalyst with organic azides (Scheme 4.16).59–63  
 
 
 
Scheme 4.16: Ru(II) catalysed C-H amidation 
 
4.2.3 Palladium (Pd) 
 
Pd-catalysed C-H activation methodologies are remarkably versatile in terms of the 
substrate and product scope and can be used for the synthesis of both simple and complex 
molecules. Pd catalysts are compatible with a variety of conditions and can be applied 
with a wide range of functional groups. These advantages make Pd catalysts possibly the 
most well-known and well-developed catalysts for C-H functionalisation in organic 
chemistry.64,65 
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Scheme 4.17: Substrate and product scope in C-H functionalisation under Pd catalysis 
 
A wide range of experimental and computational studies are available on the reactivity 
patterns of Pd complexes in C-H functionalisation.66–68 The catalytic C-H 
functionalisation reactions have used all four oxidation states Pd (0), Pd (I), Pd (II) and 
Pd (IV) and the catalytic cycles are commonly identified as Pd0/II and PdII/IV pathways, 
determined by the oxidation states of the relevant intermediate complexes in respective 
catalytic cycles. Numerous organometallic palladacycles have been isolated and 
characterised for most of these oxidation states.68–70 Although most C-H activations under 
Pd catalysis are known to occur at PdII complexes, some C-H activations have also been 
found to be occurring at PdIV centres.71,72 Subsequent C-H functionalisation steps may 
occur from different oxidation states of Pd. For instance, C-C bonds may form through 
PdII, PdIII or PdIV complexes, whereas, C-X bond formation protocols often employ strong 
oxidants and are known to occur through high-oxidation state Pd centres. Scheme 4.18 
showcases some selected examples of palladacycles with different oxidation states in Pd-
catalysed C-H activation.73–76 
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Scheme 4.18: Selected examples of palladacycles with different oxidation states in Pd-catalysed C-H activations. 
 
Functionalising several positions on an aromatic system in one-pot is also possible 
through Pd catalysed C-H activation. Such Catellani-type reactions start with an oxidative 
insertion of the catalyst into a C-X bond as shown in Scheme 4.19, followed by the 
reaction of the resulting Pd (II) complex (4.13) with norbornene to afford the Pd-
intermediate, 4.14. The intermediate undergoes C-H activation in the ortho-position to 
the original insertion site. The catalyst is finally regenerated after the elimination of 
norbornene followed by the C-H activation of the new Pd-CAr bond which generates 
functionalised products such as 4.15.77,78 
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Scheme 4.19: One-pot C-H functionalisations at more than one position. 
 
In oxidative C-H functionalisation, remarkably oxygen can be used as terminal oxidant 
under Pd catalysis. Many oxidative Heck reactions, i.e., CAr-H olefinations occur using 
O2 as an oxidant. Numerous highly selective aerobic dehydrogenative aryl couplings have 
also been developed using such protocols.79–81 Furthermore, the use of O2 as an oxidant 
is also applicable to other types of C-H functionalisation, such as C-H oxygenations. By 
varying the catalytic conditions in such reactions, formation of C-O bonds in allylic 
(Scheme 4.20), aromatic (Scheme 4.21), benzylic (Scheme 4.22) and aliphatic (Scheme 
4.23) positions can be achieved with efficient atom economy.82–84 
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Scheme 4.20: C-H oxygenation in the allylic position 
 
 
 
Scheme 4.21: C-H oxygenation in aromatic position 
 
 
 
Scheme 4.22: C-H oxygenation in the benzylic position 
 
 
 
Scheme 4.23: C-H oxygenation at the aliphatic position 
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The use of oxidants in Pd catalysed C-H activation reactions is not limited to oxygen, 
there are several examples of two electron oxidants and one electron oxidant, including 
metal salts and organic oxidants. Some studies have focused on combining C-H activation 
chemistry with other types of chemistry in order to achieve the optimal results under 
milder reaction conditions and more atom-economy.85 Scheme 4.24 represents one such 
protocol reported by Sanford et al., in which the C-H functionalisation of the 2-
phenylpyridine occurs at room temperature with visible light photocatalysis to afford the 
biaryl product 4.16.86 
 
 
 
Scheme 4.24: Pd catalysed C-H arylation with visible light photocatalysis 
 
Recently, there have been studies on the flexibility of the directing groups in Pd catalysed 
C-H bond functionalisations. A protocol developed by Yu and co-workers employs 
transient directing group to β-C(sp3)-H aliphatic ketones (Scheme 4.25). The formation 
of the six-membered Pd complex intermediate with α-benzyl β-alanine directing group 
was found to be crucial for the C-H bond activation.87 
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Scheme 4.25: C-H arylation using a transient directing group 
Another recent development by Yu and co-workers reports ligand-accelerated non-
directed C-H functionalisation of arenes (Scheme 4.26). A Pd complex is formed with the 
2-pyridone ligand that accelerates the reaction, which is compatible with a range of 
aromatic substrates. The methodology is also applicable to a variety of transformations 
including C-H olefination and C-H carboxylation reactions.  
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Scheme 4.26: Pd catalysed ligand – accelerated non-directed C-H functionalisation of arenes. 
The combined effect of steric and electronic factors controls the site selectivity in these 
reactions. The pyridone ligand enhances the effect of sterics on the selectivity, thereby, 
provides further selectivity to non-directed C-H functionalisation.88 
 
The above discussion highlights a few selected metal catalysed C-H functionalisation 
protocols. Many other metal catalytic systems have been developed in this field including 
nickel-, iron-, copper- and cobalt- catalysed C-H activations. The use of C-H 
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functionalisation protocols has enabled the synthesis of many complex molecules with a 
greener approach. Late-stage C-H functionalisation protocol, in which libraries of 
complex bioactive molecules can be synthesised efficiently, has greatly contributed in 
speeding up the process in medicinal chemistry. Direct C-H functionalisations are 
continuing to advance and therefore should continue to greatly contribute to energy 
efficient, highly selective, atom-economic transformations for the synthesis of organic 
molecules and bioactive compounds in the future.89–97 
 
4.3 NUDT7 - a peroxisomal CoA diphosphatase 
 
NUDT7 is a member of the superfamily of enzymes, Nudix hydrolases, which are found 
in all types of organisms and hydrolyse a wide range of pyrophosphates. In 1996, 
Bessman termed Nudix hydrolases as “housecleaners”, “cleansing the cell of potentially 
deleterious endogenous metabolites and modulating the accumulation of intermediates in 
biochemical pathways”.98,99 Nudix enzymes mainly act upon substrates of general 
structure nucleoside diphosphate linked to some moiety X. These include nucleoside di-
, triphosphates, nucleoside sugars and alcohols, dinucleoside polyphosphates, 
dinucleotide coenzymes and RNA caps with varying degrees of substrate specificity.100 
Along with playing a vital role in removing potentially toxic nucleotide metabolites from 
the cell, these enzymes also regulate the availability and concentrations of various 
nucleotide substrates, cofactors and signalling molecules.  
 
So far, 24 Nudix genes have been identified in mammals, many of which encode more 
than one isoform. Two isoforms of NUDT7 have been identified: NUDT7α and 
NUDT7β. The former is a peroxisomal CoA diphosphatase, whereas NUDT7β is an 
inactive variant. NUDT7α along with NUDT19 (another member of the Nudix family) 
are located in the peroxisome. Peroxisomes are ubiquitous organelles that are found in 
yeast, fungi, plants and animals, and regulate diverse metabolic functions.101 One typical 
function of peroxisome is the degradation of a wide range of carboxylic acids via α and 
β oxidation. This crucial process is suggested to be the driving force for the evolution of 
peroxisomes. A number of enzymes catalyse the β oxidation reactions. A variety of 
auxiliary enzymes are involved in the regulation of β oxidation, uptake of fatty acids and 
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cofactors required for β-oxidation. NUDT7 is one of these enzymes. The other auxiliary 
enzymes for β-oxidation include acyl-CoA thioesterases(ACOTs), membrane 
transporters/channels, acyl-CoA: amino acid N-acyltransferases and carnitine 
acyltransferases and some other members of the Nudix hudrolases.102,103 
 
CoA is involved in a vast number of reactions in intermediary metabolisms and is crucial 
in living organisms. NUDT7α and NUDT19 (members of the Nudix hydrolases contained 
in the peroxisome) catalyses the degradation of CoA by hydrolysing free CoA and CoA 
esterified to various fatty acids to varying chain lengths of acyl-phosphopantetheines and 
3’,5’-ADP. The ACOTs, on the other hand, catalyse the hydrolysis of acyl-CoAs into the 
free fatty acid and CoA.104–107 
 
 
 
Figure 4.1: NUDT7 cleaves acyl-CoA into varying chain lengths of acyl-phosphopantetheines and 3’,5’-ADP 
 
The characterisation of the NUDT7α function revealed that it cleaves acyl CoAs and 
CoAs and thereby serves two functions of regulating CoA levels and regulating β-
 145 
 
oxidation activity. NUDT7α are expressed in the tissues with high expression of β-
oxidation enzymes. NUDT7α is highly expressed in the liver, adipose tissue, heart, 
mammary gland, stomach, lungs, kidney, brain and many others. By metabolising varying 
(typically medium to long) chain lengths of acyl-CoAs, NUDT7α play key role in 
controlling β-oxidation activity in peroxisomes. Enzymes like NUDT7 have also been 
proposed to perform significant functions in clearing metabolites from the 
peroxisome.103,107 
 
As stated above CoA is indispensable in living organisms, highly involved in 
intermediary metabolism reactions and if misregulated can lead to various diseases. Thus, 
NUDT7α being one of the regulators of CoA level in the peroxisome, is also thought to 
be involved in numerous diseases. Recently, the upregulation of NUDT7α has been 
associated with high risk of inflammatory bowel disease. Other diseases it has been 
implicated in include colorectal cancer and pantothenate kinase-associated 
neurodegeneration (PKAN).108,109  
 
Although, there have been many studies to investigate and understand the important 
functions of NUDT7α, the molecular basis for its substrate recognition and the catalytic 
mechanism is still not fully understood. One of the aims of this chapter was to identify 
and synthesise a library of molecules that bind to the binding pocket of NUDT7α, which, 
may help to understand its substrate recognition pattern and thereby, provide better 
insight into the catalytic mechanism and how it affects various diseases.  
 
4.4 Results and Discussion  
 
The Pd merged photocatalysis method, introduced in Chapter 3, combined with nuisance 
effect has been extended to other substrates known to undergo C-H activation and 
originally studied by the Sanford group.110 Hence, para-fluorobenzenediazonium 
tetrafluoroborate was reacted with 1-phenylpyrrolidin-2-one (Table 1) and different 
reactions parameters were studied.  
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Table 4.1: Optimising C-H activation conditions. 
 
 
 
Entry Light 
source 
Ru(bpy)3Cl2.6H2O 
mol% 
Temp.  Conversion LC-MS (%) 
(4.18: 4.19) 
1 a 2.5 reflux 85 (8:1) 
2 daylight 2.5 reflux 60 (2:1) 
3 b 2.5 reflux 25 (2:1) 
4 a - reflux 65 (6:1) 
5 a - r.t. 58 (20: 1) 
6 b - reflux 20 (99: trace) 
 
a 26W compact fluorescent light bulb. b in absence of light. 
 
The best condition (entry 1) gave excellent conversion (85%), which equates to a good 
75% combined isolated yield of 4.18 and 4.19. Entries 4 and 5 correspond closely to the 
earlier work of Sanford et al., who obtained a 62% conversion to 4.18 in the absence of 
a Ru catalyst, at ambient temperature, whereas Entry 6 shows that low conversions are 
observed in the absence of light.  
 
Using the optimized conditions, a small array of arylated products was formed, where we 
intended to form both the expected “Sanford arylation” products 4.18, 4.22 along with 
the “nuisance product” 4.19 - 4.21, 4.23 (Scheme 4.27). In this protocol, methanol and 
ethanol worked well as solvents and resulted in decent yields of the combined fluoroaryl 
and ether products, 75% and 70% respectively. Whereas 2-propanol did not work as well, 
possibly owing to the sterics affording a combined yield of 41% and t-butanol did not 
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lead to any product at all. Interestingly, a higher ratio of the ether product from ethanol 
was achieved in comparison with methanol, i.e. 4.19 vs. 4.20.  
 
 
 
Scheme 4.27: 1-phenylpyrrolidin-2-one derivatives (isolated yields) 
 
It was anticipated that the ratio of the products can be influenced by the sequence in which 
the reactions were performed; for instance, the ratio of the methoxy-product 4.19 vs. 
product 4.18 was significantly increased when the diazonium salt was refluxed in 
methanol first, to favour the SNAr process, and the substrate and catalysts were added 
later to the reaction, albeit with significantly lower overall yields, as shown in Scheme 
4.28. 
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Scheme 4.28: Scope for controlling the ratio of products    
a One pot procedure (4h) 
 b 4-fluorobenzenediazonium salt and MeOH were refluxed first (1h) then the other components were 
added and reacted for 4h. 
 
Gratifyingly, a one-pot test reaction, employing separate alcohols led to a small array of 
ether products alongside the expected fluorobiphenyl 4.18 (Scheme 4.29). This made use 
of the relatively poor reactivity of isopropanol, which was used as the solvent and, given 
its large excess, was nevertheless able to react to a small extent. The ratio of the mixture 
was obtained by LC-MS and it was not purified further. 
 
 
 
Scheme 4.29: Small array of 1-phenyl-2-pyrrolidinone derivatives formed from a mixture of alcohols 
 
Finally, to test the limits of this chemistry, reaction of 2-phenylpyridine with the 4-
fluorobenzenediazonium salt under reflux in methanol, led to five separable products, 
resulting from a combination of mono, di-arylation and “nuisance effects” (Scheme 4.30). 
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Scheme 4.30: A small array of 2-phenylpyridine derivatives from “nuisance effect” combined C-H 
arylation 
 
We next wished to test the scope and limitations of the Sanford arylation on substrates 
incapable of undergoing the nuisance effect. Therefore, we synthesised a small array 
4.30-4.33 as well as the known 4.19. 
 
 
 
 
Scheme 4.31: Ortho-arylated 1-phenyl-2-pyrrolidinone derivatives. 
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To test the usefulness of the Sanford arylation/nuisance effect protocol in medicinal 
chemistry, we looked at synthesising small arrays, either as mixtures or as separable 
fractions, based around privileged scaffolds (e.g. BZDs in Chapter 3, 2-phenylpyridines, 
1-phenyl-2-pyrrolidinones) for biological assays. Subsequently, the arrays of the 
synthesised compounds were tested against different biological targets by our 
collaborators at the SGC. The initial biological screening revealed that compound 4.19 
readily binds to NUDT7α and the preliminary solved co-crystal x–ray structure is shown 
in Figure 4.2.  
 
 
 
Figure 4.2: X-ray co-crystal of 4.19 bound to NUDT7α  
 
Figure 4.3 shows an overlay of independent X-ray co-crystal structures of two 
compounds, where a carbamate fragment NU181 bound in close proximity of 4.19 in the 
binding pocket. 
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Figure 4.3: An overlay of 4.19 and NU181 bound to NUDT7α (top).  
 
This provided a basis/guideline for a further series of fragment-linked 
phenylpyrrolidinones. There are many examples of “fragment-linking” in medicinal 
chemistry to achieve higher biological potency. The starting point of fragment linking 
can be determined by identifying the binding mode and key interactions of the fragments 
and the target protein. Typically, two non-overlapping molecules that bind to proximal 
sites are linked together to obtain a boost in potency.111–116 An exemplary case is the 
discovery of a novel Hsp90 (heat shock protein 90 – an anti-cancer target) inhibitor by 
fragment linking. Two fragment hits were joined to give the linked molecule in Scheme 
4.32, where the successful fragment linking led to a 1000-fold increase in the binding 
efficiency. In the ternary structure fragment 1 and fragment 2 were about 3 Å apart from 
each other and computational modelling predicted that linking them with four atoms 
would provide the correct length.117  
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Scheme 4.32: Fragment 1, IC50 = 1500 µM; Fragment 2, IC50 = 1000 µM; Linked molecule IC50 = 1.5 
µM 
  
Our aim was to combine 4.19 and NU181 to synthesise compounds such as 4.35, 4.38 
and 4.39. In the attempt to synthesise compound 4.35, the following approach was taken, 
shown in Scheme 4.29. The dealkylation of 4.19 using boron tribromide resulted in 4.34, 
which was further reacted with the isocyanate, however, the resulting compound was 
highly insoluble and could not be fully purified or characterised (Scheme 4.33).  
 
 
 
Scheme 4.33: Attempted synthesis of 4.35 
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Next, the 4-nitrobiaryl pyrrolidinone compound 4.33 was reduced to 4.36 using tin (II) 
chloride dihydrate and the aminobiaryl product was further functionalised (Scheme 4.34). 
Compounds 4.37 was prepared from 4.36 by direct acylation with the corresponding acyl 
chloride. However, analogous to 4.35, compound 4.38 was highly insoluble and proved 
to be difficult to purify and characterise. 
 
 
 
Scheme 4.34: Functionalisation of 1-(4’-aminobiphenyl-2-yl)pyrrolidin-2-one. a) SnCl2.2H2O, EtOAc, 
70oC, o/n; b) 3-chlorobenzoyl chloride, Et3N, CH2Cl2, o/n; c) 3-chlorophenyl isocyanate, Et3N, CH2Cl2, 
o/n. 
 
Next, we aimed to synthesise covalent modifying compounds to target cysteine residues, 
since the trifluoromethylbiaryl compound, 4.31 shows interactions with a proximal 
cysteine residue (Figure 4.5 - E).  
 
Cysteines are good targets for non-covalent interactions such as halogen bonding, 
however, the most powerful approach for targeting cysteines is through covalent 
modifiers or ‘irreversible’ inhibitors. Covalent inhibitors are regarded as powerful tool 
for targeting cysteines as they require lower doses, have increased biochemical efficiency 
and  longer duration of action, however, they also tend to lead to off-target toxicity due 
to the lack of selectivity.118–122 Typically, covalent inhibitors contain a highly reactive 
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electrophilic species, such as an α,β unsaturated ketones.123 Figure 4.4 shows the generic 
structures of typical key units for covalent modifiers. 
 
 
 
Figure 4.4: Structures of typical covalent modification key units 
 
Compound 4.39 and 4.40 were designed with the aim to target proximal cysteine residues. 
Compound 4.39 was easily prepared from 4.36 by direct acylation with the corresponding 
acyl chloride. Compound 4.40 was synthesised via a two-step route. 4.36 was reacted 
with maleic anhydride in chloroform to produce the maleic acid derivative. The ring-
closing occurs through dehydration to form the maleimide, 4.40. (Scheme 4.35). 
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Scheme 4.35: a) chloroacetyl chloride, Et3N, CH2Cl2, o/n; b) maleic anhydride, CHCl3, 2h; c) Acetic 
anhydride, sodium acetate, 2h, reflux  
Finally, we wished to compare the effectiveness of the arylation chemistry carried out in 
a one-pot procedure versus the “single shot” protocol described above in Scheme 4.31.  
Hence, a mixture of ortho-arylated 1-phenyl-2-pyrrolidinone derivatives was synthesised 
employing different substituted diazonium salts in one-pot reaction (Scheme 4.36). The 
mixture was then subjected to X-ray crystallographic analysis as an array versus the 
individual components. 
 
 
a LC-MS conversion rates 
Scheme 4.36: One-pot C-H arylation of 1-phenyl-2-pyrrolidinone employing several diazonium salts 
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All the compounds were biologically evaluated against NUDT7α. A number of the 
compounds that bound to the protein were co-crystallised (Figure 4.5). In total, there were 
four compounds from the ortho-arylated 1-phenyl-2-pyrrolidinone derivatives that bound 
to NUDT7α, however, none of the further functionalised derivatives, such as 4.38, 4.39 
or 4.40, produced any hits. Only the para-fluorobiphenyl 4.18 was detected while 
conducting an X-ray crystallography of the mixture from Scheme 4.36. 
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Figure 4.5: A) X-ray co-crystal structure of 4.31 With NUDT7α; B) co-crystal structure of 4.32 With 
NUDT7α; C) co-crystal structure of 4.18 with NUDT7α; D) Overlay of 4.19, 4.31 and 4.32 in the 
binding pocket of NUDT7α; D) Interactions of 4.31 and cysteine residue of NUDT7α: F to S distance is 
3.38 Å and F to O is 3.67 Å.  
D 
E 
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4.5 Conclusions 
 
Small arrays of 1-phenyl-2-pyrrolidone and 2-phenylpyridine derivatives were 
synthesised using Pd and photocatalysis merged with a “nuisance effect” C-H arylation 
method. The use of reflux temperatures and more reactive solvents (methanol or ethanol) 
in this protocol can lead to the production of a more diverse array of products. 
 
The small arrays of compounds synthesised from single reactions using the “nuisance 
effect” were utilised for preliminary biological X-ray co-crystallisation studies. A number 
of derivatives of the 1-phenyl-2-pyrrolidone series showed successful binding to 
NUDT7α (Figure 4.6). Further biological assays are currently being conducted by our 
collaborators to obtain preliminary binding data, which should help to build a more 
conclusive understanding about IC50 values, the binding efficiency, binding patterns and 
SAR of these compounds. 
 
Structures with co-crystals 
  
 
 
 
Figure 4.6: Structure of compounds co-crystallised with NUDT7α 
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4.6 Experimental details for Chapter 4 
 
See Chapter 2.4 for general experimental. 
 
 
4.6.1 1-(4’-Fluorobiphenyl-2-yl)pyrrolidin-2-one (4.18); 1-(4’-
Methoxybiphenyl-2-yl)pyrrolidin-2-one (4.19) 
1-Phenyl-2-pyrrolidinone (0.065 g, 0.40 mmol), 4-fluorobenzenediazonium 
tetrafluoroborate (0.35 g, 1.67 mmol), palladium (II) acetate (0.009 g, 0.04 mmol) and 
Ru(bpy)3Cl2.6H2O (0.007 g, 0.01 mmol) were suspended in degassed, anhydrous 
methanol (4 mL). Two fluorescent light bulbs (26 W) were placed on either side of the 
reaction vessel and the reaction mixture was heated at reflux for 4 hours under inert 
atmosphere. The reaction mixture was allowed to cool to ambient temperature, diluted 
with ethyl acetate (50 mL) and washed with water (20 mL) and aqueous sodium sulphite 
(10%, 35 mL x 2). The combined aqueous layers were extracted with ethyl acetate (50 
mL) and thereafter the combined organic layer was washed with brine (50 mL), dried 
(MgSO4) and concentrated under reduced pressure. The resulting crude material was 
purified by reversed phase chromatography (water/acetonitrile with 0.1% formic acid, 5 
min at 0%, 30%-90%). The reaction generated two products, product 4.18 was obtained 
as a viscous oil (0.062 g, 61%) and Product 4.19 was obtained also as a viscous oil (0.015 
g, 14%).  
 
4.18: 1H-NMR (500 MHz) CDCl3: δ = 7.45 – 7.40 (m, ArH, 1H), 7.40 – 7.35 (m, ArH, 
3H), 7.35 – 7.31 (m, ArH, 1H), 7.10 (pt, 3JHH = 8.7 Hz, ArH, 2H), 3.25 (t, 3JHH = 7.0 Hz, 
COCH2CH2CH2N, 2H), 2.43 (t, 3JHH = 8.0 Hz, COCH2CH2CH2N, 2H), 1.92 (p, 3JHH = 
7.5 Hz, COCH2CH2CH2N, 2H). The spectral data were concurrent with those reported. 
 
4.19: 1H-NMR (500 MHz) CDCl3: δ = 7.39 – 7.36 (m, ArH, 3H), 7.33 – 7.29 (m, ArH, 
3H), 6.97 – 6.92 (m, ArH, 2H), 3.85 (s, O-CH3, 3H), 3.23 (t, 3JHH = 7.0 Hz, 
COCH2CH2CH2N, 2H), 2.44 (t, 3JHH = 8.0 Hz, COCH2CH2CH2N, 2H), 1.90 (p, 3JHH = 
7.5 Hz, COCH2CH2CH2N, 2H). The spectral data were concurrent with those reported.86 
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4.19 was synthesised on a larger scale by combining 1-Phenyl-2-pyrrolidinone (0.50 g, 
3.1 mmol), 4-methoxybenzenediazonium tetrafluoroborate (2.75 g, 12.4 mmol), 
palladium (II) acetate (0.069 g, 0.31 mmol) and Ru(bpy)3Cl2.6H2O (0.58 g, 0.078 mmol) 
were suspended in degassed, anhydrous methanol (30 mL). Two fluorescent light bulbs 
(26 W) were placed on either side of the reaction vessel and the reaction mixture was 
heated at reflux for 4 hours under inert atmosphere. The reaction mixture was allowed to 
cool to ambient temperature, diluted with ethyl acetate (50 mL) and washed with water 
(20 mL) and aqueous sodium sulphite (10%, 35 mL x 2). The combined aqueous layers 
were extracted with ethyl acetate (50 mL) and thereafter the combined organic layer was 
washed with brine (50 mL), dried (MgSO4) and concentrated under reduced pressure. The 
resulting crude material was purified by reversed phase chromatography 
(water/acetonitrile with 0.1% formic acid, 5 min at 0%, 30%-90%). Product 4.19 was 
obtained as a viscous oil (0.64 g, 77%). 
 
4.6.2 1-(4’-Ethoxybiphenyl-2-yl)pyrrolidin-2-one (4.20) 
The same method as that of 4.18/4.19 was used but ethanol (5 mL) was used as the solvent 
instead of methanol.  Starting material, 1-phenyl-2-pyrrolidinone (0.007 g, 0.043 mmol) 
was recovered and two products were generated, product 4.18 was obtained as an oil 
(0.038 g, 42%) and product 4.20 was obtained also as an oil (0.028 g, 28%).  
 
1H-NMR (500 MHz) CDCl3: δ = 7.40 – 7.34 (m, ArH, 3H), 7.33 – 7.28 (m, ArH, 3H), 
6.93 (d, 3JHH = 8.5 Hz, ArH, 2H), 4.08 (q, 3JHH = 7.0 Hz, O-CH2CH3, 2H), 3.23 (t, 3JHH 
= 7.0 Hz, COCH2CH2CH2N, 2H), 2.44 (t, 3JHH = 8.0 Hz, COCH2CH2CH2N, 2H), 1.89 
(p, 3JHH = 7.5 Hz, COCH2CH2CH2N, 2H), 1.45 (t, 3JHH = 7.0 Hz, O-CH2CH3, 3H).  
 
13C-NMR (126 MHz) CDCl3: δ = 175.6 (C=O), 158.6 (ArC), 139.4 (ArC), 136.4 (ArC), 
131.4 (ArC), 130.9 (ArC), 129.5 (2 x ArC), 128.4 (ArC), 128.1 (ArC), 127.9 (ArC), 
114.4 (2x ArC), 63.5 (O-CH2CH3), 50.1 (COCH2CH2CH2N), 31.2 (COCH2CH2CH2N), 
19.0 (COCH2CH2CH2N), 14.8 (O-CH2CH3).  
 
HRMS-ESI (m/z) calculated for C18H19NO2 [+H] +: 282.1489, found: 282.1487. LCMS 
purity (UV) = 97 %, tR 11.85 min. 
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4.6.3 1-(4’-Propoxybiphenyl-2-yl)pyrrolidin-2-one (4.21) 
The same method as that of 4.18/4.19 was used but 2-propanol (5 mL) was used as the 
solvent instead of methanol. Starting material, 1-phenyl-2-pyrrolidinone (0.027 g, 0.17 
mmol) was recovered and two products were generated, product 7c was obtained as a 
white solid (0.019 g, 32%) and a mixture of 4.18 and 4.21 was obtained an oil (0.0059 g, 
9%) in 1:4 ratio as determined by 1H-NMR and LC-MS.  
 
4.18 & 4.21: 1H-NMR (500 MHz) CDCl3: δ = 7.62 – 7.52 (m, ArH, 1H), 7.42 – 7.35 (m, 
ArH, 4H), 7.32 – 7.26 (m, ArH, 3H), 6.91 (d, 3JHH = 8.5 Hz, ArH, 2H), 4.62 – 4.55 (m, 
O-CHCH3CH3, 1H), 3.92 (t, 3JHH = 7.0 Hz, COCH2CH2CH2N, 1H), 3.22 (t, 3JHH = 7.0 
Hz, COCH2CH2CH2N, 2H), 2.64 (t, 3JHH = 8.0 Hz, COCH2CH2CH2N  1H), 2.44 (t, 3JHH 
= 8.0 Hz, COCH2CH2CH2N x 4, 8H; 7c), 2.23 – 2.16 (m, COCH2CH2CH2N, 1H), 1.90 
(q, 3JHH = 7.5 Hz, COCH2CH2CH2N, 2H), 1.37 (d, 3JHH = 6.0 Hz, O-CHCH3CH3, 6H).  
 
HRMS-ESI (m/z) calculated for C19H21NO2 [+H] +: 296.1650, found: 296.1647. LCMS 
ratio (UV) = 6a 18%, tR 12.37 min, 7c, 75%, tR 12.29 min. 
 
4.6.4 1-(2’-Fluorobiphenyl-2-yl)pyrrolidin-2-one (4.22); 1-(2’-
Methoxybiphenyl-2-yl)pyrrolidin-2-one (4.23) 
This reaction was synthesised on a 0.30 mmol scale by the same procedure as 4.18/4.19 
and 2-fluorobenzenediazonium tetrafluoroborate (0.25 g, 1.20 mmol). Starting material, 
1-Phenyl-2-pyrrolidinone was recovered (0.006 g, 0.037 mmol) and two products were 
generated, product 4.22 was obtained as a viscous oil (0.022 g, 32%) and Product 4.23 
was obtained as a viscous oil (0.027 g, 39%). 
 
4.22: 1H-NMR (500 MHz) CDCl3: δ = 7.46 – 7.42 (m, ArH, 1H), 7.41 – 7.37 (m, ArH, 
2H), 7.36 – 7.31 (m, ArH, 3H), 7.20 – 7.16 (m, ArH, 1H), 7.15 – 7.10 (m, ArH, 1H), 3.39 
(t, 3JHH = 7.0 Hz, COCH2CH2CH2N, 2H), 2.35 (t, 3JHH = 8.0 Hz, COCH2CH2CH2N, 2H), 
1.91 (p, 3JHH = 7.5 Hz, COCH2CH2CH2N, 2H).  
 
13C-NMR (126 MHz) CDCl3: δ = 174.8 (C=O), 165.4 (d, 1JFC = 246.5 Hz, ArC), 137.8 
(ArC), 133.5 (ArC), 131.6 (ArC), 131.5 (ArC), 131.4 (ArC), 129.6 (d, 3JFC = 8.0 Hz, 
ArC), 129.1 (ArC), 127.6 (d, 3JFC = 8.5 Hz, ArC), 126.7 (d, 2JFC = 16.0 Hz, ArC), 124.1 
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(d, 4JFC = 3.5 Hz, ArC), 115.4 (d, 2JFC = 22.5 Hz, ArC), 50.2 (COCH2CH2CH2N), 31.3 
(COCH2CH2CH2N), 19.08 (COCH2CH2CH2N).  
 
HRMS-ESI (m/z) calculated for C16H14FNO [+Na] +: 278.0952, found: 278.0952. LCMS 
purity (UV) = 96 %, tR 12.30 min. 
 
4.23: 1H-NMR (500 MHz) CDCl3: δ = 7.42 – 7.37 (m, ArH, 1H), 7.37 – 7.31 (m, ArH, 
4H), 7.22 (d, 3JHH = 7.5 Hz, ArH, 1H), 7.00 (d, 3JHH = 7.5 Hz, ArH, 1H), 6.98 – 6.94 (m, 
ArH, 1H), 3.76 (s, O-CH3, 3H), 3.26 (t, 3JHH = 7.0 Hz, COCH2CH2CH2CN, 2H), 2.34 
(t,3JHH = 8.0 Hz, COCH2CH2CH2N, 2H), 1.82 (p, 3JHH = 7.5 Hz, COCH2CH2CH2CN, 
2H). 
 
13C-NMR (126 MHz) CDCl3: δ = 174.7 (C=O), 156.4 (ArC), 137.3 (ArC), 136.0 (ArC), 
131.8 (ArC), 130.9 (ArC), 129.1 (ArC), 128.3 (ArC), 128.0 (ArC), 127.8 (ArC), 127.2 
(ArC), 120.6 (ArC), 110.7 (ArC), 55.5 (O-CH3), 49.9 (COCH2CH2CH2N), 31.3 
(COCH2CH2CH2N), 19.2 (COCH2CH2CH2N).  
 
HRMS-ESI (m/z) calculated for C17H17NO2 [+Na] +: 290.1151, found: 290.1151. LCMS 
purity (UV) = 94 %, tR 11.65 min. 
 
4.6.5 Reaction with 2-Phenylpyridine 
2-Phenylpyridine (0.078 g, 0.50 mmol), 4-fluorodiazonium tetrafluoroborate (0.42 g, 2.0 
mmol), palladium (II) acetate (0.011 g, 0.05 mmol) and Ru(bpy)3Cl2.6H2O (0.009 g, 
0.013 mmol) were suspended in degassed, anhydrous methanol (4 mL). Two fluorescent 
light bulbs (26 W) were placed on either side of the reaction vessel and the mixture was 
heated at reflux for 4 hours. The reaction mixture was allowed to cool to ambient 
temperature, diluted with ethyl acetate (40 mL) and washed with water (20 mL) and 
aqueous sodium sulphite (10%, 35 mL x 2). The combined aqueous layer was extracted 
with ethyl acetate (50 mL) and thereafter the combined organic layer was washed with 
brine (50 mL), dried (MgSO4) and concentrated under reduced pressure. The resulting 
crude material was purified by reversed phase chromatography (water/acetonitrile with 
0.1% formic acid, 5 min at 0%, 30%-90%). Starting material, 1-phenyl-2-pyrrolidinone 
was recovered (0.008 g, 0.052 mmol) and five products were generated from this reaction: 
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2-(4’-Methoxybiphenyl-2-yl)pyridine (4.25)  
Product 4.25 was obtained as a green/yellow oil (0.022 g, 19%). The spectral data were 
concurrent with those reported.5  
 
2-(4’-Fluorobiphenyl-2-yl)pyridine (4.26) 
Product 4.26 was obtained as a viscous oil (0.018 g, 16%). The spectral data were 
concurrent with those reported.5  
 
2-(4,4’-Methoxybiphenyl-2,6-yl)pyridine (4.27) 
Product 9c was obtained as a green/yellow oil (0.016 g, 10%). The spectral data were 
concurrent with those reported.5  
 
2-(4,4’-Fluoromethoxybiphenyl-2,6-yl)pyridine (4.28) 
Product 4.28 was obtained as a viscous oil (0.024 g, 15%). 
 
1H-NMR (500 MHz) CDCl3: δ = 8.37 – 8.32 (m, ArH, 1H), 7.49 (pt, 3JHH = 7.5 Hz, ArH, 
1H), 7.45 – 7.42 (m, ArH, 1H), 7.38 (d, 3JHH = 7.5 Hz, ArH, 1H), 7.35 – 7.30 (m, ArH, 
1H), 7.07 – 7.03 (m, ArH, 2H), 7.01 (d, 3JHH = 8.5 Hz, ArH, 2H), 6.95 – 6.92 (m, ArH, 
1H), 6.87 – 6.81 (m, ArH, 3H), 6.69 (d, ArH, 3JHH = 8.5 Hz, 2H), 3.75 (s, O-CH3, 3H).  
 
13C-NMR (126 MHz) CDCl3: δ = 161.5 (d, 1JFC = 246.0 Hz, ArC), 158.9 (ArC), 158.2 
(ArC), 148.4 (ArC), 141.5 (ArC), 140.8 (ArC), 137.5 (ArC), 135.2 (ArC), 133.7 (ArC), 
131.1 (d, 3JFC = 7.8 Hz; 2 x ArC), 130.7 (2 x ArC), 128.6 (ArC), 129.1 (ArC), 128.2 
(ArC), 126.9 (ArC), 126.6 (ArC), 121.0 (ArC), 114.5 (d, 2JFC = 21.1 Hz; 2 x ArC), 113.2 
(2 x ArC), 55.1 (O-CH3).  
 
HRMS-ESI (m/z) calculated for C24H18FNO [+H] +: 356.1445, found: 356.1444. LCMS 
purity (UV) = 93 %, tR 16.35 min. 
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2-(4,4’-Fluorobiphenyl-2,6-yl)pyridine (4.29) 
Product 4.29 was obtained as a viscous oil (0.012 g, 8%). The spectral data were 
concurrent with those reported.5 
 
4.6.6 1-(4’-Trifluoromethylbiphenyl-2-yl)pyrrolidin-2-one (4.30) 
The same method as that of 4.19 was used on a 0.3 mmol scale with 4-
trifluoromethylbenzene diazonium tetrafluoroborate (1.2 mmol, 0.31 g). Product 4.30 
was obtained as a viscous oil (0.081 g, 89%).  
 
1H-NMR (500 MHz) CDCl3: δ = 7.68 – 7.64 (m, ArH, 2H), 7.50 (d, 3JHH = 8.0 Hz, ArH, 
2H), 7.46 – 7.41 (m, ArH, 1H), 7.40 – 7.36 (m, ArH, 1H), 7.35 – 7.32 (m, ArH, 1H), 7.26 
– 7.25 (m, ArH, 1H), 3.27 (d, 3JHH = 7.0 Hz, COCH2CH2CH2N, 2H), 2.42 (t, 3JHH = 8.0 
Hz, COCH2CH2CH2N, 2H), 1.91 (p, 3JHH = 7.5 Hz, COCH2CH2CH2N, 2H). The spectral 
data were concurrent with those reported. 
 
4.6.7 1-(3’-Trifluoromethylbiphenyl-2-yl)pyrrolidin-2-one (4.31) 
The same method as that of 4.19 was used on a 0.3 mmol scale with 3-
trifluoromethylbenzene diazonium tetrafluoroborate (1.2 mmol, 0.31 g). Product 4.31 
was obtained as an oil (0.082 g, 90%). 
 
1H-NMR (500 MHz) CDCl3: δ = 7.64 – 7.57 (m, ArH, 3H), 7.53 (pt, 3JHH = 7.6 Hz, ArH, 
1H), 7.47 – 7.42 (m, ArH, 1H), 7.42 – 7.39 (m, ArH, 2H), 7.33 (d, 3JHH = 7.5 Hz, ArH, 
1H), 3.28 (t, 3JHH = 7.0 Hz, COCH2CH2CH2N, 2H), 2.40 (t, 3JHH = 8.0 Hz, 
COCH2CH2CH2N, 2H), 1.91 (p, 3JHH = 7.5 Hz, COCH2CH2CH2N, 2H).  The spectral 
data were concurrent with those reported. 
 
4.6.8 1-(4’-Methylbiphenyl-2-yl)pyrrolidin-2-one (4.32) 
The same method as that of was used on a 0.3 mmol scale with 4-methylbenzene 
diazonium tetrafluoroborate (1.21 mmol, 0.25 g). Product 4.32 was obtained as an oil 
(0.051 g, 67%).  
 
1H-NMR (500 MHz) CDCl3: δ = 7.40 – 7.33 (m, ArH, 4H), 7.31 – 7.28 (m, ArH, 1H), 
7.25 – 7.24 (m, ArH, 1H), 7.19 (d, 3JHH = 7.5 Hz, ArH, 2H), 3.20 (t, 3JHH = 7.0 Hz, 
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COCH2CH2CH2N, 2H), 2.42 (t, 3JHH = 8.0 Hz, COCH2CH2CH2N, 2H), 2.37 (s, CH3, 
3H), 1.87 (p, 3JHH = 7.5 Hz, COCH2CH2CH2N, 2H). The spectral data were concurrent 
with those reported. 
 
4.6.9 1-(4’-Nitrobiphenyl-2-yl)pyrrolidin-2-one (4.33) 
The same method as that of was used on a 3.5 mmol scale with 4-nitrobenzene diazonium 
tetrafluoroborate (11 mmol, 2.61 g). Product 4.33 was obtained as an oil (0.86 g, 87%). 
 
1H-NMR (500 MHz) CDCl3: δ = 8.26 (d, 3JHH = 9.0 Hz, ArH, 2H), 7.54 (d, 3JHH = 9.0 
Hz, ArH, 2H), 7.51 – 7.46 (m, ArH, 1H), 7.42 (pt, 3JHH = 7.5 Hz, ArH, 1H), 7.40 – 7.37 
(m, ArH, 1H), 7.34 (d, 3JHH = 8.0 Hz, ArH, 1H), 3.34 (t, 3JHH = 7.0 Hz, COCH2CH2CH2N, 
2H), 2.40 (t, 3JHH = 8.0 Hz, COCH2CH2CH2N, 2H), 1.95 (p, 3JHH = 7.5 Hz, 
COCH2CH2CH2N, 2H). The spectral data were concurrent with those reported.86 
 
4.6.10 1-(4’-Hydroxybiphenyl-2-yl)pyrrolidin-2-one (4.34) 
In a stirred solution of 1-(4’-methoxybiphenyl-2-yl)pyrrolidin-2-one (1.6 mmol, 0.42 g) 
in DCM (10mL) was added 1M BBr3 (10 mL) in DCM dropwise at 0oC under inert 
atmosphere. The reaction mixture was allowed to warm to ambient temperature and 
stirred for additional 16 h. The resulting mixture was carefully quenched with saturated 
sodium bicarbonate (50 mL) and the mixture was extracted with DCM (40mL x 2). The 
combined organic layer was dried (MgSO4) and concentrated under reduced pressure. 
The resulting crude product was triturated with diethyl ether overnight. The precipitate 
was collected by filtration to afford a grey solid (0.24 g, 58%) 
 
1H-NMR (500 MHz) DMSO-D6: δ = 7.36 – 7.29 (m, ArH, 3H), 7.26 – 7.22 (m, ArH, 
1H), 7.10 (d, 3JHH = 8.7 Hz, 2H), 6.81 – 6.76 (m, ArH, 2H), 3.19 (t, 3JHH = 7.0 Hz, 
COCH2CH2CH2N, 2H), 2.23 (t, 3JHH = 8.0 Hz, COCH2CH2CH2N, 2H), 1.81 (p, 3JHH = 
7.5 Hz, COCH2CH2CH2N, 2H).  
 
13C-NMR (126 MHz) DMSO-D6: δ = 174.7 (C=O), 157.3 (ArC), 137.3 (ArC), 139.5 
(ArC), 136.9 (ArC), 130.9 (ArC), 129.8 (ArC), 129.5 (ArC x 2), 129.0 (ArC), 128.1 
(ArC), 128.0 (ArC), 115.7 (ArC x 2), 49.9 (COCH2CH2CH2N), 31.1 
(COCH2CH2CH2N), 19.0 (COCH2CH2CH2N).  
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HRMS-ESI (m/z) calculated for C16H15NO2 [+H] +: 267.1259, found: 267.1262 LCMS 
purity (UV) = 99%, tR 18.51 min. 
 
4.6.11 1-(4’-Aminobiphenyl-2-yl)pyrrolidin-2-one (4.36) 
To a stirred solution of 1-(4’-nitrobiphenyl-2-yl)pyrrolidin-2-one (2.8 mmol, 0.8 g) in 
ethyl acetate (20mL) was added tin(ll) chloride dihydrate (14 mmol, 3.2 g) and the 
reaction was stirred at 70 0C overnight. The resulting mixture was neutralised with 
saturated sodium bicarbonate and extracted with ethyl acetate (40 mL x 2). The combined 
organic layers were dried (MgSO4) and concentrated under reduced pressure to afford the 
product as a white solid (0.62 g, 88%). 
 
1H-NMR (500 MHz) DMSO-D6: δ = 7.34 – 7.24 (m, ArH, 3H), 7.20 (d, 3JHH = 7.5 Hz, 
ArH, 1H), 6.96 (d, 3JHH = 7.5 Hz, ArH, 2H), 6.61 – 6.52 (m, ArH, 2H), 3.18 (t, 3JHH = 
7.0 Hz, COCH2CH2CH2N, 2H), 2.25 (t, 3JHH = 8.0 Hz, COCH2CH2CH2N, 2H), 1.82 (p, 
3JHH = 7.5 Hz, COCH2CH2CH2N, 2H).  
 
13C-NMR (126 MHz) CDCl3: δ = 175.7 (C=O), 145.9 (ArC), 139.6 (ArC), 136.2 (ArC), 
130.8 (ArC), 130.8 (ArC), 129.3 (ArC x 2), 129.2(ArC), 128.4 (ArC), 128.0 (ArC), 127.8 
(ArC), 115.0 (ArC x 2), 49.9 (COCH2CH2CH2N), 31.1 (COCH2CH2CH2N), 19.0 
(COCH2CH2CH2N).  
 
HRMS-ESI (m/z) calculated for C16H16N2O [+H] +: 253.1335, found: 253.1328. LCMS 
purity (UV) = 95%, tR 13.38 min. 
 
4.6.12 2-Chloro-N-[2'-(2-oxopyrrolidin-1-yl)biphenyl-4-yl]acetamide 
(4.37) 
To a stirred solution of 1-(4’-aminobiphenyl-2-yl)pyrrolidin-2-one (0.38 mmol, 0.095 g) 
and triethylamine (0.38 mmol, 0.05 mL) in anhydrous DCM  (8 mL) was added 
chloroacetyl chloride (0.46 mmol, 0.052 g) dropwise at 0oC. The reaction mixture was 
allowed to warm to ambient temperature and stirred overnight. The reaction mixture was 
concentrated under reduced pressure. The residue was washed with washed with water 
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(10 mL x 3) and the resulting precipitate was collected by filtration to afford the final 
product as a while solid (0.093g, 75%).  
 
1H-NMR (500 MHz) CDCl3: δ = 8.55 (s, NH, 1H), 7.59 (d, 3JHH = 8.1 Hz, ArH, 2H), 7.41 – 7.33 
(m, ArH, 5H), 7.30 (d, 3JHH = 7.2 Hz, ArH, 1H), 4.17 (s, COCH2Cl, 2H), 3.27 (t, 3JHH = 7.0 Hz, 
COCH2CH2CH2N, 2H), 2.42 (t, 3JHH = 8.0 Hz, COCH2CH2CH2N, 2H), 1.90 (p, 3JHH = 7.5 Hz, 
COCH2CH2CH2N, 2H).  
 
13C-NMR (126 MHz) CDCl3: δ = 175.7 (CH2NC=O), 164.0 (NHC=O), 138.9 (ArC), 
136.5 (ArC), 136.2 (ArC), 135.8 (ArC), 130.8 (ArC), 128.7 (ArC x 2), 128.3 (ArC), 
128.2 (ArC), 119.9 (ArC x 2), 50.3 (COCH2CH2CH2N), 43.0 (COCH2Cl), 31.2 
(COCH2CH2CH2N), 19.0 (COCH2CH2CH2N).  
 
HRMS-ESI (m/z) calculated for C18H17ClN2O2 [+H] +: 329.1051, found: 329.1053. LCMS 
purity (UV) = 97%, tR 19.77 min. 
 
4.6.13 2-Chloro-N-[2'-(2-oxopyrrolidin-1-yl)biphenyl-4-yl]acetamide 
(4.38) 
To a stirred solution of 1-(4’-aminobiphenyl-2-yl)pyrrolidin-2-one (0.39 mmol, 0.10 g) 
and triethylamine ( 1.98 mmol, 0.20 g) in anhydrous DCM  (10 mL) was added 3-
chlorobenzoyl chloride (1.2 mmol, 0.21 g) and the reaction mixture was stirred overnight. 
The reaction mixture was concentrated under reduced pressure and the crude product was 
purified by column chromatography (DCM/methanol over 0% - 10% gradient) to afford 
product 4.38 as a white amorphous solid (0.11 g, 72%). 
 
4.38: 1H-NMR (500 MHz) CDCl3: δ = 8.72 (s, NH, 1H), 7.95 – 7.90 (m, ArH, 1H), 7.79 (d, 3JHH 
= 7.5 Hz, ArH, 1H), 7.72 (d, 3JHH = 8.5 Hz, ArH, 2H), 7.50 (dd, 3,4JHH = 8.0, 2.0 Hz, ArH,  1H), 7.40 
– 7.34 (m, ArH, 6H), 7.32 – 7.26 (m, 1H), 3.31 (t, 3JHH = 7.0 Hz, ArH, COCH2CH2CH2N, 2H), 2.38 
(t, 3JHH = 8.0 Hz, COCH2CH2CH2N, 2H), 1.91 (p, 3JHH = 7.5 Hz, COCH2CH2CH2N, 2H).  
 
13C-NMR (126 MHz) CDCl3: δ = 175.8 (CH2NC=O), 164.6 (NHC=O), 139.1 (ArC), 
137.8 (ArC), 136.6 (ArC), 136.1 (ArC), 135.1 (ArC), 134.7 (ArC), 131.8 (ArC), 130.9 
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(ArC), 129.9 (ArC), 128.9 (ArC x 2), 128.5 (ArC), 127.6 (ArC), 125.5 (ArC x 2), 50.5 
(COCH2CH2CH2N), 31.2 (COCH2CH2CH2N), 18.9 (COCH2CH2CH2N).  
 
HRMS-ESI (m/z) calculated for C23H19ClN2O2 [+H] +: 391.1208, found: 391.1199. LCMS 
purity (UV) = 91 %, tR 18.38 min. 
 
4.6.14 1-[2'-(2-oxopyrrolidin-1-yl)biphenyl-4-yl]1H-pyrrole-2,5-dione 
(4.40) 
1-(4’-aminobiphenyl-2-yl)pyrrolidin-2-one (0.20 mmol, 0.050 g), maleic anhydride (0.24 
mmol, 0.024 g) were dissolved in CHCl3 (3 mL) and stirred for 2 h. The reaction mixture 
was concentrated under reduced pressure. To a stirred solution of the crude maleic acid 
in acetic anhydride (19.5 mmol, 2.0 g) was added sodium acetate (0.40 mmol, 0.033 g) 
and heated at reflux for 2 h. After cooling to ambient temperature, the reaction was 
quenched with water (20 mL) and extracted with ethyl acetate (20 mL x 2). The combined 
organic layers were dried (Na2SO4) and concentrated under reduced pressure. The crude 
mixture was purified by column chromatography (hexane/ethyl acetate over 0% - 10% 
gradient) to afford 4.40 as a yellow solid (0.036g, 54%).   
 
4.40: 1H-NMR (500 MHz) CDCl3: δ = 7.48 (d, 3JHH = 8.5 Hz, ArH, 2H), 7.44 – 7.41 (m, ArH, 
2H), 7.40 – 7.38 (m, ArH, 3H), 7.35 – 7.31 (m, ArH, 1H), 6.88 (s, COCHCHCO, 2H), 3.25 (t, 3JHH = 
7.0 Hz, COCH2CH2CH2N, 2H), 2.45 (t, 3JHH = 8.0 Hz, COCH2CH2CH2N, 2H), 1.91 (p, 3JHH = 
7.5 Hz, COCH2CH2CH2N, 2H).  
 
13C-NMR (126 MHz) CDCl3: δ = 175.8 (CH2NC=O), 169.4 (CHCONCOCH), 138.7 
(ArC), 136.4 (ArC), 134.3 (ArC x 2), 130.8 (ArC), 130.7 (ArC), 129.1 (ArC x 2), 129.0 
(ArC), 128.5 (ArC), 128.2 (ArC), 125.8 (ArC x 2), 50.3 (COCH2CH2CH2N), 31.2 
(COCH2CH2CH2N), 19.0 (COCH2CH2CH2N).  
 
HRMS-ESI (m/z) calculated for C20H16N2O3 [+H] +: 333.1234, found: 333.1225. LCMS 
purity (UV) = 97 %, tR 18.77 min. 
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Chapter 5 
 
 
N1-Arylation of 1,4-Benzodiazepin-2-ones with 
Diaryliodonium Salts 
 
5.1 Introduction 
 
Compounds containing a 1,4-benzodiazepine scaffold are often termed as ‘privileged 
structures’ and are of  significant interest to organic and medicinal chemists.1–18 Many 
bioactive 1,4- benzodiazepines include N-arylated benzodiazepines; for example, the 
benzodiazepine derivative, A (Figure 5.1), is a bradykinin antagonist19 and the related 
benzotriazepine B is an antagonist at the parathyroid hormone (PTH)-1 receptor.20 
Typically N-arylated benzodiazepines can be prepared by transition-metal catalysed 
couplings, often with copper, with various arylating agents. Generally, the reaction scope 
is limited with these routes and often require high temperatures and strong bases.19,21–23 
 
Being able to generate libraries of diverse analogues, in this case by adding N-H 
functionality to a privileged core unit, using mild and efficient methodologies, can 
substantially improve SAR studies (structure – activity relationship) and optimise the 
drug development process potentially to repurposing privileged scaffolds for new 
biological targets.24,25 
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Figure 5.1: Bioactive N-arylated benzodiazepine and benzotriazepine 
 
5.2 Results and discussion 
 
As apparent from Chapter 2 and 3, we have an active interest in benzodiazepines,26,27 
where protocols to functionalise 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-ones via 
a late-stage palladacycle assisted ortho C-H activation protocol have been reported.28,29 
In this Chapter, our approach to generate a series of N1-arylated 1,4-benzodiazepines 
using diaryliodonium salts is presented. The latter react with nucleophiles in the absence 
of transition metal catalysts and are commonly used in organic synthesis as electrophilic 
reagents.30–35  
 
Novak et al. recently reported a protocol for the N-arylation of pyrazoles.36  
 
 
 
Scheme 5.1: N-arylation of pyrazoles 
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A quick screen of conditions, adapting this protocol using diaryliodonium salts with weak 
bases under mild conditions, showed that it was indeed possible to perform similar 
arylations on the 1,4-benzodiazepine system. Upon initial screening of a number of 
solvents, DCE (1,2-dichloroethane) was found to give the best results (Table 5.1, Entry 
2). Solvents such as PEG (polypropylene glycol) and acetic acid gave poor yields. Similar 
results were observed on pyrazoles by Novak et al. where apolar solvents, immiscible in 
water, produced the best results. 
 
Table 5.1: Optimisation of N-arylation of 1,4-benzodiazepines – solvent effects 
 
H
N
N
O
25% w/w NH3
solvent, rt, 30 min
I+Ph
OTf-
O2N
N
N
O
O2N
 
Entry Solvent Conversion %a 
1 Toluene 95 
2 DCE 99 
3 PEG - 
4 AcOH - 
5 Chloroform 85 
 
a LCMS conversion 
 
A number of bases were tested subsequently and both NH3 (25% w/w) and NaOH (sat. 
aq.) gave similar and the best results (Table 2, entry 1, 2). 
 
Table 5.2: Optimisation of N-arylation of 1,4-benzodiazepines – base effects 
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H
N
N
O
base
DCE, rt, 30min
I+Ph
OTf-
O2N
N
N
O
O2N
 
Entry Base Conversion %a 
1 NaOH (sat. aq.) 99 
2 NH3 (25% w/w) 99 
3 K2CO3 80 
4 NaH - 
 
a LCMS conversion 
 
Hence, optimal conditions appeared to use NH3 (aq.), DCE at room temperature for 30 
min. Next, a series of functionalized 1,4-benzodiazepines was N-arylated using (4-
nitrophenyl)phenyliodonium triflate in good to excellent yields (Scheme 5.2). Generally, 
in transition-metal-free processes unsymmetrical diaryliodonium salts give a mixture of 
products where both aryl groups are transferred and the transfer of more sterically 
hindered and electron withdrawing group is preferable.34 However, in this case (Scheme 
5.1) only the nitrophenyl-group was transferred. We were able to N-arylate quite sterically 
hindered benzodiazepines such as 5.7, 5.8 and 5.9. Of note, 5.7 is a key intermediate 
towards A, the bradykinin B2 receptor antagonist. We were also pleased to be able to 
conduct N-arylation on a previously ortho-arylated hindered benzodiazepine, 5.10, in 
good yield, whose structure was also confirmed by X-ray crystallography. Such 
molecules may be useful precursors to e.g., alpha-helical mimetics in medicinal 
chemistry.37,38 
 
 180 
 
 
 
Scheme 5.2: N-arylated 1,4-benzodiazepines 
 
The use of other unsymmetrical diaryliodonium triflates was also explored (Table 5.3), 
which required longer reaction time and led to both aryl groups being transferred to obtain 
5.13 – 5.16.  As expected, the transfer of more sterically hindered or less electron rich 
groups was preferred. Further attempt to use unsymmetrical diaryliodonium salts such as 
phenyl(3-methylphenyl)iodonium triflate, phenyl(4-methylphenyl)iodonium triflate and 
(2-methylphenyl)(2,4,6-trimethylphenyliodonium triflate gave little or no products. 
Moreover, attempted N-arylation with symmetrical diaryliodonium triflates or 
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tetrafluoroborates such as bis(2-fluorophenyl)iodonium tetrafluoroborate and bis(4-
bromophenyl)iodonium triftlate, gave no products.  
 
Table 5.3: Further N-arylation of 1,4-benzodiazepines 
 
Salt Product (major) Product (minor) 
 
  
 
 
 
 
a Reaction time 8h 
 
We have briefly explored the N-arylation on a 1,3,4-benzotriazepine, 5.17, which resulted 
in di-arylation and yielded 5.18 (Scheme 5.3).  
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Scheme 5.3: N-arylation on a 1,3,4-Benzotriazepine 
 
Interestingly, the iodonium salts were observed to undergo reaction with water present in 
the reaction to give diarylether products. The ether product is only observed when the 
benzodiazepine substrates react poorly with the diaryliodonium salys (Table 5.4). The 
ether product is also obtained merely by stirring the iodonium salt with water in DCE 
with a mild base for 20 min at room temperature with a yield of 43%. Olofsson et al. have 
reported the synthesis of related diarylethers by reacting diaryliodonium salts with 
phenols in the presence of mild bases.39  
 
Table 5.4: Ether formation 
Substrate Expected 
product 
Observed product 
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5.3 Conclusion 
In summary, we have presented a mild metal-free route to N-arylated benzodiazepines, 
three of which were structurally characterized in the solid state (5.3, 5.10, 5.13, with 
CCDC numbers 1560492-1560494 respectively.40 
 
5.4 Experimental details for Chapter 5 
 
  
General experimental details are provided in Chapter 2.4.  
 
5.4.2 General Procedure 
To a stirred solution of the appropriate 1,4-benzodiazepine or 1,3,4-benzotriazepine 
(0.030 mmol – 1.00 mmol, 1 eq.) and diaryliodonium salt (0.033 – 1.10 mmol, 1.1 eq.)  
in DCE (5 – 10 mL) was added 25% w/w NH3 solution (aq. 5 - 10 mL) and the reaction 
mixture was stirred for 30 min. (unless stated otherwise). Upon completion, the reaction 
mixture was diluted with dichloromethane (3x15 mL) and the layers were separated. 
Combined organic layers were dried (MgSO4), concentrated under reduced pressure and 
purified by column chromatography, hexane/ethyl acetate (80:20 to 30:70). 
 
5.4.3 1-(4-Nitrophenyl)-5-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
(5.3)  
The product was obtained as white solid (0.60 mmol scale, 170 mg, 96%).  
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1H-NMR (500 MHz) CDCl3: δ = 8.27 – 8.21 (m, ArH, 2H), 7.62 (dd, 3JHH = 7.5, 1.5 Hz, 
ArH, 1H), 7.40 – 7.35 (m, ArH, 3H), 7.34 – 7.29 (m, ArH, 1H), 6.82 (d, 3JHH = 8.0 Hz, 
ArH, 1H), 4.70 (d, 2JHH = 10.5 Hz, COCH2, 1H), 3.83 (d, 2JHH = 10.5 Hz, COCH2, 1H), 
2.62 (s, CH3, 3H).  
 
13C-NMR (126 MHz) CDCl3: δ = 170.1 (C=O), 168.1 (C=N), 146.7 (ArC), 146.0 (ArC), 
140.8 (ArC), 131.4 (ArC), 131.3 (ArC), 128.7 (ArC x 2), 127.8 (ArC), 125.9 (ArC), 
125.1 (ArC), 124.5 (ArC x 2), 56.6 (COCH2), 25.5 (CH3).  
 
HRMS-ESI (m/z) calculated for C16H13N3O3 [+H] +: 296.1030, found: 296.1033. LCMS 
purity (UV) = 100%, tR 8.10 min. 
 
5.4.4 1-(4-Nitrophenyl)-5-(propan-2-yl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (5.4) 
The product was obtained as a white solid (0.52 mmol scale, 166 mg, 99%).  
 
1H-NMR (500 MHz) CDCl3: δ = 8.27 – 8.20 (m, ArH, 2H), 7.59 (dd, 3JHH = 7.5, 2.0 Hz, 
ArH, 1H), 7.39 – 7.35 (m, ArH, 3H), 7.34 – 7.30 (m, ArH, 1H), 6.83 (dd, 3JHH = 8.0, 1.5 
Hz, ArH, 1H), 4.72 (d, 2JHH = 10.5 Hz, COCH2, 1H), 3.82 (d, 2JHH = 10.5 Hz, COCH2, 
1H), 3.34 – 3.25 (m, 1H), 1.35 (d, 3JHH = 7.0 Hz, CNCHC2CH6, 3H), 1.11 (d, 3JHH = 7.0 
Hz, CNCHC2CH6, 3H).  
 
13C-NMR (126 MHz) CDCl3: δ = 176.9 (C=O), 168.7 (C=N), 146.7 (ArC), 145.9 (ArC), 
141.5 (ArC), 131.6 (ArC), 130.9 (ArC), 128.3 (ArC x 2), 127.0 (ArC), 126.0 (ArC), 
125.0 (ArC), 124.5 (ArC x 2), 56.5 (COCH2), 35.6 (CNCHC2H6), 22.0 (CNCHC2H6), 
19.2 (CNCHC2H6).  
 
HRMS-ESI (m/z) calculated for C18H17N3O3 [+H]+: 324.1270, found: 324.1281. LCMS 
purity (UV) = 96 %, tR 18.73 min. 
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5.4.5 1-(4-Nitrophenyl)-3-(propan-2-yl)-5-(propan-2-yl)-1,3-dihydro-2H-
1,4-benzodiazepin-2-one (5.5) 
The product was obtained as white solid (0.25 mmol scale, 91 mg, 99%).  
 
1H-NMR (500 MHz) CDCl3: δ = 8.25 – 8.18 (m, ArH, 2H), 7.61 (dd, 3JHH = 8.0, 1.5 Hz, 
ArH, 1H), 7.39 – 7.24 (m, ArH, 4H), 6.85 (dd, J = 8.0, 1.5 Hz, ArH, 1H), 3.27 (hept, 3JHH 
= 7.0 Hz, CNCHCH3CH3, 1H), 3.12 (d, 3JHH = 9.5 Hz, COCHCHC2H6, 1H), 2.72 – 2.61 
(m, COCHCHC2H6, 1H), 1.33 (d, 3JHH = 7.0 Hz, CNCHC2H6, 3H), 1.07 (d, 3JHH = 7.0 
Hz, CNCHC2CH6, 3H), 1.05 – 1.02 (m, COCHCHC2H6, 6H).  
 
13C-NMR (126 MHz) CDCl3: δ = 173.9 (C=O), 168.3 (C=N), 147.4 (ArC), 145.7 (ArC), 
141.1 (ArC), 131.9 (ArC), 130.6 (ArC), 128.4 (ArC x 2), 126.8 (ArC), 125.7 (ArC), 
125.1 (ArC), 124.4 (ArC x 2), 69.3 (COCHCHC2H6), 35.5 (CNCHCH3CH3), 22.2 
(COCHCHC2H6), 21.9 (CNCHC2H6), 20.1, (CNCHC2H6) 19.3 (COCHCHC2H6), 18.7 
(COCHCHC2H6).   
 
HRMS-ESI (m/z) calculated for C21H23N3O3 [+H] +: 366.1812, found: 366.1816. LCMS 
purity (UV) = 95%, tR 23.47 min. 
 
5.4.6 1-(4-Nitrophenyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
(5.6) 
The product was obtained as white solid (0.60 mmol scale, 176 mg, 82%).  
 
1H-NMR (500 MHz) CDCl3: δ = 8.30 – 8.23 (m, ArH, 2H), 7.77 – 7.71 (m, ArH, 2H), 
7.55 – 7.51 (m, ArH, 1H), 7.49 – 7.45 (m, ArH, 3H), 7.45 – 7.41 (m, ArH, 3H), 7.29 (d, 
3JHH = 8.0 Hz, ArH, 1H), 6.94 (d, 3JHH = 8.0 Hz, ArH, 1H), 4.96 (d, 2JHH = 10.5 Hz, 
COCH2, 1H), 4.03 (d, 2JHH = 10.5 Hz, COCH2, 1H).  
 
13C-NMR (126 MHz) CDCl3: δ = 170.3 (C=O), 168.3 (C=N), 146.7 (ArC), 146.0 (ArC), 
142.7 (ArC), 138.4 (ArC), 131.4 (ArC), 130.8 (ArC), 130.4 (ArC), 130.3 (ArC), 129.4 
(ArC x 2), 128.5 (ArC x 2), 128.4 (ArC x 2), 125.4 (ArC), 125.0 (ArC), 124.5 (ArC x 
2), 57.4 (COCH2).  
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HRMS-ESI (m/z) calculated for C21H15N3O3 [+H] +: 358.1186, found: 358.1187. LCMS 
purity (UV) = 95%, tR 18.35 min. 
 
5.4.7 1-(4-Nitrophenyl)-3-benzyl-5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (5.7) 
The product was obtained as white solid (0.40 mmol scale, 140 mg, 78%).  
1H-NMR (500 MHz) CDCl3: δ = 8.27 – 8.21 (m, ArH, 2H), 7.67 (d, 3JHH = 7.5 Hz, ArH, 
2H), 7.52 – 7.48 (m, 1H), 7.47 – 7.43 (m, ArH, 2H), 7.41 – 7.37 (m, ArH,  5H), 7.36 – 
7.30 (m, ArH, 3H), 7.25 – 7.21 (m, ArH, 2H), 6.90 (d, 3JHH = 8.0 Hz, ArH, 1H), 4.01 (dd, 
J = 7.5, 6.0 Hz, COCHCH2, 1H), 3.68 (dd, 2,3JHH = 14.0, 6.0 Hz, COCHCH2, 1H), 3.62 
(dd, 2,3JHH  = 14.0, 7.5 Hz, COCHCH2, 1H).  
 
13C-NMR (126 MHz) CDCl3: δ = 168.8 (C=O), 168.5 (C=N), 147.1 (ArC), 145.9 (ArC), 
142.1 (ArC), 138.9 (ArC), 138.4 (ArC), 131.5 (ArC), 130.8 (ArC), 130.5 (ArC), 130.3 
(ArC), 130.0 (ArC x 2), 129.5 (ArC x 2), 128.6 (ArC x 2), 128.5 (ArC x 2), 128.3 (ArC 
x 2), 126.3 (ArC), 125.3 (ArC), 125.1 (ArC), 124.5 (ArC x 2), 65.6 (COCHCH2), 37.9 
(COCHCH2).  
 
HRMS-ESI (m/z) calculated for C28H21N3O3 [+H] +: 448.1656, found: 448.1669. LCMS 
purity (UV) = 99 %, tR 20.81 min. 
 
5.4.8 7-Chloro-1-(4-nitrophenyl)-3-benzyl-5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (5.8) 
The product was obtained as white solid (0.15 mmol scale, 54 mg, 75%).  
 
1H-NMR (500 MHz) CDCl3: δ = 8.26 (d, 3JHH  = 8.5 Hz, ArH, 2H), 7.66 (d, 3JHH  = 7.5 
Hz, ArH, 2H), 7.57 – 7.50 (m, ArH, 1H), 7.51 – 7.44 (m, ArH, 2H), 7.42 – 7.36 (m, ArH, 
3H), 7.34 – 7.30 (m, ArH, 2H), 7.26 (s, ArH, 3H), 7.17 (d, J = 8.7 Hz, ArH, 1H), 6.85 
(d, 3JHH = 8.5 Hz, ArH, 1H), 3.99 (dd, J = 7.5, 6.0 Hz, COCHCH2, 1H), 3.70 – 3.57 (m, 
COCHCH2, 2H).  
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13C-NMR (126 MHz) CDCl3: δ = 168.4, (C=O), 167.2 (C=N), 146.6 (ArC), 146.1 (ArC), 
140.6 (ArC), 138.6 (ArC), 137.7 (ArC), 131.7 (ArC), 131.1 (ArC), 129.9 (ArC x 2), 
129.8 (ArC), 129.5 (ArC x 2), 128.7 (ArC x 2), 128.6 (ArC x 2), 128.3 (ArC x 2), 126.5 
(ArC), 126.4 (ArC), 126.2 (ArC), 124.6 (ArC x 2), 119.3 (ArC) 65.8 (COCHCH2), 37.9 
(COCHCH2).  
 
HRMS-ESI (m/z) calculated for C28H20ClN3O3 [+H] +: 482.1266, found: 482.1286. 
LCMS purity (UV) = 95%, tR 19.71 min. 
 
5.4.9 1-(4-Nitrophenyl)-3-benzyl-5-(pyridine-2-yl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (5.9) 
The product was obtained as white solid (0.11 mmol scale, 38 mg, 77%).  
 
1H-NMR (500 MHz) CDCl3: δ = 8.67 – 8.62 (m, ArH, 1H), 8.15 (d, 3JHH  = 8.0 Hz, ArH, 
2H), 8.18 – 8.12 (m, ArH, 1H), 7.88 – 7.81 (m, ArH, 1H), 7.44 – 7.42 (m, ArH, 2H), 7.42 
– 7.37 (m, ArH, 4H), 7.35 – 7.26 (m, ArH, 3H), 7.25 – 7.21 (m, ArH, 2H), 6.89 (d, 3JHH  
= 8.0 Hz, ArH, 1H), 4.10 (dd, 3JHH  = 8.0, 6.0 Hz, COCHCH2, 1H), 3.70 (dd, 2,3JHH  = 
14.0, 7.0 Hz, COCHCH2, 1H), 3.62 (dd, 2,3JHH  = 14.0, 7.5 Hz, COCHCH2, 1H).  
 
13C-NMR (126 MHz) CDCl3: δ = 168.6 (C=O), 167.6 (C=N), 155.9 (ArC), 148.7 (ArC), 
147.1 (ArC), 145.9 (ArC), 141.9 (ArC), 138.9 (ArC), 136.8 (ArC), 131.4 (ArC), 130.8  
(ArC), 129.9 (ArC x 2), 128.8 (ArC x 2), 128.3 (ArC x 2), 126.3 (ArC), 125.2 (ArC), 
125.1 (ArC), 124.8 (ArC x 2), 124.4 (ArC x 2), 123.8 (ArC), 65.8  (COCHCH2), 37.8 
(COCHCH2).  
 
HRMS-ESI (m/z) calculated for C27H20N4O3 [+H] +: 449.1608, found: 449.1617. LCMS 
purity (UV) = 99 %, tR 20.81 min. 
 
5.4.10 1-(4-Nitrophenyl)-3-benzyl-5-(2’-fluorobiphenyl-2-yl)-1,3-dihydro-
2H-1,4-benzodiazepin-2-one (5.10) 
The product was obtained as white solid (0.03 mmol scale, 11 mg, 70%).  
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1H-NMR (500 MHz) CDCl3: δ = 8.14 (d, 3JHH = 8.5 Hz, ArH, 2H), 7.57 – 7.52 (m, ArH, 
1H), 7.51 – 7.45 (m, ArH, 1H), 7.42 (d, 3JHH = 7.5 Hz, ArH, 1H), 7.38 (d, 3JHH = 7.5 Hz, 
ArH, 1H), 7.32 – 7.27 (m, ArH, 7H), 7.26 – 7.19 (m, ArH, 2H), 7.15 – 7.09 (m, ArH, 
1H), 7.06 (d, 3JHH = 7.5 Hz, ArH, 1H), 7.00 – 6.93 (m, ArH, 3H), 6.65 (d, 3JHH = 8.5 Hz, 
ArH, 1H), 3.80 (dd, 3JHH = 8.0, 5.5 Hz, COCHCH2, 1H), 3.69 (d, 3JHH = 8.0 Hz, 
COCHCH2, 1H), 3.66 (d, 3JHH = 8.0 Hz, COCHCH2, 1H).  
 
13C-NMR (126 MHz) CDCl3: δ = 169.5 (C=O), 167.9 (C=N), 159.2 (d, 1JFC = 247.5 Hz, 
ArC) 147.1 (ArC), 145.7 (ArC), 141.5 (ArC), 138.8 (ArC), 138.7 (ArC), 135.7 (ArC), 
132.0 (d, 3JFC = 3.5 Hz, ArC), 131.6 (ArC), 131.4 (ArC), 130.8 (ArC), 130.3 (ArC), 
129.9 (ArC x 2), 129.8 (ArC), 129.5 (ArC), 129.2 (ArC), 128.9 (d, 3JFC = 8.0 Hz, ArC), 
128.5 (ArC x 2), 128.3 (ArC x 2),  128.1 (ArC),  126.3 (ArC), 125.2 (ArC), 124.8 (ArC), 
124.5 (d, 4JFC = 3.5 Hz, ArC), 124.2 (ArC x 2), 115.4 5 (d, 2JFC = 22.0 Hz, ArC) 66.0 
(COCHCH2), 37.8 (COCHCH2).  
 
HRMS-ESI (m/z) calculated for C34H24N3O3 [+H] +: 542.1874, found: 542.1881. LCMS 
purity (UV) = 93%, tR 23.27 min. 
 
5.4.11 1-(2,4,6-Trimethylphenyl)-5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (5.13) 
The reaction was run for 8 hours. The product was obtained as white solid (1.00 mmol 
scale, 181 mg, 51%).   
 
1H NMR (500 MHz, DMSO-d6) δ 7.60 – 7.57 (m, ArH, 2H), 7.54 – 7.46 (m, ArH, 4H), 
7.32 (d, 3JHH = 8.0 Hz, ArH, 1H), 7.27 – 7.23 (m, ArH, 1H), 7.10 – 7.07 (m, ArH, 1H), 
6.88 (s, ArH, 1H), 6.78 (d, 3JHH  = 8.0, 1.1 Hz, ArH, 1H), 4.70 (d, 2JHH  = 10.0 Hz, 
COCH2,1H), 4.04 (d, 2JHH  = 10.0 Hz, COCH2, 1H), 2.26 (s, CH3, 3H), 2.24 (s, CH3, 3H), 
1.61 (s, CH3, 3H).  
 
13C-NMR (126 MHz) DMSO-d6: δ = 170.3 (C=O), 167.5 (C=N), 142.2 (ArC), 138.9 
(ArC), 137.9 (ArC), 137.0 (ArC), 136.2 (ArC), 134.7 (ArC), 132.3 (ArC), 130.9 (ArC), 
130.0 (ArC x 2), 129.6 (ArC x 2), 129.5 (ArC), 128.9 (ArC x 2), 128.7 (ArC), 124.4 
(ArC), 122.1 (ArC), 57.3 (COCH2), 21.0 (CH3), 18.5(CH3), 17.5 (CH3).  
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HRMS-ESI (m/z) calculated for C24H22N2O [+H] +: 355.1805, found: 355.1804. LCMS 
purity (UV) = 97%, tR 21.13 min. 
 
5.4.12 1-(2-Bromophenyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-
one (5.14) 
The reaction was run for 8 hours. The product was obtained as white solid (1.00 mmol 
scale, 31 mg, 8%).  
 
1H NMR (500 MHz, DMSO-d6) δ 7.84 (d, 3JHH = 8.0 Hz, ArH, 1H), 7.70 (d, 3JHH = 8.0 
Hz, ArH, 1H), 7.66 – 7.59 (m, ArH, 4H), 7.52 – 7.46 (m, ArH, 3H), 7.41 – 7.37 (m, ArH, 
1H), 7.32 (dd, J = 7.8, 1.7 Hz, ArH, 1H), 7.27 (d, 3JHH = 7.0 Hz, ArH, 1H), 6.92 – 6.83 
(m, ArH, 1H), 4.69 (d, 2JHH = 10.5 Hz, COCH2, 1H), 4.01 (d, 2JHH = 10.5 Hz, COCH2, 
1H).  
 
13C-NMR (126 MHz) CDCl3: δ = 170.7 (C=O), 168.9 (C=N), 142.0 (ArC), 138.9 (ArC), 
138.6 (ArC), 134.3 (ArC), 133.7 (ArC), 132.0 (ArC), 131.0 (ArC), 130.9 (ArC), 130.8 
(ArC), 129.9 (ArC x 2), 129.8 (ArC), 129.1 (ArC), 128.8 (ArC x 2), 124.7 (ArC), 123.0 
(ArC), 121.5 (ArC), 57.0 (COCH2).  
 
HRMS-ESI (m/z) calculated for C21H15BrN2O [+H] +: 391.0441, found: 391.0457. LCMS 
purity (UV) = 93%, tR 15.23 min. 
 
5.4.13 1-(3’-Trifluoromethylphenyl)-5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (5.15) 
The reaction was run for 8 hours. The product was obtained as white solid (0.50 mmol 
scale, 80 mg, 42%).  
 
1H-NMR (500 MHz) CDCl3: δ = 7.72 (d, 3JHH = 7.5 Hz, ArH, 2H), 7.60 – 7.55 (m, ArH, 
2H), 7.53 (d, 3JHH = 8.5 Hz, ArH, 2H), 7.49 – 7.45 (m, ArH, 2H), 7.44 – 7.38 (m, ArH, 
3H), 7.25 – 7.20 (m, ArH, 1H), 6.92 (d, 3JHH = 8.5 Hz, ArH, 1H), 4.95 (d, 2JHH = 10.5 Hz, 
1H), 4.02 (d, 2JHH = 10.5 Hz, 1H).  
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13C-NMR (126 MHz) CDCl3: δ = 170.3 (C=O), 168.3 (C=N), 143.1 (ArC), 141.3 (ArC), 
138.6 (ArC), 132.0(q, 2JFC = 29.9 Hz, ArC),131.9 (ArC), 131.6 (ArC), 131.4 (ArC), 
130.7 (ArC), 130.4 (ArC), 129.8 (ArC x 2), 129.5 (ArC), 128.5 (ArC x 2), 125.2 (q, 3JFC 
= 3.5 Hz, ArC), 124.8(ArC), 124.8(ArC), 123.5 (q, 1JFC = 273.0 Hz, ArC), 124.2 (q, 3JFC 
= 3.5 Hz, ArC), 57.3 (COCH2).  
 
HRMS-ESI (m/z) calculated for C22H15F3N2O [+H] +: 381.1209, found: 381.1208. LCMS 
purity (UV) = 96%, tR 21.35 min. 
 
5.4.14 1-Phenyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (5.16) 
The reaction was run for 8 hours. The product was obtained as white solid (0.50 mmol 
scale, 14 mg, 9%).  
 
1H-NMR (500 MHz) CDCl3: δ = 7.72 (d, 3JHH = 7.5 Hz, ArH, 2H), 7.54 – 7.49 (m, ArH, 
1H), 7.47 (d, 3JHH = 7.5 Hz, ArH, 2H), 7.43 – 7.38 (m, ArH, 2H), 7.37 – 7.30 (m, ArH, 
2H), 7.24 – 7.21 (m, ArH, 3H), 7.20 – 7.16 (m, ArH, 1H), 6.97 (d, 3JHH = 8.5 Hz, ArH, 
1H), 4.96 (d, 2JHH = 10.5 Hz, ArH, COCH2, 1H), 4.01 (d, 2JHH = 10.5 Hz, COCH2, 1H).  
 
13C-NMR (126 MHz) CDCl3: δ = 170.7 (C=O), 168.3 (C=N), 146.5 (ArC), 143.3 (ArC), 
140.7 (ArC), 138.6 (ArC), 131.3 (ArC), 130.7 (ArC), 130.3 (ArC), 129.6 (ArC x 2), 
129.3 (ArC x 2), 128.4 (ArC x 2), 128.3 (ArC x 2), 127.5 (ArC), 124.7 (ArC), 124.2 
(ArC), 57.2 (COCH2).  
 
HRMS-ESI (m/z) calculated for C21H16N2O [+H] +: 313.1335, found: 313.1338. LCMS 
purity (UV) = 90%, tR 16.10 min. 
 
5.4.15 1-(4-Nitrophenyl)-3-(4-nitrophenyl)-5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (5.18) 
The product was obtained as white solid (0.60 mmol scale, 2 eq. of diaryliodonium 
triflate, 146 mg, 51%).  
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1H-NMR (500 MHz) CDCl3: δ = 8.34 – 8.22 (m, ArH, 4H), 7.85 – 7.79 (m, ArH, 2H), 
7.77 – 7.71 (m, ArH, 2H), 7.74 – 7.57 (m, ArH, 3H), 7.59 – 7.50 (m, ArH, 3H), 7.41 – 
7.32 (m, ArH, 2H), 7.07 – 7.02 (m, ArH, 1H).  
 
13C-NMR (126 MHz) CDCl3: δ = 166.0 (C=O), 158.3 (C=N), 149.1 (ArC), 146.7 (ArC), 
145.6 (ArC), 144.1 (ArC), 143.3 (ArC), 135.0 (ArC), 132.6 (ArC), 131.5 (ArC), 129.9 
(ArC), 129.6 (ArC), 129.5 (ArC x 2), 128.9 (ArC x 2), 126.8 (ArC x 2), 126.3 (ArC), 
125.4 (ArC) 124.5 (ArC x 2), 124.3 (ArC x 2), 121.3 (ArC x 2).  
 
HRMS-ESI (m/z) calculated for C26H17N5O5 [+H] +: 480.1230 found: 480.1245. LCMS 
purity (UV) = 95%, tR 18.35 min. 
 
5.4.16 1,1’-Oxybis(4-nitrobenzene) (5.21) 
To a solution of (4-nitrophenyl)phenyliodonium triflate (30 mg, 0.06 mmol) in DCE (1 
mL) was added sodium hydroxide (aq., 1 mL) and stirred for 20 min. at room temperature. 
Upon completion, the reaction was diluted with dichloromethane (5 mL x 3) and the 
layers were separated. Combined organic layers were dried (MgSO4) and concentrated 
under reduced pressure to afford the product as a white powder (7 mg, 43%).  
 
1H-NMR (500 MHz) CDCl3: δ = 8.33 – 8.27 (m, ArH, 4H), 7.19 – 7.14 (m, ArH, 4H).13C-
NMR (126 MHz) CDCl3: δ = 160.6 (ArC x 2), 144.2 (ArC x 2), 126.2 (ArC x 4), 119.3 
(ArC x 4).  
 
HRMS-ESI (m/z) calculated for C12H8N2O5 [+H] +: 261.0511, found: 261.0513. 
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Chapter 6 
 
Gram Scale Laboratory Synthesis of TC AC 28, a 
High Affinity BET Bromodomain Ligand 
 
 
6.1 Introduction 
 
The 1,4-benzodiazepine scaffold is a well-established “privileged scaffold” in medicinal 
chemistry1–17 and as stated in the previous Chapters, we have an active interest in 
synthesising libraries of such compounds.18–22 Triazolo-benzodiazepine derivative TC 
AC 28 is a potent, selective BET (Bromo and extraterminal) bromodomain inhibitor and 
a useful epigenetic tool compound.23,24 We sought to scale up the original seven-step-
protocol towards this molecule with the aim of improving the final two problematic and 
low yielding steps.2 
 
6.2 Results and Discussion 
 
Our scale-up efforts (step 1, Scheme 6.1) started with a synthesis of the methyl ester 
hydrochloride salt 6.2, which was formed in virtually quantitative yield, followed a 
cyclization step (step 2) to afford the isatoic anhydride 6.4.25 
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Scheme 6.1: Synthesis of triazolo-benzadiazepinone, 6.7 
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Reaction of the latter, formed the benzodiazepinedione 6.5, and we employed an ether 
trituration, as opposed to our earlier reported chromatographic purification work-up. This 
was followed by treatment with Lawesson’s reagent,26,27 by mercury-mediated 
cyclization to afford the triazolo-analogue 6.7 (steps 3 – 5). At this stage, no significant 
differences in yields were noticed from our original report. However, the next two crucial 
steps were vital in our aims to obtain approximate gram quantities of product.  
 
 
 
 
Scheme 6.2: Synthesis of TC AC 28 (6.9) 
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Step 6 (Scheme 6.2) was originally performed by combining 12 batches of ca. 170 mg 
amounts of precursor 6.7, yielding the key chloroimidate intermediate 6.8, which was 
obtained as a white solid in 619 mg amounts (29% yield). Careful re-examination of this 
step led us to significantly lower the amounts of POCl3 used and we were able to avoid 
the inefficient chromatographic step by carrying out a trituration in Et2O (Table 6.1, Entry 
3). Indeed, we were delighted to obtain a yield of 76% of 6.8 in nearly gram quantities 
(0.80 g) in a one-step protocol. 
 
Table 6.1: Step 6 optimisation 
Entry POCl3 
 (eq.) 
N,N-DMA 
(eq.) 
Work up Purification Isolated Yield (8) 
(%) 
1 21 5.5 Quench 
(Et3N) 
Acetone/DCM 
(30% to 80%) 
column 
20a 
2 10 3 Quench 
(water) 
extraction 
with CHCl3 
Trituration with 
diethyl ether. 
50 
3 1.5 2 Quench 
(water) 
extraction 
with CHCl3 
Trituration with 
diethyl ether. 
76 
 
aMaterial decomposes in silica 
 
Buoyed by this result we next examined the final Pd-catalyzed Suzuki-Miyaura coupling 
reaction in order to install the indolyl group in 6.9.28,29 Maintaining the original Pd(PPh3)4 
catalyst, we obtained, by using a DME/water mixture with Na2CO3 as base, 6.9 in 49% 
yield (Table 3, Entry 2), which was scalable to 0.8 g of product (Table 2).  
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Table 6.2: Suzuki Coupling Optimization 
 
Entry Catalyst Solvent Base Conditions Isolated Yield (9)  
(%) 
1 Pd(PPh3)4 DMF Et3N 100 °C, 24 
h 
27 
2 Pd(PPh3)4 DME/ 
Water 
Na2CO3 85 °C, 2 h 49 
 
 
 
Table 6.3: Comparison of scale-up vs. original published route 
 
Step S.M.  
(g)a  
Prod. (g) yield(%) S.M. 
 (g)b  
Prod.(g)  yield (%) 
1 50.07 74.00 >99 - - - 
2 50.02 57.03 89 - - >99 
3 45.00 27.30 43c 3.70 1.77 36 
4 15.01 8.30 53 1.86 1.12 57 
5 8.00 6.57 77d 2.20 2.15 91 
6 0.99 0.80 76e 2.04 
(0.17 
x 12) 
0.619 29 
7 1.33 0.81 49 - - 27-31 
 
aScale up; S.M. =starting material, Prod.= product. bOriginal papers.  cTrituration in ether as opposed to 
chromatography. dReaction mixture quenched with NaHCO3 extracted with ethyl acetate as opposed to no 
work-up. ePOCl3 (1.5 eq), DMA (2 eq.) quenched with water, extraction with CHCl3 and trituration with 
diethyl ether as opposed to POCl3 (21 eq). DMA (5.5 eq.), quenched with Et3N and purified by 
chromatography. ePd(PPh3)4, DME/water and Na2CO3 as opposed to Pd(PPh3)4, DMF and Et3N. 
 200 
 
 
6.3 Conclusion 
 
Overall, acceptable, near gram quantities of the final product 6.9 have been synthesized, 
benefitting ultimately from improved steps 6 and 7 of the original synthetic route (Table 
6.3). 
 
6.4 Experimental details for Chapter 6 
 
All commercially purchased materials and solvents were used without further purification 
unless specified otherwise. NMR spectra were recorded on a Bruker Avance III HD 400 
MHz spectrometer and prepared in deuterated solvents such as CDCl3 and DMSO-d6. 
LC-MS spectra were acquired using an Agilent 6120 (600 Bar) HPLC with Agilent 1290 
MCT column compartment oven and Agilent 6120 Quad Mass Spectrometer and 
percentage purities were run on a Zorbax SB C18 2.1x 50 mm 1.8 µm column (0.1% aq. 
Formic Acid 0.1% Formic Acid in MeCN 5-95%, 0.1% TFA/MeCN, over 5 min, held at 
100 % for 2 min, flow rate – 0.5mL/min) with the UV detector at 250 nm, bandwidth 100 
nm. Purifications were performed by flash chromatography on silica gel columns using a 
Reveleris PREP purification system. 
 
6.4.1 (DL)-Aspartic acid dimethyl ester hydrochloride (6.2) 
To a suspension of DL-Aspartic acid (50.00 g, 375.65 mmol) in methanol (300 mL) at 0 
oC was dropwise added thionyl chloride (68.50 mL, 939.14 mmol, 2.5 eq.) at such a rate 
that the temperature was maintained below 10 oC. Upon completion of the addition, the 
reaction mixture was stirred at reflux for 2 hours, and then allowed to cool to ambient 
temperature and stirred overnight. The reaction mixture was concentrated under reduced 
pressure and the resulting viscous oil was triturated from diethyl ether, filtered and dried 
at 40 oC under vacuum, affording the product as a white solid (74.00 g, > 99%). The 
spectral data were consistent with those reported.30  
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6.4.2 5-Methoxyisatoic anhydride (6.4) 
To a stirred solution of 2-amino-5-methoxy-benzoic acid 6.3 (15.00 g, 99.23 mmol) and 
triethylamine (13.80 mL, 99.23 mmol, 1 eq.) in THF (500 mL) at 0 oC was portion-wise 
added triphosgene (29.45 g, 99.23 mmol, 1 eq.) at such a rate that the temperature was 
maintained below 5 oC. Upon completion of the addition, the reaction mixture was stirred 
for 18 hours at ambient temperature. The reaction was re-cooled to 0 oC and H2O (15 mL) 
was added in a dropwise fashion at such a rate that the temperature was maintained below 
10 oC. After stirring for further 30 min at ambient temperature, the reaction mixture was 
concentrated under reduced pressure. The residue was triturated with H2O and the 
resulting solid was collected by filtration and dried at 50 oC under vacuum, affording the 
product as a brown solid (17.00 g, 89%). LCMS purity (UV): 99%, tR 3.24 min. The 
NMR data were consistent with those reported.24  
 
6.4.3 Methyl-2-(7-methoxy-2,5-dioxo-2,3,4,5-tetrahydro-1H-
benzo[e][1,4]diazepin-3-yl)acetate (6.5) 
5-Methoxyisatoic anhydride 6.4 (45.00 g, 232.97 mmol) and DL-aspartic acid dimethyl 
ester hydrochloride (46.04 g, 232.99 mmol, 1 eq.) were suspended in pyridine (600 mL) 
and the reaction mixture was stirred at reflux for 18 hours. After cooling to ambient 
temperature, the reaction mixture was concentrated under reduced pressure. The residue 
was partitioned between ethyl acetate (500 mL) and 2 M HCl (500 mL). The organic layer 
was separated and the aqueous layer was further extracted with ethyl acetate (2 x 350 
mL). Some solid material at the phase boundary was collected by filtration giving an 
initial crop of product. The combined organic phase of the filtrate was dried (MgSO4) and 
concentrated under reduced pressure. Trituration with diethyl ether afforded the product 
as a white solid (27.30 g, 43%). LCMS purity (UV): 96%, tR 3.12 min. The NMR data 
were consistent with those reported.24  
 
6.4.4 (+-)-Methyl-2-(7-methoxy-5-oxo-2-thioxo-2,3,4,5-tetrahydro-1H-
benzo[e][1,4]diazepin-3-yl)acetate (6.6) 
To a suspension of the previous compound 6.5 (15.01 g, 53.91 mmol) in pyridine (265 
mL) was added Lawesson’s reagent (19.62 g, 48.52 mmol, 0.9 eq.) and the reaction 
mixture was stirred at reflux for 6 hours.  The reaction mixture was cooled to ambient 
temperature and concentrated under reduced pressure. The residue was suspended in 
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CH2Cl2 (3 x 300 mL) and re-concentrated under reduced pressure. Trituration with 
CH2Cl2 afforded the product as a pale yellow solid (8.30 g, 53%). LCMS purity (UV): 
92%, tR 3.51 min. The NMR data were consistent with those reported.24   
 
6.4.5 (+-)-Methyl-2-(8-methoxy-1-methyl-6-oxo-5,6-dihydro-4H-
benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)acetate (6.7) 
To a stirred suspension of compound 6.6 (8.00 g, 27.18 mmol) and acethydrazide (6.04 
g, 81.53 mmol, 3 eq.) in THF (120 mL) was added acetic acid (80 mL). The reaction 
mixture was cooled to 0oC and mercury (II) acetate (12.91 g, 40.77 mmol, 1.5 eq.) was 
added to the reaction mixture portion-wise at such a rate that the temperature was 
maintained below 5oC. Upon completion of the addition, the reaction mixture was stirred 
at 0oC for 2 hours, and then allowed to warm to ambient temperature and stirred for 48 
hours. The reaction mixture was concentrated under reduced pressure and the residue was 
partitioned between NaHCO3 (sat. aq., 450 mL) and ethyl acetate (300 mL). The aqueous 
component was separated and extracted with ethyl acetate (2 x 300 mL). The combined 
organic layer was dried (MgSO4) and concentrated under reduced pressure.  The product 
was collected as a white solid (6.57 g, 77%) after flash column chromatography (95:5 
CH2Cl2/MeOH). LCMS purity (UV): 95%, tR 3.15 min. The NMR data were consistent 
with those reported.24   
 
6.4.6 (+-)-Methyl-2-(6-chloro-8-methoxy-1-methyl-4H-
benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)acetate (6.8)  
To a solution of compound 6.7 (0.99 g, 3.13 mmol) in CHCl3 (20 mL) was added N,N-
dimethylaniline (0.79 g, 6.26 mmol) and POCl3 ( 0.72 g, 4.70 mmol) under inert atm. and 
the reaction was heated at 80oC for 18 hours. After cooling to room temperature, the 
reaction was slowly poured into lukewarm water (80 mL) with stirring. After stirring for 
15 min, it was diluted with CHCl3 (50 mL) and the layers were separated. The aqueous 
layer was extracted with further CHCl3 (50 mL). The combined organic layer was dried 
(MgSO4) and concentrated under reduced pressure. The residue was triturated with 
diethyl ether and to afford an off-white solid (0.80g, 76 %). The product was used without 
further purification. LCMS purity (UV): 97%, tR 3.94 min. The NMR data were 
consistent with those reported.24  
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6.4.7 (+-)-Methyl-2-(6-chloro-8-methoxy-1-methyl-4H-
benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)acetate (6.9)  
To a stirred suspension of compound 6.8 (1.33 g, 3.97 mmol) in DME (14 mL) was added 
a solution of Na2CO3 (0.76 g, 7.17 mmol) in water (6 mL), followed by the addition of 
indole-4-boronic acid (0.77 g, 4.76 mmol) and Pd(PPh3)4 (0.31 g, 0.27 mmol) the reaction 
was heated at 85 oC for 2.5 hours. After cooling to ambient temperature, it was filtered 
over celite and the filtrate was partitioned between EtOAc/water. The layers were 
separated and the organic layer was further washed with water and brine. The organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The product was 
collected as a white solid (0.81 g, 49%) after flash column chromatography (rf = 0.35; 
95:5 CH2Cl2/MeOH).  
 
1H-NMR (400 MHz) CDCl3: δ = 8.40 (s, 1H), 7.52 (d, J = 8.0, 1H), 7.42 (d, J = 9.0, 1H), 
7.24 (t, J = 3.0, 1H), 7.20 (dd, J = 3.0, J = 9.0, 1H), 7.15 (t, J = 7.5, 1H), 7.08 (d, J = 7.5, 
1H), 6.92 (d, J = 3.0, 1H), 6.58 (s, 1H), 4.78 (dd, J = 5.5, J = 9.0, 1H), 3.81 (s, 3H), 3.72 
– 3.78 (m, 4H), 3.63 (dd, J = 5.5, J = 16.5, 1H), 2.64 (s, 3H).  
 
LCMS purity (UV): 99%, tR 4.12 min. Elemental Analysis: Calculated for 
C23H21N5O3.3/4H2O (%): C, 64.4, H, 5.29, N, 16.33, found: C, 64.73, H, 5.12, N, 16.07. 
MS m/z (ES+) calculated for C23H21N5O3 [+H] +: 416.3 found: 416.3; m/z (ES-) 
calculated for C23H21N5O3 [-H] +: 414.3 found: 414.3.  
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Chapter 7 
 
7.1 Conclusions and Future Directions 
 
 
Despite the commercial availability and well-developed synthetic routes for 5-phenyl-
1,3-dihydro-2H-1,4-benzodiazepin-2-one skeletons, there is lack of atom economical 
late-stage functionalisation protocols for closely related BZD-based analogues. 
Therefore, this thesis aimed to develop efficient and atom economical routes for 
generating a BZD-based library. The ability to add functionality to bioactive cores and 
privileged scaffolds such as BZDs, at the final or penultimate synthetic step is very useful 
in medicinal chemistry and drug discovery to enable SAR studies that can drive efficiency 
and speed up hit-to-lead and lead optimization strategies.  
 
In summary, this project aimed to synthesise libraries of functionalised 5-phenyl-1,3-
dihydro-2H-1,4-benzodiazepin-2-one derivatives as shown in Figure 7.1, using efficient, 
one-step, atom-economical protocols. 
 
 
 
Figure 7. 27: Functionalisation scopes of BZD scaffold for library generation 
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Traditional approaches to introduce different R1 groups require their introduction early in 
the synthetic sequence, which is often followed by repetitive coupling and cyclisation 
steps. Chapter 2, therefore, sought to functionalise at the ortho-position by introducing 
varyious R1 groups via a late-stage C-H activation. Atom and step economy in library 
generation could be achieved by synthesising the BZD scaffold in large scale and adding 
the new functional groups at the final step. Moreover, microwave mediated chemistry 
was employed for quicker and further efficiency in the generation of a library of ortho-
arylated 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one. A series of over twenty 
novel BZD analogues were synthesised employing the microwave mediated Pd catalysed 
C-H arylation protocol with diaryliodonium tetrafluoroborates. The methodology is also 
applicable to nordazepam, the active metabolite of diazepam. The compounds were 
further diversified by N-alkylation and H/D exchange, which produces functionalised 
pharmaceuticals (e.g. ortho-arylated diazepam and pinazepam).  
 
Considering the relatively high commercial cost and multistep synthesis of 
diaryliodonium salts, as well as the loss of an aryl iodide, lowering the atom economy of 
these processes, this project next explored a visible-light photocatalyzed Pd-mediated 
protocol involving aryldiazonium salts. In this procedure, 5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-ones reacted with aryldiazonium salts under palladium and visible light 
photoredox catalysis in refluxing methanol. This protocol generally affords higher yields 
for generating libraries of ortho-arylated BZDs than our previous C-H method with 
diaryliodonium salts. Surprisingly, reactions with 2- and 4-fluorobenzenediazonium salts 
led to the methoxyaryl derivative in addition to the expected fluoroaryl products. The 
formation of the ether product can be explained by a competing SNAr reaction, termed 
‘nuisance effect”. The strong electron withdrawing effect of the diazo group gives rise to 
this effect for halogen substituted benzenediazonium salts, which is observed for 2- and 
4-substituted isomers. Biological tests against GABAA receptors revealed that the ortho-
arylated were significantly less active than e.g. nordazepam and diazepam. A 
computational DFT study of the Pd-catalysed and the Pd/Ru photocatalysed mechanism 
for the functionalisation of benzodiazepines conducted by our collaborators indicated that 
in the presence of the photocatalyst, the reaction proceeds via a low-energy SET pathway 
and avoids the high-energy oxidative addition step in the palladium-only catalysed 
reaction pathway.  
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To extend the arylation/nuisance effect chemistry to a wider range of privileged 
structures, this chemistry was applied with substrates such as 1-phenyl-2-pyrrolidones 
and 2-phenylpyridines for library generation. Small arrays of fluoroaryl, methoxyaryl, 
ethoxyaryl and 2-propoxyaryl derivatives of 1-phenyl-2-pyrrolidones were synthesised 
using methanol, ethanol and 2-propanol as the solvent. The ratio of the ether product 
formation can be influenced by the reaction sequence (i.e., the ether product formation 
increases when the diazonium salt is refluxed before adding the substrate and the 
catalysts). Pleasantly, a one-pot reaction with separate alcohols led to small array ether 
products in addition to the expected fluoroaryl derivative of 1-phenyl-2-pyrrolidone. 
Moreover, a reaction of 2-phenylpyridine employing the arylation/nuisance effect 
chemistry led to five separable products from a combination of mono, di-arylation and 
“nuisance effects”. Biological tests performed by our collaborators revealed that a 
number of the ortho-arylated 1-phenyl-2-pyrrolidones bound to the protein NUDT7α and 
produced X-ray co-crystals. 
 
Continuing on the late-stage functionalisation of BZD scaffolds, in Chapter 5, we sought 
to synthesise diverse analogues of BZDs by adding N-H functionality (R2 in Figure 7.1) 
at the final step. Many bioactive 1,4-benzodiazepines include N-arylated BZDs and 
typical routes for preparing such N-H arylated molecules involve transition-metal 
catalysed couplings. These procedures often require high temperatures and have limited 
reaction scopes. Therefore, in Chapter 5, we described our approach to synthesise a small 
library of N-arylated 1,4-benzodiazepines by adopting a method of using unsymmetrical 
diaryliodonium salts with weak bases at room temperature. The method was also 
successfully applied to a similar 1,3,4-benzotriazepin-2-one derivative.  
 
Finally, a scale-up synthesis of a BZD based potent BET-bromodomain inhibitor, TC AC 
28, 6-(1H-Indol-4-yl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-
a][1,4]benzodiazepine-4-acetic acid methyl ester, was conducted to enable the key 
chemical probe to be available for researchers. TC AC 28 is a high affinity and highly 
selective BET bromodomain ligand with a binding efficiency of 40 nM and 800 nM 
towards BRd2(2) and Brd2(1) respectively. Our scale-up synthesis focussed on 
improving the last two steps of the original seven-step-protocol that were crucial to obtain 
near-gram quantities of the product. Changing the reagent quantities and the purification 
method significantly improved the problematic POCl3 chlorination step. This enabled it 
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to be performed in one batch with 76% yield on about gram quantities of the final product. 
This penultimate step was originally performed in 12 small batches with a combined yield 
of 29%. The final Suzuki-Miyaura coupling step was significantly enhanced and was 
scalable to 0.8 g of product with 49% yield by modifying the reaction conditions and 
changing the base and the solvent.  
Future studies of this work could involve addressing the drug-likeliness of the library of 
C-H and N-H arylated 1,4-benzodiazepines by for example altering their lipophilicity. 
This could be achieved by exploring other types of C-H functionalisation methods, for 
instance by introducing heterocycles or by C-H amination etc.  
Moreover, further diversification of the 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-
one could be explored by meta- and para- C-H activation (Figure 7.2). 
 
 
 
Figure 7.28: Strategies for further diversification of the 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one scaffold 
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The C-H functionalisation procedures described in Chapter 4.2 can be utilised to 
accomplish the diversification of the 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
scaffold. 1–18 
 
7.2 Thesis Outcome  
 
7.2.1 Publications 
 
• R. Khan, R. Felix, P. D. Kemmitt, S. J. Coles, I. J. Day, G. J. Tizzard, and J. 
Spencer, Advanced Synthesis and Catalysis, 2016, 358, 98-109. 
 
• R. Khan, S. Boonseng, R. Felix, P. D. Kemmitt, S. J. Coles, G. J. Tizzard, G. 
Williams, O. Simmonds, J-L. Harvey, J. Atack, H. Cox, and J. Spencer, Advanced 
Synthesis and Catalysis, 2017, 359, 3261-3269. 
 
• R. Khan, G.  Marsh, R. Felix, P. D. Kemmitt, M. G. J. Baud, A. Ciulli and J. Spencer, 
ACS Omega, 2017, 2, 4328-4332. 
 
 
• R. Khan, R. Felix, P. D. Kemmitt, S. J. Coles, G. J. Tizzard, and J. Spencer, Synlett, 
2018, 29, 193-198. 
 
7.2.2 Awards and Honours 
 
• First prize - PhD presentation, Annual Research Colloquium, University of Sussex, 
December 2017. 
 
7.2.3 Presentations 
 
• ‘Late-stage C-H Functionalisation of Privileged Scaffolds: Synthesis of a library of 
Benzodiazepines’ - Annual Research Colloquium, University of Sussex, September 
2016. Poster. 
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• Late-stage C-H Functionalisation of Privileged Scaffolds: Synthesis of a library of 
Benzodiazepines’ – 23rd Lakeland Symposium on Heterocyclic Chemistry, Grasmere, 
May 2017. Talk. 
 
• Late-stage C-H Functionalisation of Privileged Scaffolds: Synthesis of a library of 
Benzodiazepines’ – iCASE conference, AstraZenneca, Macclesfield, September 
2017. Talk. 
 
• ‘Late-stage C-H Functionalisation of Privileged Scaffolds: Synthesis of a library of 
Benzodiazepines’ - Annual Research Colloquium, University of Sussex, December 
2017. Talk. 
 
7.2.4 Industrial placement 
 
• 3 months industrial placement at Tocris Biosciece.  
• Industrial scale-up synthesis and successful project delivery within tight 
timelines. 
• Featured in Tocris’s news-letter for the work conducted at the company. 
 
7.2.5 Workshops 
 
• RSC Medicinal Chemistry Residential School China, Shanghai Institute of Materia 
Medica, Shanghai, China, November 2014. 
 
7.2.6 Media & Outreach 
 
• Interviewed and featured in Worldwide Cancer Research blog for international 
women’s day 2018. https://www.worldwidecancerresearch.org/blog-
post/drraysakhan/ 
 
• Interviewed on local TV about the PhD research for Science Week 2017. 
http://www.sussex.ac.uk/lifesci/chemistry/highlights/awards 
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• Featured by a local magazine (Viva Brighton Magazine February 2018 issue #60) 
 
• Speaker at Soapbox Science Brighton, 2018. 
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